{
  "letters": 826509,
  "pages": 220,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "NuCana plc",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 62,
          "title": "Corporate History and Business Overview",
          "data": [
            {
              "key": "Company Incorporation Date",
              "value": "1997"
            },
            {
              "key": "Original Name",
              "value": "Biomed (UK) Limited"
            },
            {
              "key": "Name Change Date",
              "value": "April 28, 2008"
            },
            {
              "key": "New Name",
              "value": "NuCana BioMed Limited"
            },
            {
              "key": "Public Limited Registration Date",
              "value": "August 29, 2017"
            },
            {
              "key": "Name Change to PLC",
              "value": "NuCana plc"
            },
            {
              "key": "IPO Date",
              "value": "October 2, 2017"
            },
            {
              "key": "Ticker Symbol",
              "value": "NCNA"
            },
            {
              "key": "Registered Office Address",
              "value": "77/78 Cannon Street, London EC4N 6AF, United Kingdom"
            },
            {
              "key": "Principal Executive Office Address",
              "value": "3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom"
            },
            {
              "key": "General Telephone Number",
              "value": "+44 (0)131 357 1111"
            },
            {
              "key": "Website",
              "value": "https://www.nucana.com"
            },
            {
              "key": "US Service Agent Address",
              "value": "Corporation Service Company, 251 Little Falls Drive, Wilmington, DE 19808"
            },
            {
              "key": "Business Focus Area",
              "value": "Clinical-stage biopharmaceutical company focused on cancer"
            },
            {
              "key": "Product Technology",
              "value": "ProTide™ technology"
            },
            {
              "key": "Key Product Example",
              "value": "NUC-3373"
            },
            {
              "key": "Clinical Trial Stage of NUC-3373",
              "value": "Phase 1b/2"
            },
            {
              "key": "Additional Clinical Trial",
              "value": "NUC-7738 Phase 2 trial characteristic"
            },
            {
              "key": "Market Revenue Projection",
              "value": "$74.3 billion by 2027"
            },
            {
              "key": "Key Treatment Categories",
              "value": "Surgery, radiotherapy, therapeutics"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 76,
          "title": "Patient Treatment Duration Analysis",
          "data": [
            {
              "key": "Age",
              "value": "69"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "2"
            },
            {
              "key": "RAS Status",
              "value": "RAS unknown"
            },
            {
              "key": "Last Treatment",
              "value": "1.5 months"
            },
            {
              "key": "Duration",
              "value": "5.1"
            },
            {
              "key": "Age",
              "value": "47"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "4"
            },
            {
              "key": "RAS Status",
              "value": "RAS wt"
            },
            {
              "key": "Last Treatment",
              "value": "3 months"
            },
            {
              "key": "Duration",
              "value": "5.1"
            },
            {
              "key": "Age",
              "value": "52"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "5"
            },
            {
              "key": "RAS Status",
              "value": "RAS wt BRAF mt"
            },
            {
              "key": "Last Treatment",
              "value": "3 months"
            },
            {
              "key": "Duration",
              "value": "4.5"
            },
            {
              "key": "Age",
              "value": "48"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "4"
            },
            {
              "key": "RAS Status",
              "value": "RAS mt"
            },
            {
              "key": "Last Treatment",
              "value": "15 months"
            },
            {
              "key": "Duration",
              "value": "4.4"
            },
            {
              "key": "Age",
              "value": "69"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "4"
            },
            {
              "key": "RAS Status",
              "value": "RAS unknown"
            },
            {
              "key": "Last Treatment",
              "value": "3 months"
            },
            {
              "key": "Duration",
              "value": "4.3"
            },
            {
              "key": "Age",
              "value": "65"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "3"
            },
            {
              "key": "RAS Status",
              "value": "RAS mt"
            },
            {
              "key": "Last Treatment",
              "value": "6 months"
            },
            {
              "key": "Duration",
              "value": "4.3"
            },
            {
              "key": "Age",
              "value": "57"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "4"
            },
            {
              "key": "RAS Status",
              "value": "RAS unknown"
            },
            {
              "key": "Last Treatment",
              "value": "1 month"
            },
            {
              "key": "Duration",
              "value": "3.8"
            },
            {
              "key": "Age",
              "value": "67"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "3"
            },
            {
              "key": "RAS Status",
              "value": "RAS unknown"
            },
            {
              "key": "Last Treatment",
              "value": "3 months"
            },
            {
              "key": "Duration",
              "value": "3.5"
            },
            {
              "key": "Age",
              "value": "59"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "7"
            },
            {
              "key": "RAS Status",
              "value": "RAS wt"
            },
            {
              "key": "Last Treatment",
              "value": "3 months"
            },
            {
              "key": "Duration",
              "value": "3.2"
            },
            {
              "key": "Age",
              "value": "67"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "5"
            },
            {
              "key": "RAS Status",
              "value": "RAS mt"
            },
            {
              "key": "Last Treatment",
              "value": "2 months"
            },
            {
              "key": "Duration",
              "value": "3.1"
            },
            {
              "key": "Age",
              "value": "75"
            },
            {
              "key": "Prior Treatment Lines",
              "value": "4"
            },
            {
              "key": "RAS Status",
              "value": "RAS mt"
            },
            {
              "key": "Last Treatment",
              "value": "unknown"
            },
            {
              "key": "Duration",
              "value": "3.0"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 85,
          "title": "NuTide:121 Trial Summary and Patient Analysis",
          "data": [
            {
              "key": "Trial Name",
              "value": "NuTide:121"
            },
            {
              "key": "Drug Combination",
              "value": "Acelarin plus cisplatin"
            },
            {
              "key": "Comparator",
              "value": "gemcitabine plus cisplatin"
            },
            {
              "key": "Trial Closure Date",
              "value": "March 2022"
            },
            {
              "key": "Primary Endpoints",
              "value": "Overall Survival (OS), Overall Response Rate (ORR)"
            },
            {
              "key": "Interim Analysis Count",
              "value": "3"
            },
            {
              "key": "Overall Response Rate (Acelarin)",
              "value": "18.7% (3 Complete Responses and 50 Partial Responses)"
            },
            {
              "key": "Overall Response Rate (Gemcitabine)",
              "value": "12.4% (0 Complete Responses and 34 Partial Responses)"
            },
            {
              "key": "Median OS (Acelarin)",
              "value": "9.2 months"
            },
            {
              "key": "Median OS (Gemcitabine)",
              "value": "12.6 months"
            },
            {
              "key": "Hazard Ratio",
              "value": "1.79"
            },
            {
              "key": "Discontinuation Rate (Acelarin)",
              "value": "30%"
            },
            {
              "key": "Discontinuation Rate (Gemcitabine)",
              "value": "16%"
            },
            {
              "key": "Liver-related TEAEs (Acelarin)",
              "value": "Higher incidence"
            },
            {
              "key": "Future Development Options",
              "value": "Lower doses, alternative combinations, other indications"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 103,
          "title": "Operating and Financial Review and Prospects",
          "data": [
            {
              "key": "Reporting Standards",
              "value": "IFRS"
            },
            {
              "key": "Financial Statements Currency",
              "value": "pounds sterling"
            },
            {
              "key": "Revenue Status",
              "value": "No approved products, no revenue"
            },
            {
              "key": "Operating Expenses Categories",
              "value": "research and development expenses and administrative expenses"
            },
            {
              "key": "Research and Development Expenses Composition",
              "value": "Costs incurred under agreements with CROs, salaries, consulting fees, patent maintenance, and regulatory approval costs"
            },
            {
              "key": "Forward-looking Statements",
              "value": "Subject to risks and uncertainties"
            },
            {
              "key": "Impact of COVID-19",
              "value": "Potential delays in clinical trials due to resurgence"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 109,
          "title": "Cash Flow Statement Summary",
          "data": [
            {
              "key": "Net cash used in operating activities (2022)",
              "value": "-£23.2 million"
            },
            {
              "key": "Net cash used in operating activities (2021)",
              "value": "-£23.8 million"
            },
            {
              "key": "Net cash from (used in) investing activities (2022)",
              "value": "£0.1 million"
            },
            {
              "key": "Net cash from (used in) investing activities (2021)",
              "value": "-£3.6 million"
            },
            {
              "key": "Net cash used in financing activities (2022)",
              "value": "-£0.2 million"
            },
            {
              "key": "Net cash used in financing activities (2021)",
              "value": "-£0.1 million"
            },
            {
              "key": "Net decrease in cash and cash equivalents (2022)",
              "value": "-£23.2 million"
            },
            {
              "key": "Net decrease in cash and cash equivalents (2021)",
              "value": "-£27.5 million"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "merger_acquisition",
          "page": 109,
          "title": "Operating Lease Obligations by Time Period",
          "data": [
            {
              "key": "Total Operating lease obligations",
              "value": "£701,000"
            },
            {
              "key": "Operating lease obligations less than 1 year",
              "value": "£272,000"
            },
            {
              "key": "Operating lease obligations 1-3 years",
              "value": "£306,000"
            },
            {
              "key": "Operating lease obligations 3-5 years",
              "value": "£123,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "merger_acquisition",
          "page": 136,
          "title": "Mandatory purchases and acquisitions under the Companies Act 2006",
          "data": [
            {
              "key": "Overview",
              "value": "This section discusses the provisions relating to the acquisition of shares during a takeover offer as specified in the Companies Act 2006."
            },
            {
              "key": "Squeeze-Out Rights",
              "value": "If an offeror acquires 90% of shares, they can initiate a squeeze-out of minority shareholders after six weeks."
            },
            {
              "key": "Sell-Out Rights",
              "value": "Minority shareholders have rights to be bought out under certain conditions if the offeror acquires 90% of voting shares."
            },
            {
              "key": "Disclosure Requirements",
              "value": "Companies can ask shareholders to disclose interests in shares and penalize non-compliance."
            },
            {
              "key": "Purchase of Own Shares",
              "value": "Limited companies may only purchase their own shares under certain conditions set by the Companies Act."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 145,
          "title": "U.S. Federal Income Tax Consequences for U.S. Holders of ADSs",
          "data": [
            {
              "key": "Description",
              "value": "Discussion of U.S. federal income tax consequences relevant to U.S. Holders of American Depositary Shares (ADSs) including implications of being classified as a Passive Foreign Investment Company (PFIC)."
            },
            {
              "key": "Key Concepts",
              "value": "U.S. federal income tax consequences, ADS ownership, classification as PFIC, income and asset tests."
            },
            {
              "key": "Recommendation",
              "value": "Consult tax advisors regarding the purchase, ownership, and disposition of ADSs, as well as the applicability of tax laws."
            },
            {
              "key": "Potential Tax Consequences",
              "value": "Impacts of foreign tax credits, reduced tax rates for dividends, and compliance considerations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 160,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "11"
            },
            {
              "key": "Description",
              "value": "Articles of Association of the registrant"
            },
            {
              "key": "Schedule/Form",
              "value": "Form S-8"
            },
            {
              "key": "File Number",
              "value": "333-223476"
            },
            {
              "key": "File Date",
              "value": "03/07/2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 160,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "2.1"
            },
            {
              "key": "Description",
              "value": "Deposit Agreement by and among the registrant and Citibank, N.A. and all Holders and Beneficial Owners of ADSs issued hereunder, dated as of October 2, 2017"
            },
            {
              "key": "Schedule/Form",
              "value": "Form 20-F"
            },
            {
              "key": "File Number",
              "value": "001-38215"
            },
            {
              "key": "File Date",
              "value": "03/22/2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 160,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": "2.2"
            },
            {
              "key": "Description",
              "value": "Form of American Depositary Receipt (included in Exhibit 2.1)"
            },
            {
              "key": "Schedule/Form",
              "value": "Form 20-F"
            },
            {
              "key": "File Number",
              "value": "001-38215"
            },
            {
              "key": "File Date",
              "value": "03/22/2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 160,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit",
              "value": ""
            },
            {
              "key": "Description",
              "value": "Registration Rights Agreement by and among the registrant and the investors named therein, dated as of September 20, 2017"
            },
            {
              "key": "Schedule/Form",
              "value": "Form 20-F"
            },
            {
              "key": "File Number",
              "value": "001-38215"
            },
            {
              "key": "File Date",
              "value": "03/22/2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 202,
          "title": "Minute of Variation",
          "data": [
            {
              "key": "Custodian REIT PLC",
              "value": "Corporate entity involved"
            },
            {
              "key": "NuCana PLC",
              "value": "Corporate entity involved"
            },
            {
              "key": "Brodies LLP",
              "value": "Legal representation"
            },
            {
              "key": "DX ED",
              "value": "Document reference"
            },
            {
              "key": "Location",
              "value": "Edinburgh"
            },
            {
              "key": "Exhibit",
              "value": "14.6"
            },
            {
              "key": "Date Registered",
              "value": "28 Oct 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 203,
          "title": "Registers of Scotland Registration Document",
          "data": [
            {
              "key": "Registration Date",
              "value": "28 October 2022"
            },
            {
              "key": "Document Purpose",
              "value": "Minute of Variation"
            },
            {
              "key": "Parties Involved",
              "value": "CUSTODIAN REIT PLC and NUCANA PLC"
            },
            {
              "key": "Document Type",
              "value": "Deed"
            },
            {
              "key": "Address",
              "value": "Suite 2 (East), 2nd Floor, Lochside House, 3 Lochside Way, Edinburgh Park"
            },
            {
              "key": "FAS",
              "value": "0468"
            },
            {
              "key": "Ref",
              "value": "CFU/EKWICUS0011.00019"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 204,
          "title": "Minute of Variation between CUSTODIAN REIT PLC and NUCANA PLC",
          "data": [
            {
              "key": "Effective Date",
              "value": "14 August 2022"
            },
            {
              "key": "Landlords",
              "value": "Custodian Reit plc"
            },
            {
              "key": "Parties",
              "value": "Landlords and Tenants"
            },
            {
              "key": "Lease",
              "value": "Lease between Drum Income Plus Limited and Nucana Plc dated 7 and 21 September 2017"
            },
            {
              "key": "Premises",
              "value": "Suite 2 (East), 2nd Floor, Lochside House, 3 Lochside Way, Edinburgh Park"
            },
            {
              "key": "Tenants",
              "value": "Nucana plc"
            },
            {
              "key": "Varied Lease",
              "value": "Lease as varied by this Minute of Variation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 209,
          "title": "Minute of Variation between Custodian REIT PLC and Nucana PLC",
          "data": [
            {
              "key": "Effective Date",
              "value": "14 August 2022"
            },
            {
              "key": "Landlords",
              "value": "Custodian REIT PLC and any person succeeding to their interest under the Lease"
            },
            {
              "key": "Parties",
              "value": "Landlords and Tenants"
            },
            {
              "key": "Lease",
              "value": "Lease between Drum Income Plus Limited and Nucana PLC dated 7 and 21 September 2017"
            },
            {
              "key": "Premises",
              "value": "Suite 2 (East), 2nd Floor, Lochside House, 3 Lochside Way, Edinburgh Park"
            },
            {
              "key": "Tenants",
              "value": "Nucana PLC and any person succeeding to their interest under the Lease"
            },
            {
              "key": "Varied Lease",
              "value": "Lease as varied by this Minute of Variation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 211,
          "title": "Minute of Variation of Lease Agreement",
          "data": [
            {
              "key": "Annual Rent Waiver Period",
              "value": "15 August 2022 to 14 November 2022"
            },
            {
              "key": "Extended Lease Term",
              "value": "15 August 2022 to 14 August 2027"
            },
            {
              "key": "Termination Notice Period",
              "value": "Nine months"
            },
            {
              "key": "Termination Date",
              "value": "14 August 2025"
            },
            {
              "key": "Refund of Rents",
              "value": "All rents paid after 14 August 2025"
            },
            {
              "key": "Legal Fees",
              "value": "Each party bears their own fees"
            },
            {
              "key": "Land and Buildings Transaction Tax",
              "value": "Payable by the Tenants"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 216,
          "title": "Certification Pursuant to 18 U.S.C. Section 1350",
          "data": [
            {
              "key": "Company",
              "value": "NuCana plc"
            },
            {
              "key": "CEO",
              "value": "Hugh S. Griffith"
            },
            {
              "key": "Compliance Status",
              "value": "Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934"
            },
            {
              "key": "Report Period Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "April 4, 2023"
            },
            {
              "key": "Signature",
              "value": "Hugh S. Griffith"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 1,
          "title": "Chief Executive Officer Contact Information",
          "data": [
            {
              "key": "Name",
              "value": "Hugh S. Griffith"
            },
            {
              "key": "Title",
              "value": "Chief Executive Officer"
            },
            {
              "key": "Company",
              "value": "NuCana plc"
            },
            {
              "key": "Address",
              "value": "3 Lochside Way, Edinburgh EH12 9DT, United Kingdom"
            },
            {
              "key": "Telephone",
              "value": "+44 (0)131 357 1111"
            },
            {
              "key": "Email",
              "value": "info@nucana.com"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 91,
          "title": "FDA Drug Approval Process",
          "data": [
            {
              "key": "Significant Improvement",
              "value": "In safety or effectiveness, or provides treatment where no adequate therapy exists."
            },
            {
              "key": "PDUFA Goal Dates",
              "value": "FDA does not always meet PDUFA goal dates."
            },
            {
              "key": "Review Process Extension",
              "value": "FDA may extend the review process by three months for late-submitted information."
            },
            {
              "key": "Advisory Committee Referral",
              "value": "Applications for novel drug products may be referred to an advisory committee."
            },
            {
              "key": "REMS Plan Requirement",
              "value": "FDA may require a risk evaluation and mitigation strategy (REMS) plan."
            },
            {
              "key": "Manufacturing Site Inspections",
              "value": "FDA typically inspects clinical sites before NDA approval."
            },
            {
              "key": "Approval Decision",
              "value": "FDA issues either an approval letter or a complete response letter."
            },
            {
              "key": "Possible Withdrawal of Approval",
              "value": "Product approvals may be withdrawn if regulatory compliance is not maintained."
            },
            {
              "key": "Clinical Trial Disclosure Requirement",
              "value": "Sponsors are required to register and disclose clinical trial information."
            },
            {
              "key": "Hatch-Waxman Act",
              "value": "Applicants must list each patent whose claims cover the applicant’s product."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 111,
          "title": "Executive and Non-Executive Officers",
          "data": [
            {
              "key": "Executive Officers",
              "value": "Hugh Griffith (Chief Executive Officer, 55), Jonald Munoz (Chief Financial Officer, 54), Jeffrey Bloss (Chief Medical Officer, 66), David Harrison (Head of Translational Studies, 64)"
            },
            {
              "key": "Non-Executive Directors",
              "value": "Andrew Kay (Non-Executive Director and Chairman, 67), Martin Mellish (Non-Executive Director, 65), Adam George (Non-Executive Director, 53), Cyrille Leperlier (Non-Executive Director, 69), Elliott (Non-Executive Director, 64), Levy Bali Muralidhar (Non-Executive Director, 43)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 112,
          "title": "Leadership Changes at NuCana",
          "data": [
            {
              "key": "Jeffrey Bloss, M.D.",
              "value": "Chief Medical Officer since August 2021, prior experience includes Chief Medical Officer at Tarveda Therapeutics and Aegerion Pharmaceuticals."
            },
            {
              "key": "David Harrison, M.D.",
              "value": "Head of Translational Medicine since December 2017, also a director and research team leader at iCAIRD University."
            },
            {
              "key": "Andrew Kay",
              "value": "Chairman of board of directors since December 2020; previous roles at NeRRe Therapeutics, Blueberry Therapeutics, and Algeta."
            },
            {
              "key": "Martin Mellish",
              "value": "Board member since December 2009; founding director of Aspen Advisory Services and Chairman of Spectral MD Holdings."
            },
            {
              "key": "Adam George",
              "value": "Board member since April 2018; previously U.K. Managing Director at GW Pharmaceuticals and current Chairman of Audit Committee."
            },
            {
              "key": "Cyrille Leperlier, M.D.",
              "value": "Board member since May 2018; extensive experience in pharmaceuticals and biotechnology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 122,
          "title": "Board Practices and Director Independence",
          "data": [
            {
              "key": "Employee Benefit Trust",
              "value": "Established on December 19, 2011, under a trust deed for employee benefit schemes."
            },
            {
              "key": "Trustee",
              "value": "NuCana BioMed Trustee Company Limited, a wholly owned subsidiary."
            },
            {
              "key": "Shares held in trust",
              "value": "500,000 ordinary shares as of December 31, 2022."
            },
            {
              "key": "Board composition",
              "value": "Currently composed of seven members."
            },
            {
              "key": "Independent directors",
              "value": "Martin Mellish, Adam George, Cyrille Leperlier, Bali Muralidhar, Elliott Levy, Andrew Kay."
            },
            {
              "key": "Non-independent director",
              "value": "Hugh Griffith."
            },
            {
              "key": "Term of office",
              "value": "Members serve staggered three-year terms."
            },
            {
              "key": "No termination benefits",
              "value": "No arrangements for benefits upon termination of service."
            },
            {
              "key": "Audit Committee Chair",
              "value": "Adam George."
            },
            {
              "key": "Audit Committee Members",
              "value": "3 non-executive directors - Adam George, Martin Mellish, Cyrille Leperlier."
            },
            {
              "key": "Financial expert",
              "value": "Adam George is a financial expert."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 126,
          "title": "Beneficial Ownership Information",
          "data": [
            {
              "key": "Schedule 13D Filing Dates",
              "value": "February 28, 2022"
            },
            {
              "key": "SVP III and SVP X Address",
              "value": "c/o Sofinnova Investments, Inc., 3000 Sand Hill Road, Bldg. 4, Suite 250, Menlo Park, CA 94025"
            },
            {
              "key": "Ownership Details",
              "value": "All shares held by Sofinnova Capital VI FCPR in the form of ADSs"
            },
            {
              "key": "Management Company",
              "value": "Sofinnova Partners SAS"
            },
            {
              "key": "Managing Partners of Sofinnova Partners SAS",
              "value": "Denis Lucquin, Antoine Papiernik, Henrijette Richter, Monique Saulnier, Graziano Seghezzi"
            },
            {
              "key": "Sofinnova Capital Address",
              "value": "Sofinnova Partners, Immeuble le Centorial, 7-11 boulevard Haussmann, 75009 Paris, France"
            },
            {
              "key": "Investment Advisory Firm",
              "value": "Baillie Gifford & Co."
            },
            {
              "key": "Baillie Gifford Address",
              "value": "Calton Square, 1 Greenside Row, Edinburgh EH1 3AN, Scotland"
            },
            {
              "key": "Abingworth VII Shareholding",
              "value": "3,333,333 ADSs"
            },
            {
              "key": "Sole Shareholder of Carlyle Group Inc.",
              "value": "Carlyle Holdings I GP Inc."
            },
            {
              "key": "Delegated Investment Power",
              "value": "Abingworth LLP"
            },
            {
              "key": "Abingworth Address",
              "value": "c/o Abingworth LLP, Princes House, 38 Jermyn Street, London, England SW1Y 6DN"
            },
            {
              "key": "Carlyle Group Address",
              "value": "c/o The Carlyle Group, 1001 Pennsylvania Avenue NW, Suite 220 South, Washington, DC 20004-2505"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 139,
          "title": "Removal and Appointment of Directors",
          "data": [
            {
              "key": "Number of Directors",
              "value": "A public limited company must have at least two directors."
            },
            {
              "key": "Removal of Directors",
              "value": "Shareholders may remove a director without cause by an ordinary resolution."
            },
            {
              "key": "Vacancies on the Board of Directors",
              "value": "Vacancies and newly created directorships may be filled by a majority of the directors."
            },
            {
              "key": "Annual General Meeting",
              "value": "Public limited company must hold an annual general meeting in each six-month period."
            },
            {
              "key": "General Meeting Requirements",
              "value": "Shareholders holding at least 5% of the capital can call a general meeting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 156,
          "title": "Audit Committee Financial Expert",
          "data": [
            {
              "key": "Audit Committee Members",
              "value": "Adam George, Martin Mellish, Cyrille Leperlier"
            },
            {
              "key": "Chair of the Committee",
              "value": "Adam George"
            },
            {
              "key": "Audit Committee Financial Expert",
              "value": "Adam George"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 158,
          "title": "Exemptions from Nasdaq rules and corporate governance practices",
          "data": [
            {
              "key": "Exemption from Section 16 rules",
              "value": "Reduced data disclosure compared to U.S. companies under Exchange Act."
            },
            {
              "key": "Exemption from Nasdaq disclosure rules",
              "value": "Possibility of not disclosing waivers of business conduct and ethics."
            },
            {
              "key": "Director nominee selection exemption",
              "value": "Nominees do not have to be selected by independent directors."
            },
            {
              "key": "Reliance on home country governance practices",
              "value": "Ability to follow U.K. governance rules instead of Nasdaq rules."
            },
            {
              "key": "Shareholder protections",
              "value": "Limited protections for shareholders compared to companies fully subject to Nasdaq rules."
            },
            {
              "key": "Utilization of exemptions",
              "value": "Exemptions can be utilized as long as qualified as a foreign private issuer."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 162,
          "title": "Signature Page",
          "data": [
            {
              "key": "Company Name",
              "value": "NUCANA PLC"
            },
            {
              "key": "CEO Name",
              "value": "Hugh S. Griffith"
            },
            {
              "key": "Title",
              "value": "Chief Executive Officer"
            },
            {
              "key": "Date of Signature",
              "value": "April 4, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 207,
          "title": "Minute of Variation Execution",
          "data": [
            {
              "key": "Landlords",
              "value": "Custodian REIT PLC"
            },
            {
              "key": "Attorney",
              "value": "Custodian Capital Limited"
            },
            {
              "key": "Date of Signing",
              "value": "16 November 2020"
            },
            {
              "key": "Witness Signature",
              "value": "Jaskiran Kauryait"
            },
            {
              "key": "Director Signature",
              "value": "Edward Moore"
            },
            {
              "key": "Witness Address",
              "value": "1 NEW WALK PLACE, LEICESTER, LEI 6RU"
            },
            {
              "key": "Second Witness Signature",
              "value": "Richard James Shepherd-Cross"
            },
            {
              "key": "Second Witness Date of Signing",
              "value": "25.8.22"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 208,
          "title": "Registers of Scotland - Signing Details",
          "data": [
            {
              "key": "tenant_name",
              "value": "NUCANA PLC"
            },
            {
              "key": "signature_witness",
              "value": "signature of witness"
            },
            {
              "key": "signature_director",
              "value": "signature of director/authorised signatory"
            },
            {
              "key": "full_name_witness",
              "value": "full name of above (print)"
            },
            {
              "key": "full_name_director",
              "value": "full name of above (print)"
            },
            {
              "key": "date_signing",
              "value": "date of signing"
            },
            {
              "key": "address_witness",
              "value": "address if witness"
            },
            {
              "key": "place_signing",
              "value": "place of signing"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 213,
          "title": "Signing Documents for NUCANA PLC",
          "data": [
            {
              "key": "Witness Signature",
              "value": "Moira Adamson"
            },
            {
              "key": "Director/Authorized Signatory",
              "value": "Hugh Stephen Griffith"
            },
            {
              "key": "Date of Signing",
              "value": "26th September 2022"
            },
            {
              "key": "Witness Address",
              "value": "15 Fyvie Close, Auchterarder, Perthshire PH3 1FZ"
            },
            {
              "key": "Place of Signing",
              "value": "3 Lochside Way, Edinburgh"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 52,
          "title": "Risks Related to Employee Matters",
          "data": [
            {
              "key": "Employee Count",
              "value": "31"
            },
            {
              "key": "Executive Officers",
              "value": "4"
            },
            {
              "key": "CEO",
              "value": "Hugh Griffith"
            },
            {
              "key": "Key Person Insurance",
              "value": "None for executives (other than Mr. Griffith)"
            },
            {
              "key": "Challenges in Retaining Personnel",
              "value": "High competition in industry for qualified personnel and executive officers"
            },
            {
              "key": "Critical Personnel Areas",
              "value": "Scientific, clinical, manufacturing, finance, sales, and marketing"
            },
            {
              "key": "Impact of Personnel Loss",
              "value": "Serious harm to business strategy and research objectives"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 14,
          "title": "Financial Risks and Future Financing Needs",
          "data": [
            {
              "key": "Product Development Risks",
              "value": "Our ability to establish collaboration arrangements for the development of our product candidates on favorable terms."
            },
            {
              "key": "Milestones and Payments",
              "value": "Achievement of milestones or occurrence of developments that trigger payments under our license and collaboration agreements."
            },
            {
              "key": "Clinical Trial Costs",
              "value": "Obligations or entitlements to reimburse clinical trial costs under collaboration agreements."
            },
            {
              "key": "In-licensing",
              "value": "Extent to which we acquire or in-license product candidates and technologies."
            },
            {
              "key": "Commercialization Costs",
              "value": "Costs of future commercialization activities for product candidates that receive marketing approval."
            },
            {
              "key": "Revenue from Sales",
              "value": "Revenue from commercial sales of our product candidates."
            },
            {
              "key": "Intellectual Property Costs",
              "value": "Costs of maintaining and enforcing our intellectual property rights."
            },
            {
              "key": "Future Financing",
              "value": "Necessity to rely on additional financing to achieve business objectives."
            },
            {
              "key": "Dilution Risk",
              "value": "Raising additional capital may cause dilution to shareholders."
            },
            {
              "key": "Debt Obligations",
              "value": "Incurrance of indebtedness could increase fixed payment obligations."
            },
            {
              "key": "Financing Impact on Operations",
              "value": "Financing terms may restrict operations or impact ability to conduct business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 15,
          "title": "Regulatory Funding Impact",
          "data": [
            {
              "key": "Government Agencies affected",
              "value": "FDA, SEC and others"
            },
            {
              "key": "Impact of inadequate funding",
              "value": "Hinders ability to hire and retain key personnel"
            },
            {
              "key": "Consequences of disruption",
              "value": "Slow review and approval of new products"
            },
            {
              "key": "Cumulative tax losses as of December 31, 2022",
              "value": "£84.6 million"
            },
            {
              "key": "R&D Tax Credit rate (before April 1, 2023)",
              "value": "Up to 33.35%"
            },
            {
              "key": "Post April 1, 2023 general R&D Tax Credit rate",
              "value": "18.6%"
            },
            {
              "key": "New R&D Tax Credit rate for intensive companies",
              "value": "Up to 26.97%"
            },
            {
              "key": "R&D intensive spending requirement",
              "value": "40% or more of total expenditure"
            },
            {
              "key": "Subcontracted R&D cash rebate rate (pre April 1, 2023)",
              "value": "Up to 21.68%"
            },
            {
              "key": "General rate for subcontracted R&D (post April 1, 2023)",
              "value": "12.09% or 17.53% if intensive"
            },
            {
              "key": "Cap on payable credit claims",
              "value": "£20,000 unless exempt"
            },
            {
              "key": "Changes to R&D tax regime post April 1, 2024",
              "value": "Introduces territoriality restriction"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 21,
          "title": "Risks in Clinical Development and Commercialization of Product Candidates",
          "data": [
            {
              "key": "Regulatory Approval Challenges",
              "value": "Clinical trials may not meet statistical significance required by FDA."
            },
            {
              "key": "High Failure Rates",
              "value": "Early clinical trials in the pharmaceutical sector carry a high risk of failure."
            },
            {
              "key": "Dependence on Future Clinical Outcomes",
              "value": "Preliminary data subject to change as trials progress."
            },
            {
              "key": "Lack of Marketable Products",
              "value": "Currently, no products have gained marketing approval."
            },
            {
              "key": "Financial Investment Risks",
              "value": "Significant investment is required before any revenues can be generated."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 80,
          "title": "Encouraging Efficacy Signals",
          "data": [
            {
              "key": "condition",
              "value": "Metastatic Melanoma"
            },
            {
              "key": "age",
              "value": "62 years"
            },
            {
              "key": "gender",
              "value": "female"
            },
            {
              "key": "prior_lines",
              "value": "2"
            },
            {
              "key": "treatment_history",
              "value": "nivolumab + ipilimumab: discontinued within 1 month, CK7 inhibitor: progressed at 1 month"
            },
            {
              "key": "nuc7738_details",
              "value": "starting_dose: 14 mg/m2, dose_escalations: 8, treatment_duration: 18 months, disease_status: Stable Disease 12 months, tumor_reduction: 14%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 83,
          "title": "Acelarin Clinical Trials Efficacy and Safety Overview",
          "data": [
            {
              "key": "Trial Name",
              "value": "Phase 1b clinical trial of Acelarin with carboplatin"
            },
            {
              "key": "Responders",
              "value": "1 complete response, 8 partial responses"
            },
            {
              "key": "Overall response rate",
              "value": "39% (22% confirmed)"
            },
            {
              "key": "Disease control rate",
              "value": "96% for evaluable patients"
            },
            {
              "key": "Median progression-free survival",
              "value": "6.2 months"
            },
            {
              "key": "Adverse events",
              "value": "Grade 3 neutropenia and thrombocytopenia 52% and 28% respectively"
            },
            {
              "key": "Other Toxicities",
              "value": "Transient increases in liver enzymes, Grade 4 decreases in platelets and neutrophils."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 89,
          "title": "Cardiff Agreement and Product Development Agreements",
          "data": [
            {
              "key": "Payments to Cardiff Consultants",
              "value": "Up to £1,875,000 in clinical development milestone payments for the first product in each nucleoside family."
            },
            {
              "key": "Royalty Payments for Products Developed",
              "value": "Royalties equal to a low-single digit percentage on sales of products resulting from research."
            },
            {
              "key": "Sublicense Payments",
              "value": "High-single digit percentage of payments received from sublicensees."
            },
            {
              "key": "ProTides Agreement",
              "value": "Involves $4.5 million in development and approval milestone payments for first product."
            },
            {
              "key": "Royalties on ProTides Products",
              "value": "Mid- to high-single digits on sales of products, with potential reductions."
            },
            {
              "key": "Termination Conditions",
              "value": "Licenses terminate upon breach unless due to certain breaches by Cardiff ProTides."
            },
            {
              "key": "Assignment Back upon Termination",
              "value": "Upon termination, patents assigned back to Cardiff ProTides."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Directors’ and Executive Officers’ Compensation",
          "data": [
            {
              "key": "year",
              "value": "2022"
            },
            {
              "key": "reporting_period",
              "value": "year ended December 31, 2022"
            },
            {
              "key": "departing_director",
              "value": "James Healy"
            },
            {
              "key": "departing_date",
              "value": "April 25, 2022"
            },
            {
              "key": "effectiveness_date",
              "value": "April 27, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 114,
          "title": "Executive and Non-Executive Director Compensation",
          "data": [
            {
              "key": "Name",
              "value": "Hugh Griffith"
            },
            {
              "key": "Position",
              "value": "Chief Executive Officer"
            },
            {
              "key": "Salary/Fees",
              "value": "551623"
            },
            {
              "key": "Annual Bonus",
              "value": "414331"
            },
            {
              "key": "Benefits Excluding Pension",
              "value": "3404"
            },
            {
              "key": "Pension Benefit",
              "value": "53119"
            },
            {
              "key": "Total",
              "value": "1022477"
            },
            {
              "key": "Name",
              "value": "Andrew Kay"
            },
            {
              "key": "Position",
              "value": "Chairman and Non-Executive Director"
            },
            {
              "key": "Salary/Fees",
              "value": "72061"
            },
            {
              "key": "Annual Bonus",
              "value": "0"
            },
            {
              "key": "Benefits Excluding Pension",
              "value": "0"
            },
            {
              "key": "Pension Benefit",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "72061"
            },
            {
              "key": "Name",
              "value": "James Healy"
            },
            {
              "key": "Position",
              "value": "Non-Executive Director"
            },
            {
              "key": "Salary/Fees",
              "value": "17026"
            },
            {
              "key": "Annual Bonus",
              "value": "0"
            },
            {
              "key": "Benefits Excluding Pension",
              "value": "0"
            },
            {
              "key": "Pension Benefit",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "17026"
            },
            {
              "key": "Name",
              "value": "Martin Mellish"
            },
            {
              "key": "Position",
              "value": "Non-Executive Director"
            },
            {
              "key": "Salary/Fees",
              "value": "44525"
            },
            {
              "key": "Annual Bonus",
              "value": "0"
            },
            {
              "key": "Benefits Excluding Pension",
              "value": "0"
            },
            {
              "key": "Pension Benefit",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "44525"
            },
            {
              "key": "Name",
              "value": "George"
            },
            {
              "key": "Position",
              "value": "Non-Executive Director"
            },
            {
              "key": "Salary/Fees",
              "value": "52670"
            },
            {
              "key": "Annual Bonus",
              "value": "0"
            },
            {
              "key": "Benefits Excluding Pension",
              "value": "0"
            },
            {
              "key": "Pension Benefit",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "52670"
            },
            {
              "key": "Name",
              "value": "Bali Muralidhar"
            },
            {
              "key": "Position",
              "value": "Non-Executive Director"
            },
            {
              "key": "Salary/Fees",
              "value": "29249"
            },
            {
              "key": "Annual Bonus",
              "value": "0"
            },
            {
              "key": "Benefits Excluding Pension",
              "value": "0"
            },
            {
              "key": "Pension Benefit",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "29249"
            },
            {
              "key": "Name",
              "value": "Elliott Levy"
            },
            {
              "key": "Position",
              "value": "Non-Executive Director"
            },
            {
              "key": "Salary/Fees",
              "value": "48276"
            },
            {
              "key": "Annual Bonus",
              "value": "0"
            },
            {
              "key": "Benefits Excluding Pension",
              "value": "0"
            },
            {
              "key": "Pension Benefit",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "48276"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Outstanding Equity Awards, Grants and Option Exercises",
          "data": [
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Options Granted",
              "value": "1,237,013 ordinary shares"
            },
            {
              "key": "Pension Contributions",
              "value": "£86,671"
            },
            {
              "key": "Directors and Officers Insurance",
              "value": "Maintained for indemnification against liabilities"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 116,
          "title": "Equity Compensation Plans",
          "data": [
            {
              "key": "Scheme Name",
              "value": "2009 Share Option Scheme"
            },
            {
              "key": "Date Adopted",
              "value": "August 1, 2009"
            },
            {
              "key": "Total Options Granted",
              "value": "1,032,500"
            },
            {
              "key": "Options Exercised",
              "value": "1,022,500"
            },
            {
              "key": "Options Lapsed",
              "value": "10,000"
            },
            {
              "key": "Tax Advantages",
              "value": "Enterprise management incentive options, unapproved options"
            },
            {
              "key": "Exercise Conditions",
              "value": "Vesting schedules, performance targets, other conditions"
            },
            {
              "key": "Key Events for Exercise",
              "value": "Admission to listing, change of control, sale of company"
            },
            {
              "key": "Lapse Period",
              "value": "10th anniversary of the grant of the option"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 117,
          "title": "Share Option Scheme",
          "data": [
            {
              "key": "option_holder_death",
              "value": "If an option holder dies, their representatives may exercise options for 12 months after death."
            },
            {
              "key": "share_capital_variation",
              "value": "Adjustments will be made by the board in the event of share capital variations."
            },
            {
              "key": "transferability",
              "value": "Options cannot be transferred or assigned."
            },
            {
              "key": "amendment",
              "value": "Directors may amend the scheme without prior shareholder approval."
            },
            {
              "key": "2012_Share_Option_Scheme",
              "value": "Adopted on July 3, 2012, for employee incentives."
            },
            {
              "key": "grants",
              "value": "1,908,935 options granted as of December 31, 2022."
            },
            {
              "key": "cancellation",
              "value": "112,688 options cancelled by December 31, 2022."
            },
            {
              "key": "options_exercised",
              "value": "Multiple years of exercised options ranging from 2016 to 2022."
            },
            {
              "key": "class_of_share",
              "value": "Entitles the holder to subscribe for ordinary shares."
            },
            {
              "key": "exercise_conditions",
              "value": "Options may have performance targets and vesting schedules."
            },
            {
              "key": "leaver_provisions",
              "value": "Options retained after ceasing employment unless dismissed for cause."
            },
            {
              "key": "lapse_of_options",
              "value": "Options lapse at 5 p.m. on the day before the 10th anniversary of grant."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 118,
          "title": "Options and Share Option Scheme",
          "data": [
            {
              "key": "Option Exercise Conditions",
              "value": "If an option holder dies, personal representatives may exercise options within 12 months after death, only if conditions are met."
            },
            {
              "key": "Takeovers and Corporate Events",
              "value": "Provisions for exercising options in case of company control changes, such as share acquisition offers."
            },
            {
              "key": "Adjustment of Awards",
              "value": "Adjustments to options in case of variation in share capital affecting the value of options."
            },
            {
              "key": "Transferability",
              "value": "Options cannot be transferred or assigned, will lapse upon attempts to do so."
            },
            {
              "key": "Amendment",
              "value": "The board may amend the Share Option Scheme but cannot increase liabilities or decrease rights without consent."
            },
            {
              "key": "2016 Share Option Scheme",
              "value": "Adopted January 14, 2016, allows share options grant to employees and directors, includes a U.S. Sub-Plan."
            },
            {
              "key": "Options Granted",
              "value": "As of December 31, 2022, 5,638,435 options granted, 92,312 exercised by December 31, 2018, 23,437 in 2019."
            },
            {
              "key": "Vesting Status",
              "value": "As of December 31, 2022, 3,540,448 vested, 757,081 forfeited or cancelled, 1,225,157 unvested."
            },
            {
              "key": "Class of Shares",
              "value": "Options entitle holders to subscribe for ordinary shares."
            },
            {
              "key": "Exercise Conditions",
              "value": "Options may have vesting schedules and performance targets."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 119,
          "title": "Share Option Scheme Guidelines",
          "data": [
            {
              "key": "eligible_employee",
              "value": "Holds options only while an eligible employee."
            },
            {
              "key": "material_reduction",
              "value": "Material reduction in base compensation impact relationship with plan."
            },
            {
              "key": "leaver_provisions",
              "value": "Options exercisable for 12 months after cessation under specified reasons."
            },
            {
              "key": "lapse_of_options",
              "value": "Options lapse after 10 years if not exercised."
            },
            {
              "key": "death_provisions",
              "value": "Options can be exercised by personal representatives within 12 months post-death."
            },
            {
              "key": "takeovers_and_corporate_events",
              "value": "Options may be exercised during significant company control changes."
            },
            {
              "key": "adjustment_of_awards",
              "value": "Adjustments by board per variation of share capital."
            },
            {
              "key": "transferability",
              "value": "Options cannot be transferred or charged."
            },
            {
              "key": "amendment",
              "value": "Board may amend scheme without option holder's consent unless affecting liabilities or rights."
            },
            {
              "key": "us_sub_plan",
              "value": "Applies to U.S. federal income tax grantees and adheres to Internal Revenue Code provisions."
            },
            {
              "key": "incentive_stock_options",
              "value": "Options must not be less than 100% of fair market value at grant."
            },
            {
              "key": "share_limit",
              "value": "5,008,284 ordinary shares available for incentive stock options."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 120,
          "title": "2020 Long Term Incentive Plan (2020 LTIP) Overview",
          "data": [
            {
              "key": "Plan Adoption Date",
              "value": "June 25, 2020"
            },
            {
              "key": "Total Regular Options Granted",
              "value": "5,859,381"
            },
            {
              "key": "Total RSU-style Options Granted",
              "value": "446,404"
            },
            {
              "key": "Options Exercised (2021)",
              "value": "27,440"
            },
            {
              "key": "Options Exercised (2022)",
              "value": "79,315"
            },
            {
              "key": "Total Vested Options",
              "value": "1,164,764"
            },
            {
              "key": "Total Forfeited or Cancelled Options",
              "value": "236,802"
            },
            {
              "key": "Total Unvested Options",
              "value": "4,797,464"
            },
            {
              "key": "Cash Alternative Provision",
              "value": "Yes"
            },
            {
              "key": "Vesting Conditions",
              "value": "Performance targets and other conditions required for exercise."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 121,
          "title": "2020 Company Share Option Plan (2020 CSOP) Overview",
          "data": [
            {
              "key": "Company",
              "value": "N/A"
            },
            {
              "key": "Plan Name",
              "value": "2020 CSOP"
            },
            {
              "key": "Adoption Date",
              "value": "June 25, 2020"
            },
            {
              "key": "Eligible Recipients",
              "value": "Full-time directors or employees"
            },
            {
              "key": "Maximum Award Limit",
              "value": "£30,000 (increasing to £60,000 from April 6, 2023)"
            },
            {
              "key": "Tax Advantages",
              "value": "Tax-advantaged scheme under Schedule 4 of the Income Tax (Earnings and Pensions) Act 2003"
            },
            {
              "key": "Options Granted",
              "value": "As of December 31, 2022, no options have been granted"
            },
            {
              "key": "Exercise Conditions",
              "value": "Must be exercised by the tenth anniversary of the grant or under specific takeover terms"
            },
            {
              "key": "Capital Gains Tax",
              "value": "No CGT on grant or exercise, CGT may apply on sale of shares after exercise"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 123,
          "title": "Executive Remuneration and Governance Committees",
          "data": [
            {
              "key": "Committee Members",
              "value": "Bali Muralidhar, Elliott Levy, Hugh Griffith, Andrew Kay, Cyrille Leperlier"
            },
            {
              "key": "Roles",
              "value": "Chair of Remuneration Committee, Chair of Nominating and Governance Committee, Chair of Development Committee"
            },
            {
              "key": "Responsibilities",
              "value": "Performance review of executive officers, setting scale and structure of remuneration, overseeing board performance, reviewing board structure and composition, advising on strategic direction and R&D investment."
            },
            {
              "key": "Policy",
              "value": "No individual participates in discussions concerning own remuneration."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 125,
          "title": "Beneficial Ownership of Ordinary Shares",
          "data": [
            {
              "key": "Greater than 5% Shareholders",
              "value": ""
            },
            {
              "key": "Entities affiliated with Sofinnova Investments",
              "value": "7999999 shares (15.3%)"
            },
            {
              "key": "Sofinnova Capital VI FCPR",
              "value": "4978993 shares (G5)"
            },
            {
              "key": "Baillie Gifford & Co",
              "value": "3659030 shares (7.0%)"
            },
            {
              "key": "Entities affiliated with the Carlyle Group and Abingworth LLP",
              "value": "3333333 shares (6.4%)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 125,
          "title": "Named Executive Officers and Directors",
          "data": [
            {
              "key": "Hugh Griffith",
              "value": "4794907 shares"
            },
            {
              "key": "Donald Munoz",
              "value": "929220 shares"
            },
            {
              "key": "Bali Muralidhar",
              "value": "3362337 shares"
            },
            {
              "key": "Martin Mellish",
              "value": "121664 shares"
            },
            {
              "key": "Elliott Levy",
              "value": "22500 shares"
            },
            {
              "key": "Adam George",
              "value": "96912 shares"
            },
            {
              "key": "Cyrille Leperlier",
              "value": "96914 shares"
            },
            {
              "key": "Andrew Kay",
              "value": "100000 shares"
            },
            {
              "key": "Jeffrey Bloss",
              "value": "100100 shares"
            },
            {
              "key": "David Harrison",
              "value": "109375 shares"
            },
            {
              "key": "Total for all Executive Officers and Directors",
              "value": "9733929 shares"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 127,
          "title": "Executive Stock Options and Related Party Transactions",
          "data": [
            {
              "key": "Options to purchase ordinary shares (total)",
              "value": "425,701"
            },
            {
              "key": "Volume of options exercisable within 60 days of December 31, 2022",
              "value": "Yes"
            },
            {
              "key": "Indemnification Agreements",
              "value": "Executed with executive officers and directors"
            },
            {
              "key": "Agreements with affiliates",
              "value": "CFGI, LLC and Curia Global, Inc."
            },
            {
              "key": "Related Person Transaction Policy",
              "value": "Approved by audit committee or independent body"
            },
            {
              "key": "Major shareholders voting rights",
              "value": "Uniform among holders"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 133,
          "title": "Capital Variations and Board of Directors",
          "data": [
            {
              "key": "Capital Variation Policies",
              "value": "We may, by ordinary resolution, consolidate and divide all or any of our share capital into shares of a larger nominal amount or sub-divide our shares into shares of a smaller nominal amount."
            },
            {
              "key": "Pre-emption Rights Information",
              "value": "No pre-emption rights under the articles of association; shareholders may have statutory pre-emption rights under the Companies Act 2006 regarding new shares."
            },
            {
              "key": "Directors Overview",
              "value": "Number of directors not subject to maximum; minimum of two."
            },
            {
              "key": "Classified Board Structure",
              "value": "Board divided into three classes with directors serving staggered terms."
            },
            {
              "key": "Borrowing Powers",
              "value": "The board may borrow money, mortgage or charge assets, and issue debentures."
            },
            {
              "key": "Directors’ Interests and Restrictions",
              "value": "Board may authorize conflicts of interest; directors not accountable for benefits from authorized relationships."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 134,
          "title": "Director's Rights and Remuneration",
          "data": [
            {
              "key": "Voting Entitlement",
              "value": "A director can vote on resolutions concerning guarantees, securities, indemnities, and proposals related to shares if they have no material interest."
            },
            {
              "key": "Director's Fees",
              "value": "Directors may receive fees paid from company funds, determined by the board."
            },
            {
              "key": "Additional Remuneration",
              "value": "Directors in employment or performing additional services may receive extra pay determined by the board."
            },
            {
              "key": "Travel Expenses",
              "value": "Directors are entitled to reimbursement for reasonable travel and related expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 135,
          "title": "Pensions and Other Benefits",
          "data": [
            {
              "key": "Overview",
              "value": "The board of directors may exercise all powers to provide benefits, such as gratuities or pensions, for any director, former director, or employees."
            },
            {
              "key": "Appointment of Directors",
              "value": "The board can appoint any willing person to be a director, with conditions for re-election."
            },
            {
              "key": "Indemnity of Officers",
              "value": "Directors and officers may be indemnified against costs incurred in executing their duties."
            },
            {
              "key": "General Meetings",
              "value": "Annual general meetings of shareholders are mandatory, with specified conditions for calling general meetings."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 155,
          "title": "ADS Holder Responsibilities and Charges",
          "data": [
            {
              "key": "fees and charges responsibility",
              "value": "ADS holders are responsible for paying taxes, registration fees for ordinary shares, transmission and delivery expenses, compliance with regulations, and servicing of deposited property."
            },
            {
              "key": "ADS fees upon issuance and cancellation",
              "value": "Fees are charged to the person to whom the ADSs are issued or cancelled."
            },
            {
              "key": "DTC fees and charges",
              "value": "Fees may be deducted from distributions made through DTC and charged to DTC participants."
            },
            {
              "key": "fees for distributions",
              "value": "ADS fees for cash distributions are deducted from funds distributed, while non-cash distributions may result in invoicing."
            },
            {
              "key": "refusal to pay fees",
              "value": "Depositary may refuse services until fees are paid or set off from distributions."
            },
            {
              "key": "change in fees",
              "value": "Fees may vary over time and ADS holders will be notified of changes."
            },
            {
              "key": "reimbursement terms",
              "value": "Depositary may reimburse issuer for expenses incurred in regard to the ADR program."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 157,
          "title": "Audit and Audit-Related Fees Comparison 2022-2021",
          "data": [
            {
              "key": "Audit Fees 2022",
              "value": "407"
            },
            {
              "key": "Audit Fees 2021",
              "value": "295"
            },
            {
              "key": "Audit-Related Fees 2022",
              "value": "128"
            },
            {
              "key": "Audit-Related Fees 2021",
              "value": "193"
            },
            {
              "key": "Total 2022",
              "value": "535"
            },
            {
              "key": "Total 2021",
              "value": "488"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 161,
          "title": "Exhibit Index from SEC Filing",
          "data": [
            {
              "key": "Item Number",
              "value": "4.14#"
            },
            {
              "key": "Description",
              "value": "Form of Deed of Indemnity for directors and officers"
            },
            {
              "key": "Form Type",
              "value": "Form F-1/A"
            },
            {
              "key": "Filing Number",
              "value": "333-2220321"
            },
            {
              "key": "Exhibit",
              "value": "10.10"
            },
            {
              "key": "Date",
              "value": "09/18/2017"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 161,
          "title": "Exhibit Index from SEC Filing",
          "data": [
            {
              "key": "Item Number",
              "value": "4.15"
            },
            {
              "key": "Description",
              "value": "Description of securities of the registrant Minute of Variation between the registrant and Custodian REIT"
            },
            {
              "key": "Form Type",
              "value": "Form 20-F"
            },
            {
              "key": "Filing Number",
              "value": "001-38215"
            },
            {
              "key": "Exhibit",
              "value": "4.14"
            },
            {
              "key": "Date",
              "value": "03/10/2020"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 161,
          "title": "Exhibit Index from SEC Filing",
          "data": [
            {
              "key": "Item Number",
              "value": "12.1*"
            },
            {
              "key": "Description",
              "value": "Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002."
            },
            {
              "key": "Form Type",
              "value": ""
            },
            {
              "key": "Filing Number",
              "value": ""
            },
            {
              "key": "Exhibit",
              "value": ""
            },
            {
              "key": "Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 161,
          "title": "Exhibit Index from SEC Filing",
          "data": [
            {
              "key": "Item Number",
              "value": "12.2*"
            },
            {
              "key": "Description",
              "value": "Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002."
            },
            {
              "key": "Form Type",
              "value": ""
            },
            {
              "key": "Filing Number",
              "value": ""
            },
            {
              "key": "Exhibit",
              "value": ""
            },
            {
              "key": "Date",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 164,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Company",
              "value": "NuCana plc"
            },
            {
              "key": "Report Type",
              "value": "Independent Auditors' Report"
            },
            {
              "key": "Opinion",
              "value": "The consolidated financial statements present fairly the financial position"
            },
            {
              "key": "Date",
              "value": "December 31, 2022 and 2021"
            },
            {
              "key": "Audit Standards",
              "value": "PCAOB standards"
            },
            {
              "key": "Internal Control",
              "value": "The audit is not an audit of internal control over financial reporting."
            },
            {
              "key": "Critical Audit Matter",
              "value": "A matter arising from the audit that was communicated to the audit committee."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 180,
          "title": "Directors’ remuneration & other benefits",
          "data": [
            {
              "key": "Directors' remuneration",
              "value": "£1,290K"
            },
            {
              "key": "Pension and other benefits",
              "value": "£57K"
            },
            {
              "key": "Total",
              "value": "£1,347K"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 180,
          "title": "Personnel Expenses Breakdown",
          "data": [
            {
              "key": "Wages and salaries (2022)",
              "value": "£4,893K"
            },
            {
              "key": "Wages and salaries (2021)",
              "value": "£3,931K"
            },
            {
              "key": "Wages and salaries (2020)",
              "value": "£3,492K"
            },
            {
              "key": "Social security costs (2022)",
              "value": "£569K"
            },
            {
              "key": "Social security costs (2021)",
              "value": "£465K"
            },
            {
              "key": "Social security costs (2020)",
              "value": "£430K"
            },
            {
              "key": "Pension costs (2022)",
              "value": "£213K"
            },
            {
              "key": "Pension costs (2021)",
              "value": "£189K"
            },
            {
              "key": "Pension costs (2020)",
              "value": "£189K"
            },
            {
              "key": "Share-based payments (2022)",
              "value": "£3,125K"
            },
            {
              "key": "Share-based payments (2021)",
              "value": "£3,833K"
            },
            {
              "key": "Share-based payments (2020)",
              "value": "£2,412K"
            },
            {
              "key": "Total (2022)",
              "value": "£8,800K"
            },
            {
              "key": "Total (2021)",
              "value": "£8,418K"
            },
            {
              "key": "Total (2020)",
              "value": "£6,523K"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 180,
          "title": "Employee Benefit Expenses",
          "data": [
            {
              "key": "Subtotal (2022)",
              "value": "£3,553K"
            },
            {
              "key": "Subtotal (2021)",
              "value": "£4,414K"
            },
            {
              "key": "Subtotal (2020)",
              "value": "£3,462K"
            },
            {
              "key": "Total employee benefit expense (2022)",
              "value": "£12,353K"
            },
            {
              "key": "Total employee benefit expense (2021)",
              "value": "£12,832K"
            },
            {
              "key": "Total employee benefit expense (2020)",
              "value": "£9,985K"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 181,
          "title": "Directors' Compensation Overview",
          "data": [
            {
              "key": "Directors' remuneration (2022)",
              "value": "£966,000"
            },
            {
              "key": "Directors' remuneration (2021)",
              "value": "£850,000"
            },
            {
              "key": "Directors' remuneration (2020)",
              "value": "£861,000"
            },
            {
              "key": "Pension and other benefits (2022)",
              "value": "£57,000"
            },
            {
              "key": "Pension and other benefits (2021)",
              "value": "£57,000"
            },
            {
              "key": "Pension and other benefits (2020)",
              "value": "£59,000"
            },
            {
              "key": "Total compensation (2022)",
              "value": "£1,023,000"
            },
            {
              "key": "Total compensation (2021)",
              "value": "£907,000"
            },
            {
              "key": "Total compensation (2020)",
              "value": "£920,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 181,
          "title": "Loss and Share Data Analysis",
          "data": [
            {
              "key": "Loss per share (2022)",
              "value": "(0.61)"
            },
            {
              "key": "Loss per share (2021)",
              "value": "(0.78)"
            },
            {
              "key": "Loss per share (2020)",
              "value": "(0.81)"
            },
            {
              "key": "Weighted average shares (2022)",
              "value": "52,235,000"
            },
            {
              "key": "Weighted average shares (2021)",
              "value": "52,041,000"
            },
            {
              "key": "Weighted average shares (2020)",
              "value": "37,882,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 191,
          "title": "Share-based payments",
          "data": [
            {
              "key": "Payment Plans",
              "value": "The Company has six share-based payment plans for employees, directors and consultants."
            },
            {
              "key": "Settlement Method",
              "value": "The share options granted under these plans will be settled in equity."
            },
            {
              "key": "Maximum Life of Options",
              "value": "10 years"
            },
            {
              "key": "2020 Options",
              "value": "Share options granted under U.K. share-based payment plans will vest if the option holder remains under their respective contract of employment or contract of service for the agreed vesting period."
            },
            {
              "key": "Vesting Period for 2020 Options",
              "value": "4 years"
            },
            {
              "key": "Purchase Option upon Vesting",
              "value": "Each option allows the holder to purchase one ordinary share at a specified option price determined at grant date."
            },
            {
              "key": "2020 Long-Term Incentive Plan",
              "value": "Options granted under this plan will vest if the option holder remains under their respective contract."
            },
            {
              "key": "RSU-style option exercise",
              "value": "Automatically exercised on vesting."
            },
            {
              "key": "Cash alternative provision",
              "value": "An arrangement may be made under the 2020 Long-Term Incentive Plan to substitute the right to acquire shares with a cash alternative of equivalent value."
            },
            {
              "key": "2021 Options",
              "value": "Share options were granted under the 2020 Long-Term Incentive Plan."
            },
            {
              "key": "2022 Options",
              "value": "Share options were granted under the 2020 Long-Term Incentive Plan."
            },
            {
              "key": "Vesting Conditions for 2021 and 2022 Options",
              "value": "Same as the 2020 options."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 192,
          "title": "Share Options Movement and Exercise Price Summary",
          "data": [
            {
              "key": "Outstanding at January 1, 2020",
              "value": "5298840 shares at average exercise price £3.91"
            },
            {
              "key": "Granted",
              "value": "2665639 shares at average exercise price £4.03"
            },
            {
              "key": "Forfeited",
              "value": "192750 shares at average exercise price £10.89"
            },
            {
              "key": "Lapsed",
              "value": "14438 shares at average exercise price £7.42"
            },
            {
              "key": "Exercised",
              "value": "32500 shares at average exercise price £0.45"
            },
            {
              "key": "Outstanding at December 31, 2020",
              "value": "7724791 shares at average exercise price £3.78"
            },
            {
              "key": "Granted",
              "value": "4329913 shares at average exercise price £1.91"
            },
            {
              "key": "Forfeited",
              "value": "193949 shares at average exercise price £5.26"
            },
            {
              "key": "Lapsed",
              "value": "42750 shares at average exercise price £11.21"
            },
            {
              "key": "Exercised",
              "value": "1014939 shares at average exercise price £0.20"
            },
            {
              "key": "Outstanding at December 31, 2021",
              "value": "10803066 shares at average exercise price £3.32"
            },
            {
              "key": "Granted",
              "value": "1497013 shares at average exercise price £0.39"
            },
            {
              "key": "Forfeited",
              "value": "207833 shares at average exercise price £2.83"
            },
            {
              "key": "Lapsed",
              "value": "151350 shares at average exercise price £8.40"
            },
            {
              "key": "Exercised",
              "value": "219220 shares at average exercise price £0.30"
            },
            {
              "key": "Outstanding at December 31, 2022",
              "value": "11721676 shares at average exercise price £2.94"
            },
            {
              "key": "Vested and exercisable at December 31, 2022",
              "value": "5686556 shares at average exercise price £3.63"
            },
            {
              "key": "Vested and exercisable at December 31, 2021",
              "value": "4138803 shares at average exercise price £3.51"
            },
            {
              "key": "Vested and exercisable at December 31, 2020",
              "value": "4176281 shares at average exercise price £2.07"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "Share-based Payments - 2020 Stock Option Grants",
          "data": [
            {
              "key": "grant_date",
              "value": "June 10, 2020"
            },
            {
              "key": "vesting_dates",
              "value": "June 10, 2021, June 10, 2022, June 10, 2023, June 10, 2024"
            },
            {
              "key": "volatility",
              "value": "76.59%"
            },
            {
              "key": "dividend_yield",
              "value": "0%"
            },
            {
              "key": "risk_free_rate",
              "value": "0.003%"
            },
            {
              "key": "option_fair_value",
              "value": "£2.76"
            },
            {
              "key": "share_fair_value",
              "value": "£4.78"
            },
            {
              "key": "exercise_price",
              "value": "£4.78"
            },
            {
              "key": "lapse_date",
              "value": "June 10, 2030"
            },
            {
              "key": "expected_life",
              "value": "4.50"
            },
            {
              "key": "options_granted",
              "value": "2,186,780"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "Share-based Payments - 2020 Stock Option Grants",
          "data": [
            {
              "key": "grant_date",
              "value": "Sept 9, 2020"
            },
            {
              "key": "vesting_dates",
              "value": "Sept 9, 2021, Sept 9, 2022, Sept 9, 2023, Sept 9, 2024"
            },
            {
              "key": "volatility",
              "value": "82.98%"
            },
            {
              "key": "dividend_yield",
              "value": "0%"
            },
            {
              "key": "risk_free_rate",
              "value": "-0.08%"
            },
            {
              "key": "option_fair_value",
              "value": "£424"
            },
            {
              "key": "share_fair_value",
              "value": "£428"
            },
            {
              "key": "exercise_price",
              "value": "£0.04"
            },
            {
              "key": "lapse_date",
              "value": "Sept 9, 2030"
            },
            {
              "key": "expected_life",
              "value": "3.50"
            },
            {
              "key": "options_granted",
              "value": "290,356"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "Share-based Payments - 2020 Stock Option Grants",
          "data": [
            {
              "key": "grant_date",
              "value": "Sept 9, 2020"
            },
            {
              "key": "vesting_dates",
              "value": "Sept 9, 2021, Sept 9, 2022, Sept 9, 2023, Sept 9, 2024"
            },
            {
              "key": "volatility",
              "value": "87.21%"
            },
            {
              "key": "dividend_yield",
              "value": "0%"
            },
            {
              "key": "risk_free_rate",
              "value": "-0.08%"
            },
            {
              "key": "option_fair_value",
              "value": "£424"
            },
            {
              "key": "share_fair_value",
              "value": "£428"
            },
            {
              "key": "exercise_price",
              "value": "£0.04"
            },
            {
              "key": "lapse_date",
              "value": "—"
            },
            {
              "key": "expected_life",
              "value": "2.50"
            },
            {
              "key": "options_granted",
              "value": "108,503"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "Share-based Payments - 2020 Stock Option Grants",
          "data": [
            {
              "key": "grant_date",
              "value": "Dec 9, 2020"
            },
            {
              "key": "vesting_dates",
              "value": "Dec 9, 2021, Dec 9, 2022, Dec 9, 2023, Dec 9, 2024"
            },
            {
              "key": "volatility",
              "value": "81.269%"
            },
            {
              "key": "dividend_yield",
              "value": "0%"
            },
            {
              "key": "risk_free_rate",
              "value": "-0.03%"
            },
            {
              "key": "option_fair_value",
              "value": "£2.10"
            },
            {
              "key": "share_fair_value",
              "value": "£3.48"
            },
            {
              "key": "exercise_price",
              "value": "£3.48"
            },
            {
              "key": "lapse_date",
              "value": "Dec 9, 2030"
            },
            {
              "key": "expected_life",
              "value": "4.50"
            },
            {
              "key": "options_granted",
              "value": "80,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 194,
          "title": "Share-based payments",
          "data": [
            {
              "key": "Vesting dates",
              "value": "Jan 13, 2021; Feb 10, 2021"
            },
            {
              "key": "Volatility",
              "value": "81.42%; 87.66%; 81.459%"
            },
            {
              "key": "Dividend yield",
              "value": "0%; 0%; 0%"
            },
            {
              "key": "Risk-free investment rate",
              "value": "0.01%; 0.01%; 0.119%"
            },
            {
              "key": "Fair value of option at grant date",
              "value": "£2.37; £449; £2.74"
            },
            {
              "key": "Fair value of share at grant date",
              "value": "£3.92; £453; £4.53"
            },
            {
              "key": "Exercise price at date of grant",
              "value": "£3.92; £0.04; £4.53"
            },
            {
              "key": "Lapse date",
              "value": "Jan 13, 2031; _; Feb 10, 2031"
            },
            {
              "key": "Expected option life (years)",
              "value": "4.50; 2.50; 4.50"
            },
            {
              "key": "Number of options granted",
              "value": "200,000; 91,888; 872,775"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 195,
          "title": "Share-based payments",
          "data": [
            {
              "key": "Employee remuneration expense",
              "value": "£6.7 million"
            },
            {
              "key": "Equity-settled share-based payments",
              "value": "£4.3 million"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 195,
          "title": "Stock Option Grant Parameters",
          "data": [
            {
              "key": "Vesting dates",
              "value": "Mar 9, 2022/2023/2024/2025/2026"
            },
            {
              "key": "Volatility",
              "value": "89.32% (2021) vs 95.70% (2022)"
            },
            {
              "key": "Dividend yield",
              "value": "0%"
            },
            {
              "key": "Risk-free investment rate",
              "value": "1.36% - 1.37%"
            },
            {
              "key": "Fair value of option at grant date",
              "value": "£0.37 vs £0.53"
            },
            {
              "key": "Fair value of share at grant date",
              "value": "£0.56"
            },
            {
              "key": "Exercise price at date of grant",
              "value": "£0.56 vs £0.04"
            },
            {
              "key": "Lapse date",
              "value": "Mar 9, 2032"
            },
            {
              "key": "Expected option life (years)",
              "value": "4.50 vs 3.50"
            },
            {
              "key": "Number of options granted",
              "value": "1,020,925 vs 95,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 195,
          "title": "Share Options Details",
          "data": [
            {
              "key": "Vesting dates",
              "value": "Jul 12, 2024 to Jul 12, 2026"
            },
            {
              "key": "Volatility",
              "value": "94.05% and 103.18%"
            },
            {
              "key": "Dividend yield",
              "value": "0%"
            },
            {
              "key": "Risk-free investment rate",
              "value": "1.76% and 1.79%"
            },
            {
              "key": "Fair value of option at grant date",
              "value": "£0.64"
            },
            {
              "key": "Fair value of share at grant date",
              "value": "£0.67"
            },
            {
              "key": "Exercise price at date of grant",
              "value": "£0.04"
            },
            {
              "key": "Lapse date",
              "value": "Jul 12, 2032"
            },
            {
              "key": "Expected option life (years)",
              "value": "3.50 and 2.50"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 196,
          "title": "Share-based payments and employee remuneration expense",
          "data": [
            {
              "key": "Employee remuneration expense (2022)",
              "value": "£4.9 million"
            },
            {
              "key": "Employee remuneration expense (2021)",
              "value": "£6.7 million"
            },
            {
              "key": "Employee remuneration expense (2020)",
              "value": "£4.3 million"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 196,
          "title": "Liability Movement and Classification Statement",
          "data": [
            {
              "key": "Liability at January 1 (2022)",
              "value": "£371,000"
            },
            {
              "key": "Liability at January 1 (2021)",
              "value": "£645,000"
            },
            {
              "key": "Re-measurement of liability",
              "value": "£480,000"
            },
            {
              "key": "Payments",
              "value": "£227,000"
            },
            {
              "key": "Liability at December 31 (2022)",
              "value": "£639,000"
            },
            {
              "key": "Current liability (2022)",
              "value": "£243,000"
            },
            {
              "key": "Non-current liability (2022)",
              "value": "£396,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 196,
          "title": "Contractual undiscounted payments",
          "data": [
            {
              "key": "Total contractual undiscounted payments (2022)",
              "value": "£701,000"
            },
            {
              "key": "Total contractual undiscounted payments (2021)",
              "value": "£385,000"
            },
            {
              "key": "Discounted lease liabilities (2022)",
              "value": "£639,000"
            },
            {
              "key": "Discounted lease liabilities (2021)",
              "value": "£371,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 197,
          "title": "Employee Benefits and Compensation Summary",
          "data": [
            {
              "key": "Short-term employee benefits",
              "value": "2,770"
            },
            {
              "key": "Pension and other benefits",
              "value": "135"
            },
            {
              "key": "Share-based payments",
              "value": "4,255"
            },
            {
              "key": "Total",
              "value": "7,160"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 197,
          "title": "Lease Expenses Analysis",
          "data": [
            {
              "key": "Depreciation expense of right of use assets",
              "value": "251"
            },
            {
              "key": "Interest expense on lease liabilities (included in administrative expenses)",
              "value": "21"
            },
            {
              "key": "Total amount recognized in statements of operations",
              "value": "272"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 197,
          "title": "Extension Options Not Expected to be Exercised",
          "data": [
            {
              "key": "Not later than 5 years",
              "value": "256"
            },
            {
              "key": "Later than 5 years",
              "value": "—"
            },
            {
              "key": "Total",
              "value": "256"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "executive_compensation",
          "page": 212,
          "title": "Minute of Variation",
          "data": [
            {
              "key": "Third Party Rights",
              "value": "This Minute of Variation does not create any rights in favour of third parties under the Contract (Third Party Rights) (Scotland) Act 2017."
            },
            {
              "key": "Registration",
              "value": "The Parties consent to registration of this Minute of Variation for preservation and execution."
            },
            {
              "key": "Execution Date",
              "value": "16 NOVEMBER 2020."
            },
            {
              "key": "Signing Parties",
              "value": "FOR AND ON BEHALF OF THE SAID CUSTODIAN REIT PLC BY CUSTODIAN CAPITAL LIMITED, ATTORNEY."
            },
            {
              "key": "Witness Signatures",
              "value": "signature of witness, signature of director/authorised signatory."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 218,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Reporting Firm",
              "value": "Ernst & Young LLP"
            },
            {
              "key": "Location",
              "value": "Edinburgh, United Kingdom"
            },
            {
              "key": "Report Date",
              "value": "April 4, 2023"
            },
            {
              "key": "Related Registration Statements",
              "value": "(1) Registration Statement (Form F-3 No. 333-258941)\n(2) Registration Statement (Form S-8 No. 333-223476)\n(3) Registration Statement (Form S-8 No. 333-248135)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 16,
          "title": "Research and Development Tax Relief",
          "data": [
            {
              "key": "New Tax Relief Regime",
              "value": "Introduction of a new single research and development tax relief regime."
            },
            {
              "key": "Impact of Changes",
              "value": "Reforms may affect ability to claim relief in the future."
            },
            {
              "key": "Future Compliance",
              "value": "May not be able to claim payable research and development tax credits."
            },
            {
              "key": "Patent Box Regime",
              "value": "UK’s patent box regime allows profits from patented products to be taxed at 10%."
            },
            {
              "key": "Tax Liability Risks",
              "value": "Tax authorities may challenge income allocation and tax positions."
            },
            {
              "key": "Tax Compliance Costs",
              "value": "Contesting tax assessments may be expensive and lengthy."
            },
            {
              "key": "International Tax Risks",
              "value": "Business may face risks from international operations and differing jurisdictions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 70,
          "title": "NUC-3373 Overview",
          "data": [
            {
              "key": "drug_approvals",
              "value": "Fluorodeoxyuridine (FUDR), Capecitabine (Xeloda) - approved for cancer treatment"
            },
            {
              "key": "active_metabolite",
              "value": "5-FU aims to generate FUDR-MP, an active metabolite that inhibits TS enzyme"
            },
            {
              "key": "clinical_trials",
              "value": "NUC-3373 evaluated in Phase 1 (NuTide:301), currently in Phase 1b/2 (NuTide:302) for colorectal cancer"
            },
            {
              "key": "limitations_of_5-FU",
              "value": "Breakdown by DPD, requires transporters, inefficient metabolic pathways, poor pharmacokinetics"
            },
            {
              "key": "side_effects",
              "value": "Hand-foot syndrome, dose limiting toxicities (diarrhea, mucositis, neutropenia) associated with 5-FU"
            },
            {
              "key": "solution_offered_by_NUC-3373",
              "value": "Protected form of FUDR-MP designed to overcome limitations of fluoropyrimidines"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 73,
          "title": "NUC-3373 Clinical Data",
          "data": [
            {
              "key": "Trial Phase",
              "value": "Phase 1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 106,
          "title": "Research and Development Expenses",
          "data": [
            {
              "key": "Research and development expenses 2022",
              "value": "£36.4 million"
            },
            {
              "key": "Research and development expenses 2021",
              "value": "£36.8 million"
            },
            {
              "key": "Decrease in expenses",
              "value": "£0.4 million"
            },
            {
              "key": "Clinical trials expenses 2022",
              "value": "£16.5 million"
            },
            {
              "key": "Clinical trials expenses 2021",
              "value": "£20.4 million"
            },
            {
              "key": "Decrease in clinical trials expenses",
              "value": "£3.9 million"
            },
            {
              "key": "Manufacturing costs 2022",
              "value": "£2.2 million"
            },
            {
              "key": "Manufacturing costs 2021",
              "value": "£3.3 million"
            },
            {
              "key": "Decrease in manufacturing costs",
              "value": "£1.1 million"
            },
            {
              "key": "Patent costs increase 2022",
              "value": "£5.1 million"
            },
            {
              "key": "Total provisions recognized 2022",
              "value": "£4.1 million"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 106,
          "title": "Program Expenditure Comparison 2022-2021",
          "data": [
            {
              "key": "NUC-3373 2022",
              "value": "£12,045"
            },
            {
              "key": "NUC-3373 2021",
              "value": "£7,303"
            },
            {
              "key": "NUC-7738 2022",
              "value": "£3,711"
            },
            {
              "key": "NUC-7738 2021",
              "value": "£4,029"
            },
            {
              "key": "Acelarin 2022",
              "value": "£19,315"
            },
            {
              "key": "Acelarin 2021",
              "value": "£22,800"
            },
            {
              "key": "Other 2022",
              "value": "£1,355"
            },
            {
              "key": "Other 2021",
              "value": "£2,702"
            },
            {
              "key": "Total expenditure 2022",
              "value": "£36,426"
            },
            {
              "key": "Total expenditure 2021",
              "value": "£36,834"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 11,
          "title": "Product Development and Regulatory Approval Challenges",
          "data": [
            {
              "key": "Product Candidates",
              "value": "NUC-3373, NUC-7738"
            },
            {
              "key": "Regulatory Approval Status",
              "value": "Not yet submitted New Drug Application (NDA) or Marketing Authorization Application (MAA)"
            },
            {
              "key": "Revenue Generation",
              "value": "Currently generating no revenues from product sales"
            },
            {
              "key": "Investment Focus",
              "value": "Substantially all efforts and financial resources invested in development of product candidates"
            },
            {
              "key": "Expected Timeframe for Revenue",
              "value": "Not expected to occur for at least several years, if ever"
            },
            {
              "key": "Key Challenges",
              "value": "Requirement for successful clinical trials, regulatory approval, and significant marketing efforts"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 12,
          "title": "Product Candidate Challenges and Regulatory Approval Process",
          "data": [
            {
              "key": "product_candidates",
              "value": "NUC-3373, NUC-7738"
            },
            {
              "key": "regulatory_issues",
              "value": "Challenges in obtaining regulatory approval in multiple jurisdictions."
            },
            {
              "key": "clinical_trials",
              "value": "Potential need for additional studies due to administration challenges."
            },
            {
              "key": "commercialization_risks",
              "value": "Risks associated with third-party partnerships and commercial viability."
            },
            {
              "key": "accelerated_approval",
              "value": "Possibility of accelerated approval by FDA for serious or life-threatening illnesses."
            },
            {
              "key": "market_size_risks",
              "value": "Dependence on accurate market size estimates for revenue generation."
            },
            {
              "key": "intellectual_property",
              "value": "Potential infringements and the need to defend patents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 22,
          "title": "Product Development Challenges and Clinical Trials",
          "data": [
            {
              "key": "development_factors",
              "value": "robust sales, distribution and marketing capabilities"
            },
            {
              "key": "commercialization_risks",
              "value": "delays or inability to commercialize product candidates"
            },
            {
              "key": "clinical_trial_enrollment",
              "value": "critical to success, affected by disease severity, patient population, eligibility criteria, perceived risks, competing therapies"
            },
            {
              "key": "impact_of_COVID-19",
              "value": "potential delays in clinical trials"
            },
            {
              "key": "uncertainty_in_clinical_trials",
              "value": "high risk of failure, lengthy and expensive process"
            },
            {
              "key": "marketing_approval_requirements",
              "value": "complete preclinical development and clinical trials required"
            },
            {
              "key": "current_trials",
              "value": "NUC-3373 in Phase 1b/2 and Phase 2 trials, NUC-7738 in Phase 2 of Phase 1/2 trial"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 38,
          "title": "Collaboration and License Agreements",
          "data": [
            {
              "key": "Expiration of Cardiff Agreement",
              "value": "The research and license agreement with Cardiff University and Cardiff Consultants expired on December 31, 2021."
            },
            {
              "key": "Extension of License",
              "value": "An extension of the license for ProTide-related intellectual property was exercised for a period of three months."
            },
            {
              "key": "Consequences of Expiration",
              "value": "Expiration may result in reduced ability to identify and develop additional ProTides."
            },
            {
              "key": "Risks in Collaborations",
              "value": "Collaborators have discretion over efforts and resources, which may lead to unfulfilled obligations or abandoned projects."
            },
            {
              "key": "Competition Risk",
              "value": "Collaborators may develop competing products or cease to devote resources to the commercialization of product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 39,
          "title": "Risks Related to the Commercialization of Our Product Candidates",
          "data": [
            {
              "key": "intellectual_property_risks",
              "value": "Collaborators may not properly maintain or defend intellectual property rights."
            },
            {
              "key": "litigation_risks",
              "value": "Collaborators may expose us to potential litigation regarding ownership of intellectual property."
            },
            {
              "key": "collaboration_risks",
              "value": "Termination of collaborations may require additional capital for product development."
            },
            {
              "key": "commercial_success_risks",
              "value": "Product candidates may fail to achieve market acceptance."
            },
            {
              "key": "obligation_risks",
              "value": "Failure to comply with agreements can lead to loss of rights to intellectual property."
            },
            {
              "key": "Cardiff_ProTides_agreement",
              "value": "Exclusive agreement imposes various obligations including milestone payments and royalty payments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 40,
          "title": "Market Acceptance of Product Candidates",
          "data": [
            {
              "key": "Key Factors for Market Acceptance",
              "value": "The timing of marketing approvals, terms of approvals, countries of approval, efficacy and safety compared to alternative treatments, prevalence and severity of side effects, indications approved, publicity regarding products, competitive product approvals, pricing, convenience of administration, patient willingness and physician prescription tendencies, success of education programs, strength of marketing and distribution, reimbursement availability, and restrictions on combined use."
            },
            {
              "key": "Competition",
              "value": "Substantial competition from major pharmaceutical companies, biotechnology companies and academic institutions developing treatments for cancer, including chemotherapies, targeted therapies and immunotherapies."
            },
            {
              "key": "Commercial Opportunity Threats",
              "value": "Reduced opportunity if competitors develop safer, more effective, convenient or less expensive products or if they obtain approvals faster than us."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 41,
          "title": "Pricing and Reimbursement Challenges for Product Candidates",
          "data": [
            {
              "key": "Key Considerations",
              "value": "Efficacy, safety, convenience, and price of product candidates are critical factors in their approval and market competitiveness."
            },
            {
              "key": "Competitive Landscape",
              "value": "Major competitors possess greater financial resources and expertise in R&D and marketing, posing significant challenges for smaller firms."
            },
            {
              "key": "Regulatory Environment",
              "value": "Varying regulations across countries affect pricing approvals and reimbursement, potentially delaying product launches."
            },
            {
              "key": "Cost Containment Trends",
              "value": "U.S. and global payors are controlling drug costs through limited coverage and payments, impacting profitability."
            },
            {
              "key": "Reimbursement Challenges",
              "value": "Difficulties in obtaining consistent reimbursement levels can hinder commercialization efforts."
            },
            {
              "key": "Market Dynamics",
              "value": "Third-party payors are increasingly demanding discounts, affecting drug pricing strategies."
            },
            {
              "key": "Economic Studies",
              "value": "Expensive pharmacoeconomic studies may be needed to demonstrate cost-effectiveness for reimbursement."
            },
            {
              "key": "Impact of Approval on Sales",
              "value": "Approval does not guarantee market success due to potential reimbursement limitations."
            },
            {
              "key": "Variability of Payments",
              "value": "Reimbursement rates may vary significantly based on usage context and existing benchmarks."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 42,
          "title": "Commercialization and Sales Forces",
          "data": [
            {
              "key": "Challenges in Marketing and Sales",
              "value": "We currently have no marketing capability or sales force."
            },
            {
              "key": "Future Plans",
              "value": "Intend to commercialize or participate in the commercialization of product candidates."
            },
            {
              "key": "Building Capabilities",
              "value": "Need to establish sales and marketing capabilities or contract third parties."
            },
            {
              "key": "Risks of Building Capabilities",
              "value": "Recruitment and training of sales force is expensive and time-consuming."
            },
            {
              "key": "Potential Delays",
              "value": "Delays in commercial launch could lead to wasted commercialization expenses."
            },
            {
              "key": "Inhibition Factors for Sales",
              "value": "Inability to recruit and retain sales personnel; limited access to physicians."
            },
            {
              "key": "Third-Party Arrangements",
              "value": "May have lower revenues and profitability compared to in-house sales."
            },
            {
              "key": "Risk of Product Liability",
              "value": "Product liability lawsuits could limit commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 63,
          "title": "NUC-3373 Development Overview",
          "data": [
            {
              "key": "NUC-3373 Description",
              "value": "A novel nucleoside analog targeted for the treatment of colorectal cancer, aiming to overcome limitations of traditional 5-FU therapies."
            },
            {
              "key": "Clinical Trials",
              "value": "Evaluated in NuTide:301 and ongoing NuTide:302 trials."
            },
            {
              "key": "Trial Phases",
              "value": "Phase 1 and Phase 1b/2 trials."
            },
            {
              "key": "Patient Enrollment",
              "value": "59 patients in NuTide:301; ongoing enrollment in NuTide:302."
            },
            {
              "key": "Commercial Potential",
              "value": "Approximately 500,000 patients in North America receive intravenous 5-FU annually."
            },
            {
              "key": "Global Colorectal Cancer Statistics",
              "value": "Third most common cancer; 150,000 new cases annually in the US."
            },
            {
              "key": "Unmet Need",
              "value": "High need for improved treatment options due to late diagnoses and low survival rates in advanced stages."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 64,
          "title": "Product Development Trials and Innovations",
          "data": [
            {
              "key": "Product Name",
              "value": "NUC-3373"
            },
            {
              "key": "Trial Phase",
              "value": "Phase 1/2"
            },
            {
              "key": "Trial Name",
              "value": "NuTide:303"
            },
            {
              "key": "Combination Treatments",
              "value": "PD-1 inhibitor pembrolizumab, docetaxel"
            },
            {
              "key": "NUC-7738 Details",
              "value": "Ongoing Phase 1/2 clinical trial (NuTide:701) showing anti-tumor activity."
            },
            {
              "key": "Acelarin Details",
              "value": "Well tolerated in clinical trials, used for gemcitabine-refractory patients, Phase 3 trial discontinued."
            },
            {
              "key": "Unique Technology",
              "value": "ProTide technology developed by Professor Christopher McGuigan."
            },
            {
              "key": "Prominent Patents",
              "value": "Foundational patent estate for phosphoramidate chemistry in oncology."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 65,
          "title": "NUC-3373 Development Strategy",
          "data": [
            {
              "key": "Goal",
              "value": "Transform standards of care and improve survival for patients across a wide range of cancer indications."
            },
            {
              "key": "Key Component 1",
              "value": "Rapidly develop NUC-3373 to replace 5-FU for colorectal cancer treatment."
            },
            {
              "key": "Clinical Trials",
              "value": "Reporting additional data from NuTide:302 trial in 2023."
            },
            {
              "key": "Key Component 2",
              "value": "Initiated randomized Phase 2 clinical trial of NUC-3373, NuTide:323, against FOLFIRI."
            },
            {
              "key": "Key Component 3",
              "value": "Identify additional indications for NUC-3373, initiating Phase 1b/2 trial, NuTide:303."
            },
            {
              "key": "Key Component 4",
              "value": "Develop NUC-7738 for solid tumors, with ongoing Phase 1/2 trial NuTide:701."
            },
            {
              "key": "ProTide Technology",
              "value": "Leverage proprietary ProTide technology platform for additional product candidates."
            },
            {
              "key": "Intellectual Property",
              "value": "Protect and strengthen IP position with patents granted in key markets."
            },
            {
              "key": "Commercial Organization",
              "value": "Build focused commercial organization for product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 66,
          "title": "Clinical Trial Development Pipeline",
          "data": [
            {
              "key": "Study",
              "value": "NUTIDE 302"
            },
            {
              "key": "Indication",
              "value": "Colorectal Cancer"
            },
            {
              "key": "Combinations",
              "value": "irinotecan + bevacizumab, oxaliplatin + bevacizumab"
            },
            {
              "key": "Phase",
              "value": "Phase 3"
            },
            {
              "key": "Study",
              "value": "NUTIDE 323"
            },
            {
              "key": "Indication",
              "value": "Colorectal Cancer (second-line)"
            },
            {
              "key": "Combinations",
              "value": "irinotecan + bevacizumab"
            },
            {
              "key": "Phase",
              "value": "Phase 2"
            },
            {
              "key": "Study",
              "value": "NUTIDE 303"
            },
            {
              "key": "Indication",
              "value": "Solid Tumors, Lung Cancer"
            },
            {
              "key": "Combinations",
              "value": "pembrolizumab, docetaxel"
            },
            {
              "key": "Phase",
              "value": "Phase 1"
            },
            {
              "key": "Study",
              "value": "NUTIDE 701"
            },
            {
              "key": "Indication",
              "value": "Solid Tumors"
            },
            {
              "key": "Combinations",
              "value": "monotherapy, pembrolizumab"
            },
            {
              "key": "Phase",
              "value": "Phase 1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 68,
          "title": "ProTide Technology Overview",
          "data": [
            {
              "key": "Key Limitations of Nucleoside Analogs",
              "value": "Degraded before it gets to cancer cells, Generates toxic metabolites"
            },
            {
              "key": "Our Solution",
              "value": "Resistant to breakdown, Avoids generation of toxic metabolites"
            },
            {
              "key": "Key Limitations of Nucleoside Analogs",
              "value": "Membrane transporters required"
            },
            {
              "key": "Our Solution",
              "value": "Membrane transporters not required"
            },
            {
              "key": "Key Limitations of Nucleoside Analogs",
              "value": "Inefficient generation of active metabolite, Generates toxic metabolites"
            },
            {
              "key": "Our Solution",
              "value": "Delivers active metabolite, Avoids generation of toxic metabolites"
            },
            {
              "key": "Key Limitations of Nucleoside Analogs",
              "value": "Poor PK profile, Challenging dosing"
            },
            {
              "key": "Our Solution",
              "value": "Improved PK profile, Simplified dosing"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 69,
          "title": "Graphical Representation of Nucleoside and Nucleotide Analogs",
          "data": [
            {
              "key": "Description",
              "value": "A graphical representation of the chemical structure of nucleoside analogs, nucleotide analogs and ProTides, showing transformations between inactive and protected states."
            },
            {
              "key": "Lead Product Candidate",
              "value": "NUC-3373"
            },
            {
              "key": "Focused Treatment",
              "value": "Treatment for patients with colorectal cancer and other solid tumors."
            },
            {
              "key": "Clinical Utility of 5-FU",
              "value": "5-FU remains a cornerstone treatment for various cancers."
            },
            {
              "key": "Efficacy Improvement",
              "value": "Designed to improve efficacy and safety profile while reducing administration burdens."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 71,
          "title": "NUC-3373 Clinical Trial Overview",
          "data": [
            {
              "key": "Trial Phase",
              "value": "Phase 1b/2"
            },
            {
              "key": "Combination Treatments",
              "value": "Pembrolizumab, Docetaxel"
            },
            {
              "key": "Active Compound",
              "value": "FUDR-MP"
            },
            {
              "key": "Mechanism of Action",
              "value": "Bypasses activating enzymes, Higher efficacy than 5-FU"
            },
            {
              "key": "Key Benefits",
              "value": "Improved pharmacokinetics, Reduced toxic byproducts, Greater anti-cancer activity"
            },
            {
              "key": "Comparative Efficacy",
              "value": "Up to 330 times greater activity than 5-FU"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 72,
          "title": "EC50 Values Comparison for Cancer Cell Lines",
          "data": [
            {
              "key": "HT29 - Colon - 5-FU (µM)",
              "value": "80.0"
            },
            {
              "key": "HT29 - Colon - NUC-3373 (µM)",
              "value": "1.6"
            },
            {
              "key": "SW620 - Colon - 5-FU (µM)",
              "value": "64.6"
            },
            {
              "key": "SW620 - Colon - NUC-3373 (µM)",
              "value": "1.6"
            },
            {
              "key": "Colo205 - Colon - 5-FU (µM)",
              "value": "3.5"
            },
            {
              "key": "Colo205 - Colon - NUC-3373 (µM)",
              "value": "0.2"
            },
            {
              "key": "A2780 - Ovary - 5-FU (µM)",
              "value": "4.0"
            },
            {
              "key": "A2780 - Ovary - NUC-3373 (µM)",
              "value": "0.6"
            },
            {
              "key": "OVCAR3 - Ovary - 5-FU (µM)",
              "value": "77.0"
            },
            {
              "key": "OVCAR3 - Ovary - NUC-3373 (µM)",
              "value": "6.7"
            },
            {
              "key": "SK-MES-1 - Lung - 5-FU (µM)",
              "value": "198.0"
            },
            {
              "key": "SK-MES-1 - Lung - NUC-3373 (µM)",
              "value": "0.6"
            },
            {
              "key": "H1975 - Lung - 5-FU (µM)",
              "value": "95.6"
            },
            {
              "key": "H1975 - Lung - NUC-3373 (µM)",
              "value": "9.3"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 74,
          "title": "NUC-3373 AUC plasma vs Dose",
          "data": [
            {
              "key": "Dose (mg/m²)",
              "value": "500"
            },
            {
              "key": "NUC-3373 AUC plasma (h*μg/mL)",
              "value": "60"
            },
            {
              "key": "Dose (mg/m²)",
              "value": "1000"
            },
            {
              "key": "NUC-3373 AUC plasma (h*μg/mL)",
              "value": "72"
            },
            {
              "key": "Dose (mg/m²)",
              "value": "2000"
            },
            {
              "key": "NUC-3373 AUC plasma (h*μg/mL)",
              "value": "115"
            },
            {
              "key": "Dose (mg/m²)",
              "value": "3000"
            },
            {
              "key": "NUC-3373 AUC plasma (h*μg/mL)",
              "value": "132"
            },
            {
              "key": "Dose (mg/m²)",
              "value": "3500"
            },
            {
              "key": "NUC-3373 AUC plasma (h*μg/mL)",
              "value": "157"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 74,
          "title": "Patient Trial Overview",
          "data": [
            {
              "key": "Total Patients Enrolled",
              "value": "59"
            },
            {
              "key": "Previous Treatments Received (average)",
              "value": "3"
            },
            {
              "key": "Weekly Schedule Dose Range",
              "value": "125 mg/m² to 3,250 mg/m²"
            },
            {
              "key": "Fortnightly Schedule Dose Range",
              "value": "1,500 mg/m² to 2,500 mg/m²"
            },
            {
              "key": "Patients on Treatment for >4 months",
              "value": "10"
            },
            {
              "key": "Achieved Prolonged Stable Disease",
              "value": "3"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 75,
          "title": "NUC-3373: Phase 1b/2 clinical trial summary",
          "data": [
            {
              "key": "Trial Name",
              "value": "NuTide:302"
            },
            {
              "key": "Therapeutic Area",
              "value": "Advanced Colorectal Cancer"
            },
            {
              "key": "Main Drug",
              "value": "NUC-3373"
            },
            {
              "key": "Combination Agents",
              "value": "Leucovorin, Irinotecan, Oxaliplatin, Bevacizumab"
            },
            {
              "key": "Trial Phases",
              "value": "Phase 1b/2"
            },
            {
              "key": "Objectives",
              "value": "Determine recommended combination dose and schedule"
            },
            {
              "key": "Patient Population",
              "value": "Patients with advanced colorectal cancer"
            },
            {
              "key": "Interim Results",
              "value": "Favorable safety profile, observed tumor shrinkage"
            },
            {
              "key": "Clinical Trial Status",
              "value": "Ongoing with phases completed and ongoing"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 75,
          "title": "Clinical Trial Flow for Advanced Colorectal Cancer Treatment",
          "data": [
            {
              "key": "Phase",
              "value": "Enrollment"
            },
            {
              "key": "Treatment",
              "value": "Patient Selection"
            },
            {
              "key": "Details",
              "value": "Patients with advanced colorectal cancer"
            },
            {
              "key": "Status",
              "value": "Ongoing"
            },
            {
              "key": "Part 1",
              "value": "NUC-3373, ≥3rd line (n=28), Q2W + LV, completed"
            },
            {
              "key": "Part 2",
              "value": "NUFIRI and NUFOX, completed"
            },
            {
              "key": "Part 3",
              "value": "NUFIRI + bevacizumab and NUFOX + bevacizumab, ongoing"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 77,
          "title": "NUC-3373: Ongoing Phase 1b/2 clinical trial",
          "data": [
            {
              "key": "Trial Type",
              "value": "Phase 1b/2"
            },
            {
              "key": "Objective",
              "value": "Identify additional indications and treatment combinations for NUC-3373"
            },
            {
              "key": "Trial Design",
              "value": "Modular, multi-arm, parallel-cohort, dose-finding and expansion trial"
            },
            {
              "key": "Modules Involved",
              "value": "Combination with pembrolizumab and docetaxel"
            },
            {
              "key": "Patient Enrollment",
              "value": "6 to 20 evaluable patients"
            },
            {
              "key": "Phase 1 Purpose",
              "value": "Determine safety, preliminary efficacy and maximum tolerated dose"
            },
            {
              "key": "Colorectal Cancer Statistics",
              "value": "Third most common cancer, 150,000 new cases annually in the US"
            },
            {
              "key": "Existing Treatment",
              "value": "5-FU as standard therapy"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 78,
          "title": "NUC-7738 Preclinical Data",
          "data": [
            {
              "key": "Product Name",
              "value": "NUC-7738"
            },
            {
              "key": "Active Metabolite",
              "value": "3’-dATP"
            },
            {
              "key": "Key Feature",
              "value": "Bypasses first phosphorylation step by enzyme AK"
            },
            {
              "key": "Resistance",
              "value": "Resistant to breakdown by ADA"
            },
            {
              "key": "Application",
              "value": "Anti-cancer treatment"
            },
            {
              "key": "Mechanism",
              "value": "Disrupts RNA polyadenylation, affecting gene expression"
            },
            {
              "key": "Stability",
              "value": "Greater stability compared to 3’-dA"
            },
            {
              "key": "Transport Dependency",
              "value": "Enters cancer cells independently of nucleoside transporters"
            },
            {
              "key": "Cell Type Tested",
              "value": "Human leukemia cell lines"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 79,
          "title": "NUC-7738 Clinical Development",
          "data": [
            {
              "key": "Anti-Cancer Activity",
              "value": "NUC-7738 has greater anti-cancer activity than 3’-dA."
            },
            {
              "key": "Preclinical Study Findings",
              "value": "NUC-7738 was found to be more potent than 3’-dA in 16 of the 20 cell lines examined."
            },
            {
              "key": "Clinical Trials",
              "value": "Ongoing Phase 1/2 trial known as NuTide:701 for patients with advanced solid tumors."
            },
            {
              "key": "Maximum Tolerated Dose",
              "value": "1,350 mg/m2 administered weekly."
            },
            {
              "key": "Phase 1 Objective",
              "value": "To establish the recommended dose and schedule for NUC-7738."
            },
            {
              "key": "Phase 2 Focus",
              "value": "Evaluate efficacy and safety profile as monotherapy and in combination with pembrolizumab."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 81,
          "title": "Acelarin: A Novel Cancer Treatment for Pancreatic Cancer",
          "data": [
            {
              "key": "Product Name",
              "value": "Acelarin"
            },
            {
              "key": "Mechanism of Action",
              "value": "Overcomes key cancer resistance mechanisms associated with gemcitabine."
            },
            {
              "key": "Active Ingredient",
              "value": "Gemcitabine with phosphate group and proprietary moiety."
            },
            {
              "key": "Advantages",
              "value": "Generates and maintains higher concentrations of active anti-cancer metabolite inside tumor compared to gemcitabine."
            },
            {
              "key": "Transport Mechanism",
              "value": "Enters cancer cells independent of hENT1 transporter."
            },
            {
              "key": "Resistance Mechanisms Bypassed",
              "value": "Bypasses breakdown by CDA and deficiency of dCK enzyme."
            },
            {
              "key": "Effect on Survival",
              "value": "Promising results in overcoming resistance mechanisms in pancreatic cancer."
            },
            {
              "key": "Comparison to Gemcitabine",
              "value": "Produces much higher levels of active metabolite dFdCTP than gemcitabine."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 82,
          "title": "Clinical Data for Acelarin",
          "data": [
            {
              "key": "Clinical Trials",
              "value": "Acelarin has been evaluated in multiple clinical trials including Phase 1 and 2 for advanced solid tumors."
            },
            {
              "key": "Phase 1 Trials",
              "value": "Evaluation of Acelarin monotherapy and combinations with carboplatin and cisplatin."
            },
            {
              "key": "Patient Demographics",
              "value": "Majority had poor prognoses but showed positive responses to Acelarin treatment."
            },
            {
              "key": "Monotherapy Details",
              "value": "Phase 1 trial with 68 patients showed initial efficacy signs."
            },
            {
              "key": "Dosage",
              "value": "Doses ranged from 375 mg/m2 to 1,000 mg/m2."
            },
            {
              "key": "History of Treatment",
              "value": "Patients had on average 2.7 prior lines of chemotherapy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 86,
          "title": "Manufacturing and Competition Overview",
          "data": [
            {
              "key": "Manufacturing Dependencies",
              "value": "Rely on third-party CMOs for clinical trial materials of NUC-3373, NUC-7738, and Acelarin. Expect to source commercial quantities from CMOs if approved."
            },
            {
              "key": "cGMP Compliance",
              "value": "Manufacturing must conform to cGMP standards as specified by the FDA."
            },
            {
              "key": "Material Sourcing",
              "value": "Key materials sourced from multiple vendors to ensure a robust and cost-effective supply chain."
            },
            {
              "key": "Competitive Landscape",
              "value": "Development and commercialization of new drug therapies is highly competitive, facing competition from major pharmaceutical and biotechnology companies."
            },
            {
              "key": "Competitors in Chemotherapy",
              "value": "Compete against companies manufacturing off-patent chemotherapies and potentially newer therapies."
            },
            {
              "key": "Intellectual Property",
              "value": "Focus on protecting intellectual property and patent rights critical to business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 95,
          "title": "FDA Review Accelerated Approval Process",
          "data": [
            {
              "key": "Key Concepts",
              "value": "Priority review, Breakthrough Therapy designation, Accelerated Approval."
            },
            {
              "key": "Priority Review",
              "value": "Designed to give drugs that offer major advances in treatment an initial review within six months."
            },
            {
              "key": "Breakthrough Therapy Designation",
              "value": "Expedited development and review for drugs intended to treat serious diseases."
            },
            {
              "key": "Accelerated Approval",
              "value": "Allows approval based on surrogates or intermediate endpoints, needing confirmation through post-marketing trials."
            },
            {
              "key": "Importance of Timely Review",
              "value": "Ensures resources and attention on significant drug applications."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 104,
          "title": "Research and Development Uncertainties",
          "data": [
            {
              "key": "Product Development Risks",
              "value": "The successful development of our ProTides is highly uncertain due to increased costs in later stages of clinical development."
            },
            {
              "key": "Cost to Completion Uncertainty",
              "value": "Uncertainties in timing and costs affect the completion of clinical trials and the potential for net cash inflows."
            },
            {
              "key": "Scope and Duration Factors",
              "value": "Factors include scope, progress, and results of clinical trials as well as additional trials that may be needed."
            },
            {
              "key": "Regulatory Challenges",
              "value": "Development timelines affected by regulatory requests and approvals."
            },
            {
              "key": "Market Acceptance",
              "value": "Ability to market and achieve acceptance for product candidates is uncertain."
            },
            {
              "key": "Administrative Expenses",
              "value": "Increasing administrative expenses anticipated as headcount grows."
            },
            {
              "key": "Exchange Gains or Losses",
              "value": "Net foreign exchange gains relate to cash held in U.S. dollars."
            },
            {
              "key": "Finance Income",
              "value": "Relates to interest earned on cash and cash equivalents."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 13,
          "title": "FDA Approval and Drug Development Risks",
          "data": [
            {
              "key": "Approval Requirements",
              "value": "Potential delays in FDA marketing approval."
            },
            {
              "key": "Accelerated Approval Risks",
              "value": "Failure to obtain accelerated approval impacts timelines and costs."
            },
            {
              "key": "Post-Marketing Requirements",
              "value": "Rigorous requirements for drugs under accelerated approval."
            },
            {
              "key": "Funding Needs",
              "value": "Substantial additional funding required for commercialization."
            },
            {
              "key": "Current Cash Position",
              "value": "£41.9 million in cash and equivalents as of December 31, 2022."
            },
            {
              "key": "Expectation on Cash Sufficiency",
              "value": "Current resources sufficient for operations for at least the next twelve months."
            },
            {
              "key": "Uncertainties in R&D",
              "value": "High uncertainty in estimating funds required for development and marketing activities."
            },
            {
              "key": "Capital Requirements Factors",
              "value": "Factors influencing capital needs include scope and progress of development, regulatory reviews, and collaboration arrangements."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "capital_expenditure",
          "page": 110,
          "title": "Operating and Capital Expenditure Requirements",
          "data": [
            {
              "key": "Operating Lease Obligations",
              "value": "Relate to rental of office space."
            },
            {
              "key": "Contingent Payment Obligations",
              "value": "Payments not included in the table as the amount, timing and likelihood are not fixed or determinable."
            },
            {
              "key": "Profitability Status",
              "value": "Have not achieved profitability on an annual basis since inception."
            },
            {
              "key": "Future Net Losses",
              "value": "Expect to incur net losses in the future."
            },
            {
              "key": "Operating Expenses",
              "value": "Expect an increase as investment in research and development continues."
            },
            {
              "key": "Research and Development Programs",
              "value": "ProTide pipeline and expansion of organization with additional employees."
            },
            {
              "key": "Funding Requirements",
              "value": "Dependent on several factors including clinical trials progress and success."
            },
            {
              "key": "Commercial Supplies Cost",
              "value": "Cost of manufacturing clinical supplies and establishing commercial supplies."
            },
            {
              "key": "Regulatory Approvals Cost",
              "value": "Cost and timing of regulatory approvals of ProTide product candidates."
            },
            {
              "key": "Hiring Skilled Employees",
              "value": "Costs associated with hiring additional skilled employees."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Developments related to COVID-19 may affect costs and timing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 154,
          "title": "ADS Fee Schedule",
          "data": [
            {
              "key": "service",
              "value": "Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares or upon a change in the ADS(s)-to-ordinary shares ratio), excluding ADS issuances as a result of distributions of ordinary shares"
            },
            {
              "key": "fee",
              "value": "Up to $0.05 per ADS issued"
            },
            {
              "key": "service",
              "value": "Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property or upon a change in the ADS(s)-to-ordinary shares ratio)"
            },
            {
              "key": "fee",
              "value": "Up to $0.05 per ADS cancelled"
            },
            {
              "key": "service",
              "value": "Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)"
            },
            {
              "key": "fee",
              "value": "Up to $0.05 per ADS held"
            },
            {
              "key": "service",
              "value": "Distribution of ADSs pursuant to (i) share dividends or other distributions, or (ii) exercise of rights to purchase additional ADSs"
            },
            {
              "key": "fee",
              "value": "Up to $0.05 per ADS held"
            },
            {
              "key": "service",
              "value": "Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off)"
            },
            {
              "key": "fee",
              "value": "Up to $0.05 per ADS held"
            },
            {
              "key": "service",
              "value": "ADS services"
            },
            {
              "key": "fee",
              "value": "Up to $0.05 per ADS held on the applicable record date(s) established by the depositary"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 165,
          "title": "Recognition of clinical trial and contracted manufacturing expenses",
          "data": [
            {
              "key": "Company recognized manufacturing expenses",
              "value": "£6.6 million and £0.4 million"
            },
            {
              "key": "Prepayments for clinical trials and contracted manufacturing expenses",
              "value": "£1.8 million and £0.1 million"
            },
            {
              "key": "Accounting considerations",
              "value": "Recognition depends on management's assessment of clinical trial progress and contracted manufacturing completeness"
            },
            {
              "key": "Challenges in auditing",
              "value": "Judgment and subjectivity in estimating related accruals and prepayments"
            },
            {
              "key": "Audit procedures",
              "value": "Testing completeness and accuracy of data, reviewing contracts, inquiring with research and development personnel and comparing reports with contracts"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "capital_expenditure",
          "page": 176,
          "title": "Significant Accounting Policies",
          "data": [
            {
              "key": "Income tax credit",
              "value": "The Company benefits from the U.K. and U.S. research and development tax credit regimes."
            },
            {
              "key": "Lease recognition",
              "value": "The Company assesses whether a contract is, or contains, a lease."
            },
            {
              "key": "Right of use assets",
              "value": "Right of use assets are recognized at the commencement date of the lease, measured at cost."
            },
            {
              "key": "Lease liability",
              "value": "Lease liability is measured at the present value of lease payments to be made over the lease term."
            },
            {
              "key": "Provisions",
              "value": "Provisions are recognized for legal or constructive obligations at the balance sheet date."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 182,
          "title": "Capital commitments and contingencies",
          "data": [
            {
              "key": "Collaboration and License Agreements",
              "value": "In August 2009, we entered into a research, collaboration and license agreement with Cardiff University..."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "capital_expenditure",
          "page": 183,
          "title": "Capital Commitments and Contingencies",
          "data": [
            {
              "key": "Development and Approval Milestone Payments",
              "value": "Up to approximately $4.5 million for the first product."
            },
            {
              "key": "Royalty Payments",
              "value": "Royalties equal to a percentage in mid- to high-single digits on sales."
            },
            {
              "key": "ProTides Agreement Expiration",
              "value": "Until the expiration of patent claims or 10 years from the first commercial sale."
            },
            {
              "key": "Termination Conditions",
              "value": "Can be terminated on material breach, bankruptcy, or failure to pay."
            },
            {
              "key": "Contingent Liabilities",
              "value": "Employer Class 1 National Insurance based on market value upon exercise."
            },
            {
              "key": "Employer National Insurance Contingent Liability",
              "value": "£0.1 million based on December 31, 2022 closing share price."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 186,
          "title": "Intangible assets Computer",
          "data": [
            {
              "key": "Cost at December 31, 2020",
              "value": "£6,168,000"
            },
            {
              "key": "Cost at December 31, 2022",
              "value": "£7,441,000"
            },
            {
              "key": "Additions (2021)",
              "value": "£1,001,000"
            },
            {
              "key": "Additions (2022)",
              "value": "£506,000"
            },
            {
              "key": "Impairment charge (2021)",
              "value": "£2,809,000"
            },
            {
              "key": "Impairment charge (2022)",
              "value": "£292,000"
            },
            {
              "key": "Net book value at December 31, 2021",
              "value": "£2,410,000"
            },
            {
              "key": "Net book value at December 31, 2022",
              "value": "£2,365,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "capital_expenditure",
          "page": 187,
          "title": "Asset Cost and Depreciation Statement (in thousands £)",
          "data": [
            {
              "key": "Asset Cost at December 31, 2020",
              "value": "£2,122k"
            },
            {
              "key": "Asset Cost at December 31, 2021",
              "value": "£2,187k"
            },
            {
              "key": "Asset Cost at December 31, 2022",
              "value": "£2,297k"
            },
            {
              "key": "Net Book Value 2022",
              "value": "£866k"
            },
            {
              "key": "Net Book Value 2021",
              "value": "£851k"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "capital_expenditure",
          "page": 205,
          "title": "Lease Definitions and Variations",
          "data": [
            {
              "key": "Landlords Interest",
              "value": "The Landlords are entitled to the landlords interest in the Lease."
            },
            {
              "key": "Tenants Interest",
              "value": "The Tenants are entitled to the tenant's interest in the Lease."
            },
            {
              "key": "Leased Premises",
              "value": "The Premises is leased to the Tenants on the terms and conditions of the Lease."
            },
            {
              "key": "Effective Date of Variations",
              "value": "Effective from 15 August 2022."
            },
            {
              "key": "Annual Rent",
              "value": "EIGHTY ONE THOUSAND NINE HUNDRED POUNDS (£81,000) Sterling per annum."
            },
            {
              "key": "Tax Exclusion",
              "value": "Annual rent exclusive of rates, service charge and VAT."
            },
            {
              "key": "Car Parking Charges",
              "value": "Included in the annual rent."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "capital_expenditure",
          "page": 210,
          "title": "Lease Variations",
          "data": [
            {
              "key": "Landlords Interest",
              "value": "The Landlords are entitled to the landlord’s interest in the Lease."
            },
            {
              "key": "Tenants Interest",
              "value": "The Tenants are entitled to the tenant's interest in the Lease."
            },
            {
              "key": "Annual Rent",
              "value": "£81,900 Sterling per annum exclusive of value added tax."
            },
            {
              "key": "Effective Date",
              "value": "15 August 2022."
            },
            {
              "key": "Duration",
              "value": "The terms and conditions of the Lease will remain unchanged except for the variations stated."
            }
          ],
          "currency": "GBP"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 3,
          "title": "Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020",
          "data": [
            {
              "key": "Description",
              "value": "Operating results over three years."
            },
            {
              "key": "Period Covered",
              "value": "2020, 2021, 2022"
            },
            {
              "key": "Page Number",
              "value": "F-3"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 4,
          "title": "Consolidated Statements of Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020",
          "data": [
            {
              "key": "Description",
              "value": "Comprehensive income (loss) results."
            },
            {
              "key": "Period Covered",
              "value": "2020, 2021, 2022"
            },
            {
              "key": "Page Number",
              "value": "F-4"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 5,
          "title": "Consolidated Statements of Financial Position at December 31, 2022 and 2021",
          "data": [
            {
              "key": "Description",
              "value": "Financial position summary."
            },
            {
              "key": "Period Covered",
              "value": "2021, 2022"
            },
            {
              "key": "Page Number",
              "value": "F-5"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 6,
          "title": "Consolidated statement of operations and comprehensive loss data",
          "data": [
            {
              "key": "Research and development expenses",
              "value": "-36426, -36834, -25899, -19728, -16846"
            },
            {
              "key": "Administrative expenses",
              "value": "-7291, -8529, -7050, -5953, -5184"
            },
            {
              "key": "Impairment of intangible assets",
              "value": "-292, -2809, 0, 0, 0"
            },
            {
              "key": "Net foreign exchange gains (losses)",
              "value": "4887, 267, -3472, -1019, 2902"
            },
            {
              "key": "Operating loss",
              "value": "-39122, -47905, -36421, -26700, -19128"
            },
            {
              "key": "Finance income",
              "value": "669, 103, 246, 1049, 1065"
            },
            {
              "key": "Loss before tax",
              "value": "-38453, -47802, -36175, -25651, -18063"
            },
            {
              "key": "Income tax credit",
              "value": "6432, 7269, 5493, 4239, 4223"
            },
            {
              "key": "Loss for the year",
              "value": "-32021, -40533, -30682, -21412, -13840"
            },
            {
              "key": "Exchange differences on translation of foreign operations",
              "value": "61, 0, -12, -11, 12"
            },
            {
              "key": "Total comprehensive loss for the year",
              "value": "-31960, -40528, -30694, -21423, -13828"
            },
            {
              "key": "Basic and diluted loss per share",
              "value": "-0.61, -0.78, -0.81, -0.66, -0.43"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 6,
          "title": "Consolidated Statements of Changes in Equity for the years ended December 31, 2022, 2021 and 2020",
          "data": [
            {
              "key": "Description",
              "value": "Changes in equity over the three years."
            },
            {
              "key": "Period Covered",
              "value": "2020, 2021, 2022"
            },
            {
              "key": "Page Number",
              "value": "F-6"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 7,
          "title": "Consolidated statement of financial position data",
          "data": [
            {
              "key": "Cash and cash equivalents",
              "value": "41,912 (2022), 60,264 (2021), 87,356 (2020), 51,962 (2019), 76,972 (2018)"
            },
            {
              "key": "Total assets",
              "value": "58,254 (2022), 77,474 (2021), 107,792 (2020), 70,268 (2019), 87,185 (2018)"
            },
            {
              "key": "Share capital",
              "value": "2,095 (2022), 2,087 (2021), 2,047 (2020), 1,299 (2019), 1,289 (2018)"
            },
            {
              "key": "Share premium",
              "value": "141,108 (2022), 141,050 (2021), 140,890 (2020), 79,541 (2019), 79,426 (2018)"
            },
            {
              "key": "Accumulated deficit",
              "value": "-180,573 (2022), -149,726 (2021), -110,594 (2020), -80,055 (2019), -58,813 (2018)"
            },
            {
              "key": "Capital reserve (1)",
              "value": "42,466 (2022), 42,466 (2021), 42,466 (2020), 42,466 (2019), 42,466 (2018)"
            },
            {
              "key": "Net assets/Total equity attributable to equity holders of the Company",
              "value": "38,502 (2022), 65,548 (2021), 99,230 (2020), 63,522 (2019), 81,594 (2018)"
            },
            {
              "key": "Total liabilities",
              "value": "-19,752 (2022), -11,926 (2021), -8,562 (2020), -6,746 (2019), -5,591 (2018)"
            },
            {
              "key": "Number of shares",
              "value": "52,373 (2022), 52,180 (2021), 51,175 (2020), 32,479 (2019), 32,226 (2018)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 7,
          "title": "Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020",
          "data": [
            {
              "key": "Description",
              "value": "Cash flows across three years."
            },
            {
              "key": "Period Covered",
              "value": "2020, 2021, 2022"
            },
            {
              "key": "Page Number",
              "value": "F-7"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 8,
          "title": "Notes to the Consolidated Financial Statements",
          "data": [
            {
              "key": "Description",
              "value": "Accompanying notes for financial statements."
            },
            {
              "key": "Page Number",
              "value": "F-8"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 10,
          "title": "Projections of Financial Performance and Investment Risks",
          "data": [
            {
              "key": "financial outlook",
              "value": "We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future."
            },
            {
              "key": "net losses",
              "value": "The net losses we incur may fluctuate significantly from quarter to quarter."
            },
            {
              "key": "development plans",
              "value": "We anticipate that our expenses will increase substantially as we continue development of our ProTides and other product candidates."
            },
            {
              "key": "intellectual property risks",
              "value": "Protecting our intellectual property may result in litigation aimed at enforcing or defending our patents."
            },
            {
              "key": "regulatory impacts",
              "value": "Our expenses could increase beyond expectations due to additional regulatory requirements."
            },
            {
              "key": "market potential",
              "value": "To become profitable, we must develop and commercialize products with significant market potential."
            },
            {
              "key": "capital needs",
              "value": "Our failure to remain profitable could impair our ability to raise capital and maintain operations."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 105,
          "title": "Income Tax Credit and Income Statement Comparison",
          "data": [
            {
              "key": "Research and development expenses (2022)",
              "value": "-36426"
            },
            {
              "key": "Research and development expenses (2021)",
              "value": "-36834"
            },
            {
              "key": "Administrative expenses (2022)",
              "value": "-7291"
            },
            {
              "key": "Administrative expenses (2021)",
              "value": "-8529"
            },
            {
              "key": "Impairment of intangible assets (2022)",
              "value": "-292"
            },
            {
              "key": "Impairment of intangible assets (2021)",
              "value": "-2809"
            },
            {
              "key": "Net foreign exchange gains (2022)",
              "value": "4887"
            },
            {
              "key": "Net foreign exchange gains (2021)",
              "value": "267"
            },
            {
              "key": "Operating loss (2022)",
              "value": "-39122"
            },
            {
              "key": "Operating loss (2021)",
              "value": "-47905"
            },
            {
              "key": "Finance income (2022)",
              "value": "669"
            },
            {
              "key": "Finance income (2021)",
              "value": "103"
            },
            {
              "key": "Loss before tax (2022)",
              "value": "-38453"
            },
            {
              "key": "Loss before tax (2021)",
              "value": "-47802"
            },
            {
              "key": "Income tax credit (2022)",
              "value": "6432"
            },
            {
              "key": "Income tax credit (2021)",
              "value": "7269"
            },
            {
              "key": "Loss for the year (2022)",
              "value": "-32021"
            },
            {
              "key": "Loss for the year (2021)",
              "value": "-40533"
            },
            {
              "key": "Total comprehensive loss for the year (2022)",
              "value": "-31960"
            },
            {
              "key": "Total comprehensive loss for the year (2021)",
              "value": "-40528"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 107,
          "title": "Financial Statement Comparison 2020-2021",
          "data": [
            {
              "key": "Finance Income",
              "value": "£0.7 million for the year ended December 31, 2022 and £0.1 million for the year ended December 31, 2021."
            },
            {
              "key": "Income Tax Credit",
              "value": "£6.4 million for the year ended December 31, 2022 and £7.3 million for the year ended December 31, 2021."
            },
            {
              "key": "Research and Development Expenses (2021)",
              "value": "£36.8 million"
            },
            {
              "key": "Research and Development Expenses (2020)",
              "value": "£25.9 million"
            },
            {
              "key": "Operating Loss (2021)",
              "value": "-£47.9 million"
            },
            {
              "key": "Operating Loss (2020)",
              "value": "-£36.4 million"
            },
            {
              "key": "Total Comprehensive Loss (2021)",
              "value": "-£40.5 million"
            },
            {
              "key": "Total Comprehensive Loss (2020)",
              "value": "-£30.7 million"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 108,
          "title": "Financial Performance Summary",
          "data": [
            {
              "key": "Administrative Expenses",
              "value": "£8.5 million for 2021, an increase from £7.1 million in 2020, primarily due to higher insurance, professional fees, and share-based payment expenses."
            },
            {
              "key": "Impairment of Intangible Assets",
              "value": "Recognized an impairment charge of £2.8 million related to the Acelarin clinical trial."
            },
            {
              "key": "Net Foreign Exchange Gains",
              "value": "£0.3 million gain in 2021 compared to £3.5 million loss in 2020."
            },
            {
              "key": "Finance Income",
              "value": "£0.1 million for 2021, down from £0.2 million in 2020."
            },
            {
              "key": "Income Tax Credit",
              "value": "£7.3 million for 2021 compared to £5.5 million in 2020, largely from research and development tax credits."
            },
            {
              "key": "Liquidity and Capital Resources Overview",
              "value": "Cash and cash equivalents were £41.9 million on December 31, 2022, and £60.3 million on December 31, 2021. Company continues to incur losses and will need additional capital."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 159,
          "title": "Financial Statements Reference",
          "data": [
            {
              "key": "Financial Statements Location",
              "value": "Beginning on page F-1"
            },
            {
              "key": "Item Reference",
              "value": "Item 18"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 166,
          "title": "Financial Performance Summary",
          "data": [
            {
              "key": "Research and development expenses",
              "value": "-£36,426k"
            },
            {
              "key": "Administrative expenses",
              "value": "-£7,291k"
            },
            {
              "key": "Impairment of intangible assets",
              "value": "-£292k"
            },
            {
              "key": "Net foreign exchange gains (losses)",
              "value": "£4,887k"
            },
            {
              "key": "Operating loss",
              "value": "-£39,122k"
            },
            {
              "key": "Finance income",
              "value": "£669k"
            },
            {
              "key": "Loss before tax",
              "value": "-£38,453k"
            },
            {
              "key": "Income tax credit",
              "value": "£6,432k"
            },
            {
              "key": "Loss for the year attributable to equity holders of the Company",
              "value": "-£32,021k"
            },
            {
              "key": "Basic and diluted loss per share",
              "value": "-£0.61"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 167,
          "title": "Comprehensive Income Statement",
          "data": [
            {
              "key": "Loss for the year",
              "value": "-32,021"
            },
            {
              "key": "Exchange differences on translation of foreign operations",
              "value": "61"
            },
            {
              "key": "Other comprehensive income (expense) for the year",
              "value": "61"
            },
            {
              "key": "Total comprehensive loss for the year",
              "value": "-31,960"
            },
            {
              "key": "Equity holders of the Company",
              "value": "-31,960"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 168,
          "title": "Consolidated Statements of Financial Position",
          "data": [
            {
              "key": "Total Assets 2022",
              "value": "58,254"
            },
            {
              "key": "Total Assets 2021",
              "value": "77,474"
            },
            {
              "key": "Total Liabilities 2022",
              "value": "19,752"
            },
            {
              "key": "Total Liabilities 2021",
              "value": "11,926"
            },
            {
              "key": "Total Equity 2022",
              "value": "38,502"
            },
            {
              "key": "Total Equity 2021",
              "value": "65,548"
            },
            {
              "key": "Cash and Cash Equivalents 2022",
              "value": "41,912"
            },
            {
              "key": "Cash and Cash Equivalents 2021",
              "value": "60,264"
            },
            {
              "key": "Accumulated Deficit 2022",
              "value": "(180,573)"
            },
            {
              "key": "Accumulated Deficit 2021",
              "value": "(149,726)"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 169,
          "title": "Statement of Changes in Equity",
          "data": [
            {
              "key": "Balance at January 1, 2020",
              "value": "Share Capital: £1,299k, Share Premium: £79,541k, Own Share Reserve: -£339, Share Option Reserve: £20,620k, Foreign Currency Translation Reserve: -£10, Capital Reserve: £42,466k, Accumulated Deficit: -£80,055k, Total Equity: £63,522k"
            },
            {
              "key": "Balance at December 31, 2020",
              "value": "Share Capital: £2,047k, Share Premium: £140,890k, Own Share Reserve: -£339, Share Option Reserve: £24,782k, Foreign Currency Translation Reserve: -£22, Capital Reserve: £42,466k, Accumulated Deficit: -£110,594k, Total Equity: £99,230k"
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "Share Capital: £2,087k, Share Premium: £141,050k, Own Share Reserve: -£339, Share Option Reserve: £30,027k, Foreign Currency Translation Reserve: -£7, Capital Reserve: £42,466k, Accumulated Deficit: -£149,726k, Total Equity: £65,548k"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "Share Capital: £2,095k, Share Premium: £141,108k, Own Share Reserve: -£339, Share Option Reserve: £33,701k, Foreign Currency Translation Reserve: £44, Capital Reserve: £42,466k, Accumulated Deficit: -£180,573k, Total Equity: £38,502k"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Cash Flow Statement Summary",
          "data": [
            {
              "key": "Period 1 (2022) Loss for the year",
              "value": "£-32,021,000"
            },
            {
              "key": "Period 2 (2021) Loss for the year",
              "value": "£-40,533,000"
            },
            {
              "key": "Period 3 (2020) Loss for the year",
              "value": "£-30,682,000"
            },
            {
              "key": "Income tax credit for Period 1",
              "value": "£-6,432,000"
            },
            {
              "key": "Income tax credit for Period 2",
              "value": "£-7,269,000"
            },
            {
              "key": "Income tax credit for Period 3",
              "value": "£-5,493,000"
            },
            {
              "key": "Net cash used in operating activities - Period 1",
              "value": "£-23,158,000"
            },
            {
              "key": "Net cash used in operating activities - Period 2",
              "value": "£-23,824,000"
            },
            {
              "key": "Net cash used in operating activities - Period 3",
              "value": "£-21,619,000"
            },
            {
              "key": "Net cash from investing activities - Period 1",
              "value": "£120,000"
            },
            {
              "key": "Net cash from investing activities - Period 2",
              "value": "£-3,561,000"
            },
            {
              "key": "Net cash from investing activities - Period 3",
              "value": "£-1,313,000"
            },
            {
              "key": "Net cash from financing activities - Period 1",
              "value": "£-161,000"
            },
            {
              "key": "Net cash from financing activities - Period 2",
              "value": "£-98,000"
            },
            {
              "key": "Net cash from financing activities - Period 3",
              "value": "£61,800,000"
            },
            {
              "key": "Cash at beginning of Period 1",
              "value": "£60,264,000"
            },
            {
              "key": "Net change in cash for Period 1",
              "value": "£-23,199,000"
            },
            {
              "key": "Net change in cash for Period 2",
              "value": "£-27,483,000"
            },
            {
              "key": "Net change in cash for Period 3",
              "value": "£38,868,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 174,
          "title": "Significant Accounting Policies",
          "data": [
            {
              "key": "Non-monetary items measurement",
              "value": "Measured in terms of historical cost in a foreign currency using exchange rates at the dates of initial transactions."
            },
            {
              "key": "Consolidation of foreign operations",
              "value": "Assets and liabilities translated into pounds sterling at the rate of exchange at reporting date; operations statements translated at average exchange rate for the financial period."
            },
            {
              "key": "Exchange differences",
              "value": "Recognized in the consolidated statements of comprehensive income or loss."
            },
            {
              "key": "Operating segment recognition",
              "value": "Company operates in one operating segment, managed as a single business of developing and commercializing ProTides for use in Oncology."
            },
            {
              "key": "Share issue costs",
              "value": "Incremental costs directly attributable to share issuance deducted from proceeds; non-incremental costs recorded as expense."
            },
            {
              "key": "Property, plant and equipment accounting",
              "value": "Stated at cost, net of accumulated depreciation and impairment losses."
            },
            {
              "key": "Depreciation methods",
              "value": "Office and computer equipment: Straight-line over 3 years; Fixtures and fittings: Straight-line over 5 years or remaining lease term; Right of use assets: Straight-line over lease terms."
            },
            {
              "key": "Intangible assets accounting",
              "value": "Stated at cost, net of accumulated amortization and impairment losses; Includes registration, documentation, legal fees for patents."
            },
            {
              "key": "Amortization methods for intangible assets",
              "value": "Patents: Straight-line over 20 years; Computer software: Straight-line between 3 and 5 years."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 178,
          "title": "Significant Accounting Policies",
          "data": [
            {
              "key": "fair_value_measurement",
              "value": "The fair value of financial assets and liabilities is included at the amount at which an instrument could be exchanged in a current transaction."
            },
            {
              "key": "fair_value_hierarchy",
              "value": "Established under IFRS 13, prioritizes observable and unobservable inputs into three levels: Level 1 (Quoted prices), Level 2 (Observable inputs), Level 3 (Non-observable inputs)."
            },
            {
              "key": "accounting_standards",
              "value": "The Company applied all relevant IAS, IFRS and IFRIC Interpretations mandatory for the financial year ended December 31, 2022."
            },
            {
              "key": "amendments_effective_jan_2022",
              "value": "1. Amendments to IFRS 3 – Reference to the Conceptual Framework. 2. Amendments to IAS 16 – Proceeds before Intended Use. 3. Amendments to IAS 37 – Onerous Contracts: Costs of Fulfilling a Contract."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 184,
          "title": "Tax Position Summary",
          "data": [
            {
              "key": "Current tax (In respect of current year U.K.)",
              "value": "£6,366k for 2022, £7,185k for 2021, £5,516k for 2020"
            },
            {
              "key": "Current tax (In respect of current year U.S.)",
              "value": "-£3k for 2022"
            },
            {
              "key": "Current tax (In respect of prior years U.K.)",
              "value": "£35k for 2022, £69k for 2021, -£22k for 2020"
            },
            {
              "key": "Total current tax",
              "value": "£6,398k for 2022, £7,254k for 2021, £5,494k for 2020"
            },
            {
              "key": "Deferred tax (In respect of current year U.S.)",
              "value": "£34k for 2022, £15k for 2021"
            },
            {
              "key": "Total deferred tax",
              "value": "£34k for 2022, £15k for 2021"
            },
            {
              "key": "Income tax credit",
              "value": "£6,432k for 2022, £7,269k for 2021, £5,493k for 2020"
            },
            {
              "key": "Current income tax receivable (U.K. tax)",
              "value": "£6,366k for 2022, £7,185k for 2021, £9,818k for 2020"
            },
            {
              "key": "Current income tax receivable (U.S. tax)",
              "value": "£1k for 2022, £3k for 2021, £4k for 2020"
            },
            {
              "key": "Current income tax receivable",
              "value": "£6,367k for 2022, £7,188k for 2021, £9,822k for 2020"
            },
            {
              "key": "Deferred tax (U.S. tax)",
              "value": "£103k for 2022, £60k for 2021, £44k for 2020"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 185,
          "title": "Tax Reconciliation Statement",
          "data": [
            {
              "key": "Loss before tax",
              "value": "-38453"
            },
            {
              "key": "Tax on loss at standard U.K. tax rate of 19%",
              "value": "-7306"
            },
            {
              "key": "Expenses not deductible",
              "value": "4595"
            },
            {
              "key": "Deduction for R&D",
              "value": "-8342"
            },
            {
              "key": "Losses surrendered for R&D tax credit",
              "value": "8342"
            },
            {
              "key": "Overseas tax payable - current year",
              "value": "3"
            },
            {
              "key": "R&D tax credit - U.S.",
              "value": "-34"
            },
            {
              "key": "R&D tax credit - current year",
              "value": "-6366"
            },
            {
              "key": "R&D tax credit - prior years",
              "value": "-35"
            },
            {
              "key": "Deferred tax asset not recognized",
              "value": "2711"
            },
            {
              "key": "Income tax credit",
              "value": "-6432"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 190,
          "title": "Other Reserves Statement",
          "data": [
            {
              "key": "Own share reserve 2022",
              "value": "-339"
            },
            {
              "key": "Own share reserve 2021",
              "value": "-339"
            },
            {
              "key": "Own share reserve 2020",
              "value": "-339"
            },
            {
              "key": "Foreign currency translation reserve 2022",
              "value": "44"
            },
            {
              "key": "Foreign currency translation reserve 2021",
              "value": "-17"
            },
            {
              "key": "Foreign currency translation reserve 2020",
              "value": "-22"
            },
            {
              "key": "Capital reserve 2022",
              "value": "42466"
            },
            {
              "key": "Capital reserve 2021",
              "value": "42466"
            },
            {
              "key": "Capital reserve 2020",
              "value": "42466"
            },
            {
              "key": "Balance at beginning of year 2022",
              "value": "30027"
            },
            {
              "key": "Balance at beginning of year 2021",
              "value": "24782"
            },
            {
              "key": "Balance at beginning of year 2020",
              "value": "20620"
            },
            {
              "key": "Share-based payments 2022",
              "value": "5133"
            },
            {
              "key": "Share-based payments 2021",
              "value": "6974"
            },
            {
              "key": "Share-based payments 2020",
              "value": "4823"
            },
            {
              "key": "Exercise of share options 2022",
              "value": "-362"
            },
            {
              "key": "Exercise of share options 2021",
              "value": "-1222"
            },
            {
              "key": "Exercise of share options 2020",
              "value": "-68"
            },
            {
              "key": "Forfeiture of share options 2022",
              "value": "-243"
            },
            {
              "key": "Forfeiture of share options 2021",
              "value": "-310"
            },
            {
              "key": "Forfeiture of share options 2020",
              "value": "-518"
            },
            {
              "key": "Lapse of share options 2022",
              "value": "-854"
            },
            {
              "key": "Lapse of share options 2021",
              "value": "-197"
            },
            {
              "key": "Lapse of share options 2020",
              "value": "-75"
            },
            {
              "key": "Balance at end of year 2022",
              "value": "33701"
            },
            {
              "key": "Balance at end of year 2021",
              "value": "30027"
            },
            {
              "key": "Balance at end of year 2020",
              "value": "24782"
            },
            {
              "key": "Total other reserves 2022",
              "value": "75872"
            },
            {
              "key": "Total other reserves 2021",
              "value": "72137"
            },
            {
              "key": "Total other reserves 2020",
              "value": "66887"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 198,
          "title": "Cash and cash equivalents",
          "data": [
            {
              "key": "2022 Cash and cash equivalents",
              "value": "£41,912,000"
            },
            {
              "key": "2021 Cash and cash equivalents",
              "value": "£60,264,000"
            },
            {
              "key": "Reduction in cash position",
              "value": "£18.35 million or 30.4%"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 198,
          "title": "Interest Rate Sensitivity",
          "data": [
            {
              "key": "Cash and cash equivalents at short-term fixed rates (2022)",
              "value": "£9,360,000"
            },
            {
              "key": "Cash and cash equivalents at short-term fixed rates (2021)",
              "value": "£24,515,000"
            },
            {
              "key": "Cash and cash equivalents at variable rates (2022)",
              "value": "£24,348,000"
            },
            {
              "key": "Cash and cash equivalents at variable rates (2021)",
              "value": "£31,024,000"
            },
            {
              "key": "Non-interest bearing cash balances (2022)",
              "value": "£8,204,000"
            },
            {
              "key": "Non-interest bearing cash balances (2021)",
              "value": "£4,725,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "financial_performance",
          "page": 214,
          "title": "Certification of Financial Reporting",
          "data": [
            {
              "key": "Certification Officer",
              "value": "Hugh S. Griffith"
            },
            {
              "key": "Position",
              "value": "Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 20-F"
            },
            {
              "key": "Certification Date",
              "value": "April 4, 2023"
            },
            {
              "key": "Key Responsibilities",
              "value": "Reviewed financial statements, ensured controls and procedures are followed, disclosed any significant deficiencies."
            },
            {
              "key": "Internal Control Evaluation",
              "value": "Evaluated effectiveness of internal controls over financial reporting."
            },
            {
              "key": "Disclosure of Internal Control Changes",
              "value": "Disclosed changes that materially affected internal controls."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 217,
          "title": "Certification Pursuant to 18 U.S.C. Section 1350",
          "data": [
            {
              "key": "Company",
              "value": "NuCana plc"
            },
            {
              "key": "CFO",
              "value": "Donald Munoz"
            },
            {
              "key": "Report Date",
              "value": "April 4, 2023"
            },
            {
              "key": "Report Period Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Compliance",
              "value": "The Annual Report on Form 20-F complies with Section 13(a) or 15(d) of the Securities Exchange Act of 1934."
            },
            {
              "key": "Financial Condition Presentation",
              "value": "The information in the Report fairly presents the financial condition and results of operations of the Company."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 131,
          "title": "Articles of Association Summary",
          "data": [
            {
              "key": "Rights of Shares",
              "value": "All ordinary shares have the same rights and rank pari passu in all respects."
            },
            {
              "key": "Authority to Allot Shares",
              "value": "Board of directors may allot and issue shares following an ordinary resolution."
            },
            {
              "key": "Voting Rights",
              "value": "Shareholders vote on resolutions on a show of hands unless a poll is demanded."
            },
            {
              "key": "Poll Voting",
              "value": "A poll vote may be demanded by chairman, five shareholders, or shareholders with 10% of voting rights."
            },
            {
              "key": "Restrictions on Voting",
              "value": "Shareholders cannot vote on shares if amounts payable are overdue."
            },
            {
              "key": "Calls on Shares",
              "value": "Directors can make calls on unpaid shares, requiring 14 clear days' notice."
            },
            {
              "key": "Dividends Declaration",
              "value": "Dividends can be declared out of profits by ordinary resolution, not exceeding board's recommendation."
            },
            {
              "key": "Fixed Dividends",
              "value": "Board may pay fixed dividends on shares with preferential rights."
            },
            {
              "key": "Dividend Rights",
              "value": "All dividends shall be based on amounts paid up on the shares."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 132,
          "title": "Dividend Policy",
          "data": [
            {
              "key": "dividend payment method",
              "value": "Can be directed to pay wholly or partly in the distribution of specific assets."
            },
            {
              "key": "unclaimed dividends",
              "value": "All unclaimed dividends for one year may be invested for the company's benefit until claimed."
            },
            {
              "key": "forfeiture of unclaimed dividends",
              "value": "Unclaimed dividends after 12 years shall be forfeited."
            },
            {
              "key": "shareholder dividend election",
              "value": "Holders of ordinary shares may elect to receive shares instead of dividends."
            },
            {
              "key": "check delivery",
              "value": "Checks may be ceased if consecutive dividends are returned undelivered."
            },
            {
              "key": "record date",
              "value": "Specified record date for dividend entitlement."
            },
            {
              "key": "winding-up distribution",
              "value": "Surplus assets after liabilities will be distributed among shareholders."
            },
            {
              "key": "liquidator authority",
              "value": "Liquidator may divide assets in specie or in kind with necessary sanctions."
            },
            {
              "key": "variation of rights",
              "value": "Rights attached to shares may be varied with consent or special resolution."
            },
            {
              "key": "transfer of shares",
              "value": "Shares may be transferred in registered form and various specified conditions apply."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 138,
          "title": "Dividend Distribution Regulations",
          "data": [
            {
              "key": "Distributable Profit Requirement",
              "value": "A public company can only make a distribution if it meets specific profit and net assets requirements."
            },
            {
              "key": "Capital Maintenance Requirement",
              "value": "The net worth of the company must equal the amount of its capital."
            },
            {
              "key": "Restrictions on Distribution",
              "value": "Distributions cannot reduce the net assets below the total of called up share capital and undistributable reserves."
            },
            {
              "key": "Exchange Controls",
              "value": "No UK laws restrict the export of capital or remittance of payments, aside from withholding taxes."
            },
            {
              "key": "Corporate Law Differences",
              "value": "Differences between the Companies Act 2006 and U.S. corporate law affect shareholders’ rights."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 148,
          "title": "Taxation of Dividends and Other Distributions on the ADSs",
          "data": [
            {
              "key": "PFIC Reporting Requirement",
              "value": "Each U.S. Holder may be required to file IRS Form 8621 if the entity is classified as a PFIC."
            },
            {
              "key": "Taxation of Dividends",
              "value": "Distributions are generally treated as dividends if paid from current or accumulated earnings."
            },
            {
              "key": "Return of Capital",
              "value": "Any distribution exceeding earnings will be treated as a tax-free return of tax basis."
            },
            {
              "key": "Dividend Eligibility",
              "value": "Dividends will not qualify for the dividends-received deduction."
            },
            {
              "key": "Long Term Capital Gains Tax Rate",
              "value": "Non-corporate U.S. Holders may qualify for lower rates."
            },
            {
              "key": "50% U.S. Ownership",
              "value": "If 50%+ of ADSs are U.S. owned, dividends may be split between U.S. and foreign earnings."
            },
            {
              "key": "Foreign Tax Credit Implications",
              "value": "Complex rules govern the foreign tax credit determination."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 150,
          "title": "Dividend Taxation and UK Holders",
          "data": [
            {
              "key": "Tax Residency",
              "value": "United Kingdom"
            },
            {
              "key": "Dividend Classification",
              "value": "U.K. dividends"
            },
            {
              "key": "Advised Actions for Non-Residents",
              "value": "Seek professional advice"
            },
            {
              "key": "Dividend Allowance 2022/2023",
              "value": "£2,000"
            },
            {
              "key": "Basic Rate Tax on Dividends",
              "value": "8.75% after the allowance"
            },
            {
              "key": "Future Dividend Allowance Changes",
              "value": "Will reduce to £1,000 on April 6, 2023 and £500 on April 6, 2024"
            }
          ],
          "currency": "GBP"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": true,
      "elements": [
        {
          "type": "share_buyback",
          "page": 130,
          "title": "Ordinary Shares and Registration Rights Overview",
          "data": [
            {
              "key": "Date of allotment",
              "value": "October 2, 2017"
            },
            {
              "key": "Series B shares allotted",
              "value": "9 series B convertible participating shares for each series B convertible participating share held"
            },
            {
              "key": "Initial public offering",
              "value": "7,596,505 ordinary shares issued on October 2, 2017"
            },
            {
              "key": "Ordinary shares issued in 2018",
              "value": "415,312 ordinary shares exercised from share options"
            },
            {
              "key": "Ordinary shares issued in 2019",
              "value": "252,187 ordinary shares exercised from share options"
            },
            {
              "key": "Follow-on public offering",
              "value": "17,888,889 ordinary shares issued on September 21, 2020"
            },
            {
              "key": "Ordinary shares issued in 2020 (ATM sales agreement)",
              "value": "774,511 ordinary shares"
            },
            {
              "key": "Ordinary shares issued in 2020 (share options)",
              "value": "32,500 ordinary shares"
            },
            {
              "key": "Ordinary shares issued in 2021",
              "value": "1,005,434 ordinary shares from share options"
            },
            {
              "key": "Ordinary shares issued in 2022",
              "value": "192,908 ordinary shares from share options"
            },
            {
              "key": "Total issued and outstanding ordinary shares as of December 31, 2022",
              "value": "52,372,887 shares of £0.04 each"
            },
            {
              "key": "Voting rights",
              "value": "One vote per ordinary share without cumulative voting rights"
            },
            {
              "key": "Distribution rights",
              "value": "Proportional distribution in case of winding-up, dissolution, or liquidation"
            },
            {
              "key": "Demand registration rights",
              "value": "25% of registrable securities have right to demand filing of Form F-3 registration"
            },
            {
              "key": "Company registration notice",
              "value": "Holders of registrable securities notified of equity securities registration"
            },
            {
              "key": "Termination of registration rights",
              "value": "After five years from IPO or upon no registrable securities remaining."
            }
          ],
          "currency": "GBP"
        }
      ]
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 129,
          "title": "Changes to Our Issued Share Capital",
          "data": [
            {
              "key": "Name Change",
              "value": "NuCana BioMed Limited to NuCana plc"
            },
            {
              "key": "Issued Share Capital",
              "value": "£2,094,915"
            },
            {
              "key": "Ordinary Shares",
              "value": "52,372,887 shares of £0.04 each"
            },
            {
              "key": "Initial Issuance",
              "value": "One quarter of one ordinary share of £4.00 to London Law Services Limited and London Law Secretarial Limited"
            },
            {
              "key": "Share Subdivision on March 20, 2008",
              "value": "Subdivided £4.00 shares into 50 ordinary shares of £0.04"
            },
            {
              "key": "Authorized Share Capital Increase",
              "value": "Increased from £100 to £500,000"
            },
            {
              "key": "Subsequent Issuances",
              "value": "Various share issuances detailed with dates and amounts"
            },
            {
              "key": "Share Options Exercise",
              "value": "Shares issued pursuant to the exercise of share options under various Share Option Schemes"
            },
            {
              "key": "Reverse Share Split on September 14, 2017",
              "value": "One-for-four reverse share split with associated bonus allotment"
            },
            {
              "key": "Initial Public Offering Conversion",
              "value": "Converted all series A and B participating shares to ordinary shares prior to IPO on October 2, 2017"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "capital_structure",
          "page": 189,
          "title": "Share Capital and Premium Overview",
          "data": [
            {
              "key": "Share capital",
              "value": "2,095"
            },
            {
              "key": "Share premium",
              "value": "141,108"
            },
            {
              "key": "Total",
              "value": "143,203"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 189,
          "title": "Issued Share Capital",
          "data": [
            {
              "key": "Issued share capital comprises:",
              "value": ""
            },
            {
              "key": "Ordinary shares of £0.04 each",
              "value": "52,373"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 189,
          "title": "Share Capital and Premium Statement",
          "data": [
            {
              "key": "Balance at December 31, 2020",
              "value": "51175"
            },
            {
              "key": "Exercise of share options",
              "value": "1005"
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "52180"
            },
            {
              "key": "Exercise of share options",
              "value": "193"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "52373"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 8,
          "title": "Risks Related to Our Product Candidates",
          "data": [
            {
              "key": "COVID-19 impact",
              "value": "Our business could be significantly and adversely affected by the COVID-19 pandemic."
            },
            {
              "key": "Exchange rate fluctuations",
              "value": "Exchange rate fluctuations may adversely affect our results of operations and financial condition."
            },
            {
              "key": "Early-stage clinical trials results",
              "value": "Initial success in the ongoing and completed early-stage clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials."
            },
            {
              "key": "Drug development process",
              "value": "Drug development involves a lengthy and expensive process, with an uncertain outcome."
            },
            {
              "key": "Cost overruns and delays",
              "value": "We may incur additional costs or experience delays in completing product development."
            },
            {
              "key": "Prioritization of development",
              "value": "Due to limited resources, certain ProTide candidates may be prioritized over others."
            },
            {
              "key": "Dependence on third parties",
              "value": "We rely on third parties to conduct our clinical trials and manufacture our product candidates."
            },
            {
              "key": "Marketing approvals",
              "value": "Delays in obtaining marketing approvals could impair our ability to commercialize product candidates."
            },
            {
              "key": "Side effects and market approval",
              "value": "Product candidates may cause undesirable side effects that could delay or prevent marketing approval."
            },
            {
              "key": "Post-marketing requirements",
              "value": "Any approved product candidate will be subject to extensive post-marketing regulatory requirements."
            },
            {
              "key": "Competition",
              "value": "We face substantial competition in commercializing our product candidates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 9,
          "title": "Risks Related to Our Intellectual Property and Employee Matters",
          "data": [
            {
              "key": "Intellectual Property Risks",
              "value": "Inability to obtain and maintain protection can allow competitors to commercialize similar technology and products."
            },
            {
              "key": "Patent Litigation",
              "value": "Potential for significant resource expenditure and distraction from normal responsibilities."
            },
            {
              "key": "Employee Retention Risks",
              "value": "Future success depends on retaining key executives and attracting qualified personnel."
            },
            {
              "key": "Volatility of ADSs",
              "value": "Price of ADSs may fluctuate due to external factors."
            },
            {
              "key": "Operational Losses",
              "value": "Significant operating losses reported since inception, with an accumulated deficit of £180.6 million as of December 31, 2022."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "risk_factor",
          "page": 19,
          "title": "Bankruptcy and Impact of COVID-19 on Business",
          "data": [
            {
              "key": "Bankruptcy Risk",
              "value": "Any bankruptcy or insolvency of counterparties could result in material losses."
            },
            {
              "key": "Public Health Crises",
              "value": "COVID-19 and future pandemics could adversely impact clinical trials and business operations."
            },
            {
              "key": "Supply Chain Disruption",
              "value": "Dependence on third-party manufacturers and logistical partners may hinder operations due to health controls."
            },
            {
              "key": "Clinical Trials Disruption",
              "value": "Delays in clinical trials due to patient withdrawals, site initiation issues, and health restrictions."
            },
            {
              "key": "Regulatory Delays",
              "value": "Interruption in operations of FDA and EMA may affect approval timelines."
            },
            {
              "key": "Financial Condition Impact",
              "value": "Potential difficulties in raising capital due to trading volatility linked to the pandemic."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 23,
          "title": "Risks associated with clinical trials",
          "data": [
            {
              "key": "Foreseen events during clinical trials",
              "value": "Numerous unforeseen events may delay or prevent marketing approval."
            },
            {
              "key": "COVID-19 impact",
              "value": "Affect initiation and completion of preclinical studies or ongoing clinical trials."
            },
            {
              "key": "Regulatory agreements",
              "value": "Agreement with the FDA or EMA on trial design could be delayed."
            },
            {
              "key": "Authorization delays",
              "value": "Failure to obtain trial commencement authorization."
            },
            {
              "key": "Trial site negotiation",
              "value": "Terms with prospective trial sites may vary and be under extensive negotiation."
            },
            {
              "key": "Trial site issues",
              "value": "Failure in identifying sufficient trial sites engaged in other programs."
            },
            {
              "key": "Subject recruitment",
              "value": "Delays in recruiting and enrolling suitable subjects."
            },
            {
              "key": "Protocol deviations",
              "value": "Investigators may deviate from the clinical protocol."
            },
            {
              "key": "Funding issues",
              "value": "Lack of adequate funding to continue clinical trials."
            },
            {
              "key": "Negative results",
              "value": "Clinical trials may produce negative or inconclusive results."
            },
            {
              "key": "Patient enrollment",
              "value": "Number of required patients may be larger than anticipated."
            },
            {
              "key": "Contractor compliance",
              "value": "Third-party contractors may fail to meet regulatory requirements."
            },
            {
              "key": "Regulatory oversight",
              "value": "Regulators may suspend or terminate clinical trials."
            },
            {
              "key": "Supply quality",
              "value": "Supply quality may be insufficient for clinical trial needs."
            },
            {
              "key": "Data requirements",
              "value": "Regulatory authorities may impose additional data requirements."
            },
            {
              "key": "Regulatory changes",
              "value": "Changes in governmental regulations may affect trial processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 24,
          "title": "Regulatory Concerns and Risks in Clinical Trials",
          "data": [
            {
              "key": "FDA Regulation Delays",
              "value": "Significant delays and expenses due to FDA's requirements for additional studies."
            },
            {
              "key": "Clinical Trial Risks",
              "value": "Market approval could be delayed, restricted, or denied based on clinical trial outcomes."
            },
            {
              "key": "Data Protection Regulations",
              "value": "Compliance with HIPAA, GDPR, and U.K. GDPR for personal data protection."
            },
            {
              "key": "Increased Development Costs",
              "value": "Higher costs associated with delay in preclinical and clinical development."
            },
            {
              "key": "Competitor Risks",
              "value": "Competitors may commercialize similar products before us due to delays."
            },
            {
              "key": "Privacy Liability",
              "value": "Potential liability for breaches of health information privacy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Risk Factors Related to Compliance and Third Parties",
          "data": [
            {
              "key": "Potential Legal Violations",
              "value": "Investigation of potential violations of anti-corruption laws could adversely impact reputation and financial condition."
            },
            {
              "key": "Environmental Compliance",
              "value": "Failure to comply with environmental laws may result in fines and additional costs."
            },
            {
              "key": "Hazardous Materials Liability",
              "value": "Liability from contamination or injury due to hazardous materials used in operations."
            },
            {
              "key": "Dependence on Third Parties",
              "value": "Reliance on third parties for clinical trials may hinder marketing approval if they fail to meet obligations."
            },
            {
              "key": "Compliance with GCPs",
              "value": "Non-compliance with Good Clinical Practices could result in the need to repeat trials and delays in marketing."
            },
            {
              "key": "Clinical Trials Registration",
              "value": "Failure to register trials could lead to fines and sanctions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 44,
          "title": "Risks Related to Intellectual Property and Patent Protection",
          "data": [
            {
              "key": "Patent Invalidation Risk",
              "value": "Certain innovations may not be patentable, leading to potential invalidation of patents in court."
            },
            {
              "key": "Future Changes in Patent Law",
              "value": "Proposals for changes to patent laws could impact ability to obtain or enforce patents."
            },
            {
              "key": "Competitors Circumvention Risk",
              "value": "Competitors may develop similar technologies that circumvent existing patents."
            },
            {
              "key": "Challenges to Our Patents",
              "value": "Patents may be challenged in courts or patent offices, potentially leading to loss of exclusivity."
            },
            {
              "key": "Impact of Third-Party Submissions",
              "value": "Third parties may submit prior art which could affect the issuance of our patent applications."
            },
            {
              "key": "Reissuance of Patents",
              "value": "Requests for reissuance may not succeed and could lead to lost patents."
            },
            {
              "key": "Dependency on Licensed Patents",
              "value": "We may not control the prosecution or enforcement of licensed patents."
            },
            {
              "key": "Geographic Patent Conflicts",
              "value": "Third-party patents may conflict with ours, restricting commercial viability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 49,
          "title": "Intellectual Property Risks and Litigation",
          "data": [
            {
              "key": "Key Risks",
              "value": "Non-compliance with patent fee payments may result in abandonment or lapse of patents."
            },
            {
              "key": "Litigation Costs",
              "value": "Intellectual property litigation could be unpredictable and expensive."
            },
            {
              "key": "Confidentiality Risk",
              "value": "There is a risk of compromising confidential information during litigation."
            },
            {
              "key": "Adverse Effects on Securities",
              "value": "Negative public announcements during litigation could adversely affect stock prices."
            },
            {
              "key": "Example Case",
              "value": "EP 190 was appealed and revoked by EPO, leading to litigation implications."
            },
            {
              "key": "Competitor Advantage",
              "value": "Competitors may afford better litigation costs due to greater resources."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 53,
          "title": "Potential Risks Related to Expansion and Regulatory Changes",
          "data": [
            {
              "key": "Risk of Growth Management Issues",
              "value": "We may encounter difficulties in managing our growth, which could disrupt our operations."
            },
            {
              "key": "Impact on Financial Performance",
              "value": "Our future financial performance will depend on our ability to effectively manage development and expansion."
            },
            {
              "key": "UK Withdrawal from the EU",
              "value": "The implications of the United Kingdom’s withdrawal from the European Union may negatively affect global economic conditions."
            },
            {
              "key": "Changes in UK-EU Relationship",
              "value": "The Trade and Cooperation Agreement (TCA) has resulted in substantial changes for U.K. businesses."
            },
            {
              "key": "Employee Retention Issues",
              "value": "Uncertainties created by political changes could affect our ability to attract and retain employees, including key scientists."
            },
            {
              "key": "Scotland Independence Referendum",
              "value": "Future referendums on Scottish independence may disrupt our operations and market stability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 55,
          "title": "Risks Related to Product Candidates and Acquisitions",
          "data": [
            {
              "key": "limited resources",
              "value": "We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success."
            },
            {
              "key": "resource allocation decisions",
              "value": "Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities."
            },
            {
              "key": "acquisitions and strategic alliances",
              "value": "We may acquire businesses or drugs or form strategic alliances in the future and we may not realize the benefits of such acquisitions."
            },
            {
              "key": "natural disasters",
              "value": "We or the third parties upon which we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster."
            },
            {
              "key": "ADS price volatility",
              "value": "The price of our ADSs may be volatile and may fluctuate due to factors beyond our control."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 67,
          "title": "Shortcomings of Nucleoside Analogs",
          "data": [
            {
              "key": "Major Shortcomings",
              "value": "Breakdown, poor pharmacokinetic properties, requirement for uptake by transporters, inefficient metabolic pathways."
            },
            {
              "key": "Breakdown",
              "value": "Multiple enzymatic processes can break down nucleoside analogs, resulting in their degradation prior to phosphorylation."
            },
            {
              "key": "Off-target Toxicity Example",
              "value": "Breakdown of 5-FU generates a toxic byproduct called FBAL, associated with side effects like hand-foot syndrome."
            },
            {
              "key": "Uptake Requirements",
              "value": "Nucleoside analogs require specific active-transport proteins to enter cancer cells."
            },
            {
              "key": "Impact of Transport Proteins",
              "value": "Insufficient expression of transport proteins in solid tumors results in poorer outcomes."
            },
            {
              "key": "Inefficient Activation",
              "value": "Nucleoside analogs must undergo complex activation pathways; variability in enzyme levels affects efficacy."
            },
            {
              "key": "Pharmacokinetic Challenges",
              "value": "Rapid breakdown requires challenging administration schedules; 5-FU has a very short plasma half-life."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 153,
          "title": "Market Risk Disclosures",
          "data": [
            {
              "key": "Exposure to interest rate risk",
              "value": "The Company’s surplus cash and cash equivalents are invested in interest-bearing accounts and certificates of deposit."
            },
            {
              "key": "Net annual interest income sensitivity",
              "value": "An increase in the bank interest rates by 0.5 percentage points would increase the net annual interest income by £169,000."
            },
            {
              "key": "Currency risk management",
              "value": "Maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in other currencies."
            },
            {
              "key": "Impact of currency fluctuations",
              "value": "A 1% increase in the value of the pound sterling relative to the U.S. dollar would reduce the carrying value of net financial assets by £283,000."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "risk_factor",
          "page": 199,
          "title": "Financial Instruments Risk Management",
          "data": [
            {
              "key": "Currency Risk",
              "value": "The Company’s functional currency is U.K. pounds sterling, with exposure to expenses incurred in U.S. dollars. Weakening of the pound makes purchases more expensive."
            },
            {
              "key": "Financial Assets and Liabilities Summary",
              "value": "The table presents a financial statement showing assets and liabilities in thousands of pounds across two periods. Significant items include cash and cash equivalents, which decreased from £41,371k to £27,924k. Total assets significantly outweigh total liabilities."
            },
            {
              "key": "Impact of Currency Fluctuations",
              "value": "A 1% increase in the value of the U.K. pound sterling relative to the U.S. dollar would reduce the carrying value of net financial assets and liabilities in foreign currencies by £283,000."
            },
            {
              "key": "Credit Risk",
              "value": "All cash and cash equivalents at December 31, 2022 were held at U.K. and U.S. financial institutions with A-rated credit ratings. No expected credit losses provision recognized."
            }
          ],
          "currency": "GBP"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 3,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Summary",
              "value": "This table appears to be a table of contents or index from a financial report or regulatory filing (likely a Form 20-F or similar document). It contains various sections including corporate governance items, financial statements, and regulatory disclosures. The document spans pages 123-154, with major sections including Share Capital, Material Contracts, Financial Statements, and various corporate governance items (Items 16A through 16I). The content is organized in a hierarchical structure with main sections and subsections, each with corresponding page numbers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Forward-Looking Statements",
          "data": [
            {
              "key": "description",
              "value": "This section discusses the estimates and forward-looking statements regarding the development of NUC-3373, NUC-7738, and Acelarin, including expectations on clinical trials, potential commercial ability, and factors that could impact financial results."
            },
            {
              "key": "risks",
              "value": "Actual results may differ materially due to known and unknown risks, uncertainties, and assumptions."
            },
            {
              "key": "forward_looking_terms",
              "value": "Words indicating forward-looking statements include believe, may, will, estimate, continue, anticipate, intend, and expect."
            },
            {
              "key": "factors_affecting_results",
              "value": "Risks discussed under 'Risk Factors' could cause variations in actual outcomes."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 5,
          "title": "Forward-Looking Statements and Estimates",
          "data": [
            {
              "key": "Cautionary Statement",
              "value": "The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect' and similar words identify estimates and forward-looking statements."
            },
            {
              "key": "Nature of Estimates",
              "value": "Estimates speak only at the date they were made and involve risks and uncertainties."
            },
            {
              "key": "Obligation to Update",
              "value": "No obligation to update or review estimates and forward-looking statements because of new information, future events, or other factors."
            },
            {
              "key": "Investment Decisions Warning",
              "value": "Investors should not make decisions based solely on forward-looking statements."
            },
            {
              "key": "Website Disclosure",
              "value": "Public website as a channel for disclosing company information, including investor reports and compliance with Regulation FD."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 20,
          "title": "Impact of Global Factors on Clinical Trials and Financial Operations",
          "data": [
            {
              "key": "Travel Restrictions",
              "value": "Imposition of travel restrictions and actions to contain the pandemic."
            },
            {
              "key": "Ukraine Conflict Impact",
              "value": "Ongoing conflict in Ukraine could adversely impact business, particularly in clinical trials."
            },
            {
              "key": "Regulatory Challenges",
              "value": "Future changes in regulatory regimes may negatively impact operations."
            },
            {
              "key": "Clinical Trial Sites",
              "value": "Risk of suspension or termination of clinical trial sites in affected regions."
            },
            {
              "key": "Exchange Rate Fluctuations",
              "value": "International operations subject to fluctuations in currency values."
            },
            {
              "key": "Regulatory Framework Changes",
              "value": "Changes in regulatory frameworks could delay approval of new medicines."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 27,
          "title": "Risks Related to Marketing Approval of Our Product Candidates",
          "data": [
            {
              "key": "Risks Overview",
              "value": "Describes the risks related to obtaining marketing approval for product candidates."
            },
            {
              "key": "Approval Requirement",
              "value": "Each product candidate must be approved by regulatory authorities such as the FDA and EMA."
            },
            {
              "key": "Approval Process Duration",
              "value": "The process is expensive and can take several years to obtain marketing approval."
            },
            {
              "key": "Clinical Trials",
              "value": "Limited experience in planning and conducting necessary clinical trials."
            },
            {
              "key": "Regulatory Discretion",
              "value": "Regulatory authorities may refuse to accept applications or require additional studies."
            },
            {
              "key": "Potential Issues",
              "value": "Candidates may not demonstrate safety, effectiveness, or may encounter side effects that hinder approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 29,
          "title": "Regulatory Challenges and FDA Fast Track Designation",
          "data": [
            {
              "key": "Key Points",
              "value": "Discretionary nature of FDA's Fast Track Designation and uncertainty of faster development."
            },
            {
              "key": "Potential Risks",
              "value": "Possible negative consequences affecting commercialization and market acceptance."
            },
            {
              "key": "Post-Marketing Obligations",
              "value": "Extensive regulatory requirements and potential penalties for non-compliance."
            },
            {
              "key": "Compliance Monitoring",
              "value": "Mandated ongoing compliance with cGMP and regulatory authorities."
            },
            {
              "key": "Consequences of Violations",
              "value": "Investigations and enforcement actions due to off-label promotion."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 32,
          "title": "Impact of ACA and IRA on Healthcare and Drug Pricing",
          "data": [
            {
              "key": "Legislation Enacted",
              "value": "American Rescue Plan Act of 2021"
            },
            {
              "key": "Key Changes",
              "value": "Eliminates Medicaid drug rebate cap to start January 1, 2024"
            },
            {
              "key": "New Initiatives",
              "value": "Development of new payment and delivery models by CMS"
            },
            {
              "key": "Legislation Affecting Drug Pricing",
              "value": "Inflation Reduction Act of 2022"
            },
            {
              "key": "Key Provisions of IRA",
              "value": "Price negotiations with Medicare, rebates for price increases outpacing inflation"
            },
            {
              "key": "Biden Administration Measures",
              "value": "Executive order to promote competition and lower drug prices"
            },
            {
              "key": "State Legislation",
              "value": "Measures to control pharmaceutical product pricing"
            },
            {
              "key": "Court Ruling",
              "value": "U.S. Supreme Court ruling on state regulation of PBMs"
            },
            {
              "key": "Impact on Revenue",
              "value": "Potential downward pressure on pricing and profitability due to ACA and IRA reforms"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 57,
          "title": "Adverse reactions in financial markets due to shareholder control",
          "data": [
            {
              "key": "shareholder_control",
              "value": "Certain of our existing shareholders, members of our board of directors and senior management maintain the ability to exercise significant control over us."
            },
            {
              "key": "ownership_percentage",
              "value": "As of December 31, 2022, our senior management, board of directors and greater than 5% shareholders and their respective affiliates owned 40.8% of our ordinary shares."
            },
            {
              "key": "voting_control",
              "value": "Shareholders controlling more than 50% may control any shareholder resolution requiring a simple majority."
            },
            {
              "key": "SEC_regulation",
              "value": "SEC regulations could limit the amount of funds we can raise during any 12-month period."
            },
            {
              "key": "dividend_policy",
              "value": "We do not anticipate paying any cash dividends on our ADSs or ordinary shares in the foreseeable future."
            },
            {
              "key": "voting_rights_ADS",
              "value": "Holders of our ADSs may not have the same voting rights as the holders of our ordinary shares."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 61,
          "title": "Management Assessment of Internal Controls and PFIC Status",
          "data": [
            {
              "key": "Inadequate internal controls",
              "value": "Could lead to loss of confidence in financial information and negatively affect ADS trading price."
            },
            {
              "key": "Assessment requirement",
              "value": "Management must assess the effectiveness of internal controls annually."
            },
            {
              "key": "OSC exemption",
              "value": "Exempt from external audit for internal controls under Section 404(b) due to non-accelerated filer status."
            },
            {
              "key": "EGC status",
              "value": "Cessation of EGC status as of last day of 2022."
            },
            {
              "key": "Impact of analysts",
              "value": "Lack of coverage or unfavorable research by analysts could lead to decline in ADS price."
            },
            {
              "key": "PFIC status implications",
              "value": "Potential adverse U.S. federal income tax consequences for U.S. investors."
            },
            {
              "key": "Factors determining PFIC status",
              "value": "Depends on income characterization and asset valuation."
            },
            {
              "key": "Current PFIC status",
              "value": "Believed to be PFIC for the taxable year ended December 31, 2022."
            },
            {
              "key": "U.S. tax considerations for PFIC",
              "value": "May include adverse tax consequences and additional reporting obligations."
            },
            {
              "key": "Advisors recommendation",
              "value": "Investors should consult tax advisors regarding PFIC rules."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 84,
          "title": "Clinical Trials Results Update",
          "data": [
            {
              "key": "Trial Name",
              "value": "ACELARATE"
            },
            {
              "key": "Primary Objective",
              "value": "Determine whether Acelarin is superior to gemcitabine in terms of overall survival."
            },
            {
              "key": "Total Patients Enrolled",
              "value": "200"
            },
            {
              "key": "Patients Receiving Acelarin",
              "value": "100"
            },
            {
              "key": "Male Patients",
              "value": "48"
            },
            {
              "key": "Female Patients",
              "value": "52"
            },
            {
              "key": "Average Age",
              "value": "73 years"
            },
            {
              "key": "Futility Analysis Result",
              "value": "Primary efficacy objective unlikely to be met."
            },
            {
              "key": "Trial Status",
              "value": "Closed in June 2021."
            },
            {
              "key": "Comments",
              "value": "Patients benefiting could continue treatment."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 90,
          "title": "Clinical Trials and NDA Submissions",
          "data": [
            {
              "key": "Description",
              "value": "Clinical trials involve the administration of investigational new drugs to assess safety and efficacy."
            },
            {
              "key": "Phases",
              "value": "Clinical trials typically occur in three phases: Phase 1 (initial testing in humans), Phase 2 (testing for effectiveness and safety in a larger patient group), Phase 3 (confirmation of efficacy and monitoring for adverse effects in a diverse population)."
            },
            {
              "key": "NDA Submission",
              "value": "An NDA must include all preclinical and clinical test results, and a substantial application user fee is required."
            },
            {
              "key": "FDA Review Timelines",
              "value": "The FDA review takes twelve months for standard applications and eight months for priority applications."
            },
            {
              "key": "Costs",
              "value": "The application user fee for NDAs exceeds $3.2 million for fiscal year 2023."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 99,
          "title": "Impact of Regulatory Environments on Pharmaceutical Pricing and Marketability",
          "data": [
            {
              "key": "IRA Provisions Implementation",
              "value": "Many provisions will be implemented through guidance rather than regulation."
            },
            {
              "key": "Regulatory Approval Impact",
              "value": "Marketability of products may suffer if adequate coverage and reimbursement from government and third-party payors are not provided."
            },
            {
              "key": "Pressure on Pharmaceutical Pricing",
              "value": "Increasing cost containment measures in the US are expected to raise pricing pressures."
            },
            {
              "key": "Reimbursement Variability",
              "value": "Coverage policies and reimbursement rates may change at any time."
            },
            {
              "key": "Foreign Pricing Requirements",
              "value": "Proposed pricing for drugs must often be approved in foreign countries before marketing."
            },
            {
              "key": "Health Technology Assessment",
              "value": "Some countries require cost-effectiveness studies to obtain reimbursement."
            },
            {
              "key": "U.S. Healthcare Laws",
              "value": "Operations are subject to various U.S. federal, state, and foreign laws affecting healthcare programs."
            },
            {
              "key": "Anti-Kickback Statute",
              "value": "Prohibits soliciting or receiving anything of value to induce referrals."
            },
            {
              "key": "False Claims Act",
              "value": "Prohibits presenting fraudulent claims for payment of federal funds."
            },
            {
              "key": "HIPAA Compliance",
              "value": "Imposes obligations regarding safeguarding privacy and security of health information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 124,
          "title": "Board of Directors Diversity Matrix",
          "data": [
            {
              "key": "category",
              "value": "Directors"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "African American or Black"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "Alaskan Native or Native American"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "Asian"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "Hispanic or Latinx"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "Native Hawaiian or Pacific Islander"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "White"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "Two or More Races or Ethnicities"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "LGBTQ+"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            },
            {
              "key": "category",
              "value": "Did Not Disclose Demographic Background"
            },
            {
              "key": "female",
              "value": "null"
            },
            {
              "key": "male",
              "value": "null"
            },
            {
              "key": "non_binary",
              "value": "null"
            },
            {
              "key": "did_not_disclose",
              "value": "null"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 124,
          "title": "Employee Distribution Analysis",
          "data": [
            {
              "key": "category",
              "value": "Research and development"
            },
            {
              "key": "2022",
              "value": "25"
            },
            {
              "key": "2021",
              "value": "27"
            },
            {
              "key": "2020",
              "value": "23"
            },
            {
              "key": "category",
              "value": "Management and administrative"
            },
            {
              "key": "2022",
              "value": "6"
            },
            {
              "key": "2021",
              "value": "6"
            },
            {
              "key": "2020",
              "value": "6"
            },
            {
              "key": "category",
              "value": "Total"
            },
            {
              "key": "2022",
              "value": "31"
            },
            {
              "key": "2021",
              "value": "33"
            },
            {
              "key": "2020",
              "value": "29"
            },
            {
              "key": "category",
              "value": "United Kingdom"
            },
            {
              "key": "2022",
              "value": "29"
            },
            {
              "key": "2021",
              "value": "30"
            },
            {
              "key": "2020",
              "value": "27"
            },
            {
              "key": "category",
              "value": "North America"
            },
            {
              "key": "2022",
              "value": "2"
            },
            {
              "key": "2021",
              "value": "3"
            },
            {
              "key": "2020",
              "value": "2"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 128,
          "title": "Dividend Policy",
          "data": [
            {
              "key": "Dividend Declaration",
              "value": "We have never declared or paid a dividend, and we do not anticipate declaring or paying dividends in the foreseeable future."
            },
            {
              "key": "Future Earnings Use",
              "value": "We intend to retain all available funds and any future earnings to fund the development and expansion of our business."
            },
            {
              "key": "Legal Framework",
              "value": "Under English law, dividends may only be paid if we have sufficient distributable reserves."
            },
            {
              "key": "Significant Changes",
              "value": "Any significant changes since December 31, 2022 are disclosed in Note 20 to the consolidated financial statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 137,
          "title": "Exclusion of Preemptive Rights and Takeover Code Compliance",
          "data": [
            {
              "key": "Preemptive Rights Exclusion Approval Date",
              "value": "June 23, 2022"
            },
            {
              "key": "Amount Approved for New Allotment",
              "value": "£1,200,000"
            },
            {
              "key": "Expiry of Approval",
              "value": "2023 AGM"
            },
            {
              "key": "Amount for Share Option Schemes",
              "value": "£200,000"
            },
            {
              "key": "Directors Approval Duration",
              "value": "Until June 22, 2027"
            },
            {
              "key": "Additional Exclusions Approved Date (2021 AGM)",
              "value": "June 24, 2021"
            },
            {
              "key": "Amount for Approved Share Option Schemes (2021)",
              "value": "£80,000"
            },
            {
              "key": "Expiry of Share Option Schemes (2021)",
              "value": "2026 AGM"
            },
            {
              "key": "Additional Exclusions Approved Date (2020 AGM)",
              "value": "June 25, 2020"
            },
            {
              "key": "Amount for Approved Share Option Schemes (2020)",
              "value": "£160,000"
            },
            {
              "key": "Expiry of Share Option Schemes (2020)",
              "value": "2025 AGM"
            },
            {
              "key": "Compliance with City Code on Takeovers and Mergers",
              "value": "Yes"
            },
            {
              "key": "Impact of Takeover Code on Share Acquisitions",
              "value": "Anti-takeover provisions exist"
            },
            {
              "key": "Distributable Reserves Requirement",
              "value": "Must have sufficient reserves to pay dividends."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "guidance_update",
          "page": 140,
          "title": "Notice of General Meetings Proxy Pre-emptive Rights Under the Companies Act 2006",
          "data": [
            {
              "key": "Notice period for general meetings (Companies Act 2006)",
              "value": "21 clear days’ notice for an annual general meeting; 14 clear days’ notice for other general meetings, unless specified otherwise."
            },
            {
              "key": "Special notice requirement",
              "value": "28 clear days’ notice is required for resolutions to remove directors or auditors."
            },
            {
              "key": "Shorter notice consent",
              "value": "100% consent of shareholders required for annual general meetings; majority consent for other general meetings."
            },
            {
              "key": "Proxy representation",
              "value": "Shareholders can designate another person to attend, speak and vote at the meeting on their behalf by proxy."
            },
            {
              "key": "Equity securities pre-emption",
              "value": "Existing equity shareholders must be offered new equity securities in proportion to their holdings."
            },
            {
              "key": "Delaware law notice requirements",
              "value": "Written notice of meetings must be given 10 to 60 days before the meeting."
            },
            {
              "key": "Delaware law proxy rules",
              "value": "Proxy must not be acted upon after three years, except if a longer period is specified."
            },
            {
              "key": "Delaware shareholder rights",
              "value": "Shareholders have no preemptive rights unless expressly provided in the certificate of incorporation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 141,
          "title": "Authority to Allot Liability of Directors and Officers Under the Companies Act 2006",
          "data": [
            {
              "key": "Overview",
              "value": "Directors of a company must not allot shares or grant rights to subscribe unless exceptions apply or an ordinary resolution has been passed."
            },
            {
              "key": "Provisions",
              "value": "Any provision purporting to exempt a director from liability due to negligence or breach of trust is void."
            },
            {
              "key": "Indemnity",
              "value": "Indemnities for directors are void unless permitted by the Companies Act 2006, allowing for insurance against liability."
            },
            {
              "key": "Delaware Law",
              "value": "Under Delaware law, the board may authorize stock issuance for cash or property, and may eliminate personal liability for fiduciary duty breaches."
            },
            {
              "key": "Limitations of Liability",
              "value": "No provision can limit liability for breaches of loyalty, intentional misconduct, or deriving improper personal benefits."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 142,
          "title": "Voting Rights Shareholder Vote on Certain Transactions",
          "data": [
            {
              "key": "Summary",
              "value": "Discusses the voting rights of shareholders under the Companies Act 2006 and Delaware law for various transactions."
            },
            {
              "key": "Key Points",
              "value": "1. Shareholder voting usually by show of hands unless a poll is demanded. 2. Poll may be demanded by five shareholders or 10% voting rights. 3. Ordinary resolutions require a simple majority; special resolutions require 75% approval. 4. Schemes of arrangement need court approval and a 75% majority from shareholders or creditors."
            },
            {
              "key": "Jurisdictions",
              "value": "England, Delaware"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 146,
          "title": "Potential PFIC Classification and Election Options for U.S. Holders",
          "data": [
            {
              "key": "Tax implications of PFIC",
              "value": "U.S. Holders may face specific tax consequences if the entity is classified as a PFIC."
            },
            {
              "key": "QEF Election process",
              "value": "Information necessary for making QEF Elections will be posted on the company website."
            },
            {
              "key": "Tax basis adjustments",
              "value": "A U.S. Holder's tax basis in ADSs will be adjusted based on income inclusion under a QEF Election."
            },
            {
              "key": "Mark-to-Market Election",
              "value": "U.S. Holders may elect mark-to-market to include gains as ordinary income instead of under special tax regime."
            },
            {
              "key": "Uncertainty of PFIC status",
              "value": "PFIC status depends on various factors and may change from year to year."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 147,
          "title": "Provisions regarding U.S. holders and PFICs.",
          "data": [
            {
              "key": "Approval for Listing",
              "value": "Approval to list ADSs on the Nasdaq Global Select Market."
            },
            {
              "key": "Tax implications of ADSs",
              "value": "U.S. Holders may face ordinary income tax on excess fair market value over basis in ADSs."
            },
            {
              "key": "Mark-to-Market Election",
              "value": "A U.S. Holder making a mark-to-market election must include excess fair market value over basis in income."
            },
            {
              "key": "Controlled Foreign Corporation (CFC) rules",
              "value": "Changes in tax law have impacted CFC definitions and obligations for U.S. Shareholders."
            },
            {
              "key": "Consultation recommendation",
              "value": "U.S. Holders should consult tax advisors regarding ownership and compliance with CFC and PFIC rules."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 151,
          "title": "Tax implications for U.K. and non-U.K. Holders of ADSs",
          "data": [
            {
              "key": "U.K. income tax",
              "value": "33.75% for additional rate, 39.35% for higher rate"
            },
            {
              "key": "UK Corporation Tax rate 2022/2023",
              "value": "19%, rising to 25% for profits over £250,000 after April 1, 2023"
            },
            {
              "key": "Capital Gains Tax rates",
              "value": "20% for higher/additional rate taxpayers, 10% for basic rate taxpayers"
            },
            {
              "key": "Annual Capital Gains Tax exemption for 2022/2023",
              "value": "£12,300, reducing to £6,000 on April 6, 2023, and to £3,000 on April 6, 2024"
            },
            {
              "key": "Non-U.K. holders",
              "value": "Not liable to U.K. capital gains tax unless carrying on a trade in the U.K."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "guidance_update",
          "page": 171,
          "title": "Notes to the Consolidated Financial Statements",
          "data": [
            {
              "key": "Company Name",
              "value": "NuCana plc"
            },
            {
              "key": "Nature of Business",
              "value": "Clinical-stage biopharmaceutical company developing new medicines for cancer treatment."
            },
            {
              "key": "Financial Year End",
              "value": "December 31, 2022"
            },
            {
              "key": "Functional Currency",
              "value": "Pounds sterling"
            },
            {
              "key": "Cash and Cash Equivalents",
              "value": "£41.9 million"
            },
            {
              "key": "Going Concern Status",
              "value": "Board satisfied with resources for foreseeable future."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Potential delays in clinical trials due to resurgence, but no impact on financial estimates."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "guidance_update",
          "page": 172,
          "title": "Significant accounting policies",
          "data": [
            {
              "key": "Judgements and estimates",
              "value": "Management makes judgements, estimates, and assumptions affecting assets, liabilities, revenue, and expenses."
            },
            {
              "key": "Research and development expenses",
              "value": "Recognized in operations as incurred; can be capitalized if development reaches advanced stage."
            },
            {
              "key": "Taxation",
              "value": "Management judgement on deferred tax assets based on future taxable profits."
            },
            {
              "key": "Recognition of clinical trial expenses",
              "value": "Estimates are made for accrued or prepaid clinical trial expenses."
            },
            {
              "key": "Accruals for clinical trial expenses",
              "value": "£6.6 million at Dec 31, 2022; £7.2 million at Dec 31, 2021."
            },
            {
              "key": "Prepayments for clinical trial expenses",
              "value": "£1.8 million at Dec 31, 2022; £1.5 million at Dec 31, 2021."
            },
            {
              "key": "Recognition of contracted manufacturing expenses",
              "value": "Estimates are made for accrued or prepaid manufacturing expenses."
            },
            {
              "key": "Accruals for contracted manufacturing expenses",
              "value": "£0.4 million at Dec 31, 2022; £0.1 million at Dec 31, 2021."
            },
            {
              "key": "Prepayments for contracted manufacturing expenses",
              "value": "£0.1 million at Dec 31, 2022; £0.1 million at Dec 31, 2021."
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "guidance_update",
          "page": 177,
          "title": "Impairment of non-financial assets",
          "data": [
            {
              "key": "Assessment of impairment",
              "value": "The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired."
            },
            {
              "key": "Recoverable amount",
              "value": "The recoverable amount is determined as the higher of fair value less costs to sell and value in use."
            },
            {
              "key": "Reversal of impairment",
              "value": "An assessment is made at each reporting date as to whether there is an indication that a previously recognized impairment loss may no longer exist."
            },
            {
              "key": "Share-based payments",
              "value": "Employees, directors and consultants receive remuneration in the form of share options."
            },
            {
              "key": "IFRS 2 Compliance",
              "value": "Equity share-based payments are measured at fair value at the grant date."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 188,
          "title": "Other assets",
          "data": [
            {
              "key": "Total Other assets",
              "value": "£2,540,000"
            },
            {
              "key": "Current",
              "value": ""
            },
            {
              "key": "Non-current",
              "value": ""
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "guidance_update",
          "page": 188,
          "title": "Receivables and Repayments Breakdown",
          "data": [
            {
              "key": "repayments - manufacturing and clinical",
              "value": "£1,890,000"
            },
            {
              "key": "repayments - other",
              "value": "£1,416,000"
            },
            {
              "key": "accrued income",
              "value": "£36,000"
            },
            {
              "key": "VAT",
              "value": "£601,000"
            },
            {
              "key": "other receivables",
              "value": "£14,000"
            },
            {
              "key": "Total",
              "value": "£3,957,000"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "guidance_update",
          "page": 206,
          "title": "Variation of Lease Agreement",
          "data": [
            {
              "key": "Annual Rent Waiver Period",
              "value": "from 15 August 2022 to 14 November 2022"
            },
            {
              "key": "Extended Term of Lease",
              "value": "for a further period of five years from 15 August 2022 to 14 August 2027"
            },
            {
              "key": "Termination Right",
              "value": "Tenants can terminate on 14 August 2025 with nine months' notice"
            },
            {
              "key": "Refund of Rents",
              "value": "Refund of rents paid relating to the period after 14 August 2025"
            },
            {
              "key": "Landlords' Obligations",
              "value": "Landlords must observe and perform obligations in the Varied Lease"
            },
            {
              "key": "Tenants' Obligations",
              "value": "Tenants must observe and perform obligations in the Varied Lease"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 17,
          "title": "Regulatory and Compliance Challenges",
          "data": [
            {
              "key": "difficulties in compliance with non-U.S. laws and regulations",
              "value": "Changes in regulations, tariffs, and trade barriers"
            },
            {
              "key": "currency exchange rate changes",
              "value": "Impact of pound sterling, euro, and currency controls"
            },
            {
              "key": "changes in political/economic environment",
              "value": "Implications of the UK's withdrawal from the EU"
            },
            {
              "key": "trade protection measures",
              "value": "U.S. and non-U.S. governmental actions"
            },
            {
              "key": "differing reimbursement regimes",
              "value": "Impacts in non-U.S. markets"
            },
            {
              "key": "compliance issues",
              "value": "Tax, employment, immigration, and labor laws"
            },
            {
              "key": "workforce uncertainty",
              "value": "Labor unrest in various regions"
            },
            {
              "key": "staffing difficulties",
              "value": "Managing international operations"
            },
            {
              "key": "production shortages",
              "value": "Raw material supply issues"
            },
            {
              "key": "business interruptions",
              "value": "Geo-political actions, natural disasters"
            },
            {
              "key": "changes in financial markets",
              "value": "Effects of recession, interest rates, inflation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 18,
          "title": "Impact of Financial Crises and Regulatory Measures on Liquidity",
          "data": [
            {
              "key": "Transaction implications for depositors",
              "value": "Depositors may have access to all their money; dependency on the stability of counterparties."
            },
            {
              "key": "Risks from financial institutions",
              "value": "If counterparties are put into receivership, funds may not be accessible."
            },
            {
              "key": "Historical context",
              "value": "Similar impacts observed during the 2008-2010 financial crisis."
            },
            {
              "key": "Government response",
              "value": "U.S. Department of Treasury, FDIC, and Federal Reserve announced a $25 billion loan program."
            },
            {
              "key": "Potential liquidity risks",
              "value": "Widespread demands for withdrawals may exceed program capacity."
            },
            {
              "key": "Access to funding sources",
              "value": "Future access to uninsured funds and funding arrangements may be compromised."
            },
            {
              "key": "Impact on business operations",
              "value": "Material and adverse impacts on financial condition and results of operations."
            },
            {
              "key": "Investor concerns",
              "value": "Negative expectations could lead to reduced commercial financing terms."
            },
            {
              "key": "Consequences of liquidity constraints",
              "value": "Adverse impact on ability to meet operating expenses and obligations."
            },
            {
              "key": "Macroeconomic effects",
              "value": "Further deterioration in financial services could lead to losses by business parties."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 25,
          "title": "Regulatory Framework and Risks Regarding Personal Data Transfer",
          "data": [
            {
              "key": "GDPR",
              "value": "General Data Protection Regulation (GDPR) impacts personal data transfer."
            },
            {
              "key": "U.K. GDPR",
              "value": "U.K. GDPR applies similarly to the GDPR regarding data protection laws."
            },
            {
              "key": "CJEU Ruling",
              "value": "On July 16, 2020, the CJEU clarified that standard contractual clauses are case-dependent."
            },
            {
              "key": "Adequacy Decision UK",
              "value": "June 28, 2021 - European Commission adopted adequacy decision for unrestricted data transfer to the UK."
            },
            {
              "key": "Risks of Compliance Costs",
              "value": "Invalidation of the adequacy decision could lead to additional compliance costs."
            },
            {
              "key": "E.U. - U.S. Data Privacy Framework",
              "value": "December 13, 2022 - process for new adequacy decision for data transfer to U.S."
            },
            {
              "key": "Divergence of Data Laws",
              "value": "Post-Brexit divergence in data laws and their enforcement between U.K. and EU."
            },
            {
              "key": "Data Protection and Digital Information Bill",
              "value": "March 8, 2023 - U.K. Government presented new bill impacting data protection."
            },
            {
              "key": "EHDS Regulation",
              "value": "European Health Data Space Regulation mandates anonymized health data access."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 26,
          "title": "Regulatory Landscape and Compliance",
          "data": [
            {
              "key": "General Regulatory Compliance",
              "value": "The law is in initial stages, likely not applicable for several years."
            },
            {
              "key": "Costs and Complexity of Compliance",
              "value": "Complying with complex and changing regulations is expensive and difficult."
            },
            {
              "key": "Potential GDPR Fines",
              "value": "Fines could be up to €20 million or 4% of total worldwide annual turnover."
            },
            {
              "key": "UK GDPR Compliance Post-Brexit",
              "value": "Separate compliance for GDPR and UK GDPR is now required."
            },
            {
              "key": "Consequences of Non-Compliance",
              "value": "Failure to comply could result in fines, audits, and reputational damage."
            },
            {
              "key": "Liability for Third-Party Processors",
              "value": "Data controllers are accountable for third-party service providers' compliance."
            },
            {
              "key": "Conflicting Jurisdictions",
              "value": "Compliance may conflict with laws in different jurisdictions."
            },
            {
              "key": "Impact of Security Breaches",
              "value": "Breaches could adversely affect business and lead to legal claims."
            },
            {
              "key": "R&D Resource Allocation",
              "value": "Limited resources impact decision-making for ProTide development."
            },
            {
              "key": "Product Development Risks",
              "value": "Decisions on ProTide candidates may prove suboptimal."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 28,
          "title": "Regulatory Challenges and Risks Associated with Product Candidates",
          "data": [
            {
              "key": "Issue",
              "value": "Insufficient data for NDA submission"
            },
            {
              "key": "Regulatory Authority",
              "value": "FDA and other foreign authorities"
            },
            {
              "key": "Potential Outcomes",
              "value": "Approval with limited indications or costly post-marketing trials"
            },
            {
              "key": "Commercial Impact",
              "value": "Delayed approval may impair revenue generation"
            },
            {
              "key": "Side Effects Risks",
              "value": "Undesirable side effects could prevent approval or limit market profile"
            },
            {
              "key": "Consequences of Side Effects",
              "value": "Withdrawal of approval or requirement for additional safety measures"
            },
            {
              "key": "Patient Profile Risk",
              "value": "Increased claims related to side effects in seriously ill patients"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 30,
          "title": "Regulatory Compliance Risks",
          "data": [
            {
              "key": "Suspension of Marketing Approvals",
              "value": "Non-compliance may lead to suspension or withdrawal of marketing approvals."
            },
            {
              "key": "Financial Penalties",
              "value": "Non-compliance with EU requirements can result in significant financial penalties."
            },
            {
              "key": "Regulatory Authority Changes",
              "value": "Policies may change, potentially delaying marketing approvals."
            },
            {
              "key": "Healthcare Laws and Regulations",
              "value": "Compliance with healthcare laws is crucial to avoid penalties."
            },
            {
              "key": "Anti-Kickback Statute",
              "value": "Prohibits remunerations to influence healthcare decisions."
            },
            {
              "key": "False Claims Act",
              "value": "Imposes penalties for false claims to the federal government."
            },
            {
              "key": "HIPAA Violations",
              "value": "Criminal and civil liabilities for defrauding healthcare programs."
            },
            {
              "key": "Physician Payments Sunshine Act",
              "value": "Requires reporting of payments and transfers of value to healthcare providers."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 31,
          "title": "Regulatory Compliance Challenges",
          "data": [
            {
              "key": "context",
              "value": "The document discusses the compliance requirements related to individually identifiable health information and the penalties for non-compliance with healthcare laws."
            },
            {
              "key": "issues",
              "value": "State and foreign laws complicating compliance, potential penalties for violating healthcare laws."
            },
            {
              "key": "recent_legislation",
              "value": "FDA Reauthorization Act, FDA User Fee Reauthorization Act of 2022, ACA, Consolidated Appropriations Act of 2021."
            },
            {
              "key": "impact",
              "value": "Challenges to marketing approval, potential adverse effects on business and profitability."
            },
            {
              "key": "government_initiatives",
              "value": "Efforts at federal and state levels to reduce healthcare costs and improve quality."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 33,
          "title": "Regulatory and Legislative Challenges for Marketing Approvals",
          "data": [
            {
              "key": "Description",
              "value": "Legislative and regulatory proposals have been made to expand post-approval requirements and restrict promotional activities for pharmaceutical products."
            },
            {
              "key": "Potential Impact",
              "value": "Uncertainty regarding the effect of changes on marketing approvals of product candidates."
            },
            {
              "key": "Congressional Scrutiny",
              "value": "Increased scrutiny by the U.S. Congress may delay or prevent marketing approvals."
            },
            {
              "key": "Foreign Market Penetration",
              "value": "Future growth may depend on penetrating foreign markets subject to different regulatory burdens."
            },
            {
              "key": "Approval Variability",
              "value": "Approval procedures differ substantially among countries and regions, affecting timelines and requirements."
            },
            {
              "key": "Compliance Risks",
              "value": "Failure to comply with regulatory requirements may reduce target markets and harm commercialization."
            },
            {
              "key": "Third-party Collaborators",
              "value": "Necessary approvals from regulatory authorities are required to market products internationally."
            },
            {
              "key": "Reimbursement Approval",
              "value": "In some countries, products must be approved for reimbursement before sales approval."
            },
            {
              "key": "Patent Enforcement",
              "value": "Enforcement of patents may be problematic in foreign jurisdictions."
            },
            {
              "key": "Compulsory Licensing",
              "value": "Possibility of compulsory licenses that allows third parties to manufacture products."
            },
            {
              "key": "Currency Risks",
              "value": "Foreign currency exchange rate fluctuations may affect profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 34,
          "title": "Regulatory Compliance and Anti-Corruption",
          "data": [
            {
              "key": "Trade Control Laws",
              "value": "Compliance with the Bribery Act, the FCPA, and anti-corruption laws including the Criminal Finances Act 2017."
            },
            {
              "key": "Potential Penalties",
              "value": "Subject to criminal and civil penalties, disgorgement, and other sanctions if not compliant."
            },
            {
              "key": "Impact on Revenue",
              "value": "Pricing negotiations with governments may adversely affect revenues."
            },
            {
              "key": "International Operations",
              "value": "Operations subjected to different regulations administrated by various countries."
            },
            {
              "key": "Corruption Risks",
              "value": "Operations in jurisdictions with high corruption risks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 36,
          "title": "Risks Associated with Third-Party Contractors in Clinical Trials",
          "data": [
            {
              "key": "Risks of third-party involvement",
              "value": "Reliance on third parties increases risks regarding staffing, compliance with contractual obligations, regulatory issues, and relationship management."
            },
            {
              "key": "Impact of failure of CROs",
              "value": "Failure of clinical research organizations (CROs) may result in delays, inability to obtain marketing approvals, and harm to development programs."
            },
            {
              "key": "Financial implications",
              "value": "Unexpected cost increases may occur due to third-party challenges, which can affect revenue generation."
            },
            {
              "key": "Manufacturing reliance",
              "value": "Dependence on third parties for manufacturing and shipment increases risks related to quality and compliance with regulatory requirements."
            },
            {
              "key": "Regulatory compliance and consequences",
              "value": "Non-compliance with cGMP by third-party manufacturers could lead to delays, sanctions, and operational restrictions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 37,
          "title": "Regulatory and Supply Chain Risks",
          "data": [
            {
              "key": "reliance_on_third_party",
              "value": "Reliance on third party for regulatory compliance and quality assurance."
            },
            {
              "key": "manufacturing_agreement_breach",
              "value": "Possible breach of the manufacturing agreement by the third party."
            },
            {
              "key": "misappropriation_of_information",
              "value": "Possible misappropriation of proprietary information, trade secrets, and know-how."
            },
            {
              "key": "termination_of_agreement",
              "value": "Possible termination or non-renewal of the agreement by the third party."
            },
            {
              "key": "manufacturer_reduction",
              "value": "Limited number of manufacturers under cGMP regulations."
            },
            {
              "key": "performance_failure",
              "value": "Performance failure of manufacturers could delay clinical development."
            },
            {
              "key": "replacement_costs",
              "value": "Costs and delays in identifying and qualifying replacement manufacturers."
            },
            {
              "key": "third_party_capacity",
              "value": "Dependence on third parties for drug candidates may affect profit margins."
            },
            {
              "key": "scale_up_issues",
              "value": "Potential inability to scale up manufacturing of product candidates."
            },
            {
              "key": "suppliers_loss",
              "value": "Loss of sole suppliers may harm business."
            },
            {
              "key": "supplier_capaity",
              "value": "Single-source suppliers with limited capacity are risk factors."
            },
            {
              "key": "need_for_additional_manufacturers",
              "value": "Need to identify and qualify additional manufacturers prior to NDA submission."
            },
            {
              "key": "inventory_management",
              "value": "Interruption in supply of components could limit development efforts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 43,
          "title": "Risks Related to Intellectual Property and Product Liability Insurance",
          "data": [
            {
              "key": "regulatory_risks",
              "value": "Changes in patent laws or interpretation of the patent laws may diminish the value of patents or narrow the scope of patent protection."
            },
            {
              "key": "insurance_coverage_risks",
              "value": "Product liability insurance may not be adequate to cover all liabilities."
            },
            {
              "key": "litigation_risks",
              "value": "The patent position of biotechnology and pharmaceutical companies involves complex legal questions and has been the subject of litigation."
            },
            {
              "key": "Leahy-Smith_America_Invents_Act",
              "value": "The act introduced significant changes to U.S. patent law affecting prosecution and patent litigation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 45,
          "title": "Patent Litigation and Administrative Proceedings",
          "data": [
            {
              "key": "company_name",
              "value": "BrightGene"
            },
            {
              "key": "issue",
              "value": "Patent validity and potential infringement lawsuits"
            },
            {
              "key": "jurisdictions",
              "value": "United States, Japan, Canada"
            },
            {
              "key": "potential_outcome",
              "value": "Significant liabilities and impact on business operations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 46,
          "title": "Patent Infringement and Regulatory Litigation Risks",
          "data": [
            {
              "key": "Patent Invalidity Risk",
              "value": "A court may decide that a patent is invalid or unenforceable."
            },
            {
              "key": "Litigation Consequences",
              "value": "An adverse result in litigation could put patents at risk."
            },
            {
              "key": "License Agreements",
              "value": "May require payment of royalties and fees."
            },
            {
              "key": "Discovery Risks",
              "value": "Confidential information could be compromised."
            },
            {
              "key": "Hatch-Waxman Act",
              "value": "Allows generic companies to challenge patents post-commercialization."
            },
            {
              "key": "FDA ANDA Process",
              "value": "Generic companies can submit ANDA after drug approval."
            },
            {
              "key": "Market Loss Risk",
              "value": "Failure to litigate patent listings timely can lead to market loss."
            },
            {
              "key": "Cost of Litigation",
              "value": "Litigation could incur significant costs and resource allocation issues."
            },
            {
              "key": "FTC Scrutiny",
              "value": "Patent settlements could lead to FTC reviews and antitrust investigations."
            },
            {
              "key": "Reverse Payment Settlement",
              "value": "Settlements may be scrutinized under antitrust laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 47,
          "title": "Potential Legal Issues Related to Trademarks and Intellectual Property",
          "data": [
            {
              "key": "Subject",
              "value": "Intellectual Property and Trademark Litigation"
            },
            {
              "key": "Key Issues",
              "value": "Potential infringement claims, trademark protection, legal proceedings regarding proprietary rights"
            },
            {
              "key": "Consequences",
              "value": "Increased expenses, potential penalties, impact on business operations, requirement to obtain licenses, risk of market confusion"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 48,
          "title": "Intellectual Property Rights Protection and Enforcement Risks",
          "data": [
            {
              "key": "Issue",
              "value": "Challenges in enforcing intellectual property rights worldwide."
            },
            {
              "key": "Patent Filing Process",
              "value": "First patent application at the UK Intellectual Property Office; international applications under the PCT within 12 months."
            },
            {
              "key": "Country-Specific Issues",
              "value": "Different patentability requirements in foreign countries."
            },
            {
              "key": "Compulsory Licensing",
              "value": "Some countries issue compulsory licenses for patented drugs."
            },
            {
              "key": "TRIPS Agreement",
              "value": "Countries must allow drug exportation to developing countries lacking manufacturing capability."
            },
            {
              "key": "WTO Exemption",
              "value": "Exemption against enforcing pharmaceutical drug patents in least developed countries until 2033."
            },
            {
              "key": "Compliance Risks",
              "value": "Non-compliance with patent agency requirements could reduce or eliminate patent protection."
            },
            {
              "key": "Competitive Impact",
              "value": "Forced licensing to third parties may impair competitive positions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 50,
          "title": "Intellectual Property Licensing Risks",
          "data": [
            {
              "key": "Summary",
              "value": "The company faces risks related to intellectual property licenses, including potential disagreements over contract interpretations that could affect rights and obligations."
            },
            {
              "key": "Potential Impacts",
              "value": "Loss of rights to develop products, loss of patent protection, significant delays in development, inability to negotiate acceptable license terms."
            },
            {
              "key": "Future Considerations",
              "value": "The company may need additional licenses and may face difficulties in obtaining them at reasonable costs."
            },
            {
              "key": "Compliance Risks",
              "value": "Failure to comply with obligations under licensing agreements could lead to loss of critical license rights."
            },
            {
              "key": "Litigation Potential",
              "value": "Disputes may arise concerning the scope of rights under licensing agreements, which could impact the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 51,
          "title": "Intellectual Property Risks and Litigation",
          "data": [
            {
              "key": "patented_technology_priority",
              "value": "priority of invention of patented technology"
            },
            {
              "key": "disputes_risks",
              "value": "disputes over intellectual property could impair licensing arrangements"
            },
            {
              "key": "claims_by_third_parties",
              "value": "potential claims of misappropriation of intellectual property"
            },
            {
              "key": "employee_backgrounds",
              "value": "employees' previous employment at competitors or universities"
            },
            {
              "key": "litigation_needs",
              "value": "litigation may be necessary to defend against claims"
            },
            {
              "key": "assignment_agreements",
              "value": "policy to require employees to assign intellectual property"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 54,
          "title": "Risk Factors Related to Regulatory Compliance and Economic Conditions",
          "data": [
            {
              "key": "adverse_effects_of_independence",
              "value": "Possible outcomes of independence could significantly impact costs, including levels of taxation applicable."
            },
            {
              "key": "global_economic_conditions",
              "value": "Unfavorable global economic conditions could adversely affect business, financial condition, or results of operations."
            },
            {
              "key": "historical_crises_impact",
              "value": "Historical examples such as the 2008 financial crisis and COVID-19 caused volatility and disruptions."
            },
            {
              "key": "risks_due_to_economic_downturn",
              "value": "Severe economic downturns could result in risks, including inability to raise additional capital."
            },
            {
              "key": "supply_chain_disruptions",
              "value": "A weak economy could strain suppliers and result in supply disruptions."
            },
            {
              "key": "information_technology_risks",
              "value": "Risks associated with IT failures and vulnerabilities despite security measures."
            },
            {
              "key": "data_loss_risk",
              "value": "Loss of clinical trial data due to disruptions could delay marketing approvals."
            },
            {
              "key": "misconduct_risk",
              "value": "Employees and contractors may engage in misconduct or improper activities."
            },
            {
              "key": "regulatory_compliance_risks",
              "value": "Compliance with extensive laws aimed at preventing fraud and misconduct is critical."
            },
            {
              "key": "potential_legal_actions",
              "value": "Allegations of fraud could result in significant legal actions and penalties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 56,
          "title": "Risks Related to Compliance and Internal Controls",
          "data": [
            {
              "key": "Key Risks",
              "value": "Loss of key scientific or senior management personnel, potential delisting from Nasdaq."
            },
            {
              "key": "Securities Class Action Litigation",
              "value": "Previous volatility may lead to securities class action lawsuits."
            },
            {
              "key": "Increased Costs",
              "value": "Operating as a public company incurs significant legal, accounting, and compliance costs."
            },
            {
              "key": "Sarbanes-Oxley Compliance",
              "value": "Required reporting on internal control over financial reporting."
            },
            {
              "key": "Regulatory Uncertainty",
              "value": "Varying interpretations and lack of specificity in rules can lead to higher compliance costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 58,
          "title": "Rights of ADS Holders and Takeover Code Provisions",
          "data": [
            {
              "key": "ADS holder rights",
              "value": "Holders of ADSs may not receive distributions on ordinary shares if it is illegal or impractical to do so."
            },
            {
              "key": "cash dividends",
              "value": "Depositary for ADSs will pay cash dividends after deducting fees and certain taxes."
            },
            {
              "key": "impact on market value",
              "value": "Restrictions may negatively impact the market value of ADSs."
            },
            {
              "key": "transfer limitations",
              "value": "Holders may face limitations on the transfer of their ADSs."
            },
            {
              "key": "governing law",
              "value": "Rights governed by English law and Companies Act 2006."
            },
            {
              "key": "Takeover Code applicability",
              "value": "Takeover Code applicability depends on management and control location."
            },
            {
              "key": "mandatory takeover bids",
              "value": "Not subject to mandatory bids if outside UK management."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 59,
          "title": "Takeover Offer Regulations and Implications",
          "data": [
            {
              "key": "Independent Adviser Requirement",
              "value": "The offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all shareholders."
            },
            {
              "key": "Equal Information for Shareholders",
              "value": "All shareholders must be given the same information and favorable deals for selected shareholders are banned."
            },
            {
              "key": "Accountability for Takeover Circulars",
              "value": "Those issuing takeover circulars must include statements taking responsibility for the contents."
            },
            {
              "key": "Profit Forecasts and Asset Valuations",
              "value": "Profit forecasts and asset valuations must be reported on by professional advisers and made to specified standards."
            },
            {
              "key": "Correction of Misleading Statements",
              "value": "Misleading statements made in documents or to the media must be publicly corrected."
            },
            {
              "key": "Actions During Offers",
              "value": "Actions during the course of an offer by the offeree company which might frustrate the offer are generally prohibited unless shareholders approve."
            },
            {
              "key": "Disclosure Requirements for Securities",
              "value": "Stringent disclosure requirements for dealings in relevant securities during an offer."
            },
            {
              "key": "Employee Notification Clause",
              "value": "Employees of both the offeror and offeree must be informed about the offer."
            },
            {
              "key": "Pension Scheme Representation",
              "value": "The offeree company’s employee representatives and pension scheme trustees have the right to append their opinion on employment effects to the offeree board’s circular."
            },
            {
              "key": "Jurisdictional Limitations",
              "value": "Claims of U.S. civil liabilities may not be enforceable against us due to jurisdictional limitations."
            },
            {
              "key": "Status as Foreign Private Issuer",
              "value": "We qualify as a foreign private issuer and are exempt from certain U.S. proxy rules."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 60,
          "title": "Regulatory Compliance as a Foreign Private Issuer",
          "data": [
            {
              "key": "Annual Reporting Requirements",
              "value": "Foreign private issuers have 120 days to file annual reports on Form 20-F; U.S. domestic accelerated filers have 75 days for Form 10-K."
            },
            {
              "key": "Regulation Fair Disclosure Exemption",
              "value": "Foreign private issuers are exempt from Regulation Fair Disclosure."
            },
            {
              "key": "Corporate Governance Practices",
              "value": "Permitted to adopt home country corporate governance practices that differ from Nasdaq standards."
            },
            {
              "key": "Loss of Foreign Private Issuer Status",
              "value": "May lose status as of June 30, 2023, requiring compliance with domestic issuer reporting requirements."
            },
            {
              "key": "Impact of Status Loss",
              "value": "Increased legal and financial compliance costs; difficulties in obtaining liability insurance."
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "No longer an EGC as of end of 2022; new reporting requirements in effect."
            },
            {
              "key": "Internal Controls",
              "value": "Failures can result in loss of shareholder confidence and harm business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 92,
          "title": "FDA Drug Approval Process and Patent Regulations",
          "data": [
            {
              "key": "Key Terms",
              "value": "FDA, NDA, ANDA, 505(b)(2), Orange Book, Bioequivalence"
            },
            {
              "key": "Main Topics",
              "value": "Drug approval process, patent certification, exclusivity periods"
            },
            {
              "key": "Certification Types",
              "value": "Paragraph IV, Section viii statement"
            },
            {
              "key": "Exclusivity Details",
              "value": "5 years for new chemical entities, 3 years for new clinical investigations"
            },
            {
              "key": "Patent Term Extension",
              "value": "Up to 5 years based on testing and review phases."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 93,
          "title": "FDA Regulations on Post-Marketing Requirements and Compliance",
          "data": [
            {
              "key": "Post-Marketing Requirements",
              "value": "Manufacturers and new drug products are subject to ongoing FDA regulation, including monitoring and recordkeeping."
            },
            {
              "key": "Interim Patent Extension",
              "value": "Can increase patent term by one year, renewable up to four times."
            },
            {
              "key": "Off-Label Use Promotion",
              "value": "Manufacturers cannot promote drugs for unapproved uses, which may result in significant liabilities."
            },
            {
              "key": "NDA Supplement Requirements",
              "value": "Changes to approved applications require submission of new NDA or NDA supplement."
            },
            {
              "key": "cGMP Compliance",
              "value": "Manufacturers must adhere to current Good Manufacturing Practices post-approval."
            },
            {
              "key": "Enforcement Actions",
              "value": "FDA can impose a range of enforcement actions for non-compliance, including recalls and product withdrawals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 94,
          "title": "FDA Regulations on Pediatric Drug Studies",
          "data": [
            {
              "key": "Pediatric Research Equity Act (PREA)",
              "value": "Amendments to require sponsors to submit a Pediatric Study Plan for new drug applications."
            },
            {
              "key": "FDA Reauthorization Act of 2017",
              "value": "Amended the FD&C Act to require pediatric investigations of drugs for adult cancers if relevant to pediatric cancers."
            },
            {
              "key": "Pediatric Exclusivity",
              "value": "Provides an additional six months of marketing protection if pediatric data is submitted in response to a Written Request from the FDA."
            },
            {
              "key": "Special Protocol Assessment (SPA)",
              "value": "Agreement with FDA on trial design and size, which is generally binding unless specific issues arise."
            },
            {
              "key": "Expedited Development and Review Programs",
              "value": "Programs authorized for addressing unmet medical needs for serious or life-threatening diseases, including Fast Track designation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 96,
          "title": "Regulation of Companion Diagnostic Devices",
          "data": [
            {
              "key": "Approval Pathway",
              "value": "The accelerated approval pathway is contingent on post-approval studies."
            },
            {
              "key": "FDA Review",
              "value": "Promotional materials for candidates under accelerated approval are subject to FDA review."
            },
            {
              "key": "Companion Diagnostics Regulation",
              "value": "Companion diagnostics are regulated as medical devices by the FDA."
            },
            {
              "key": "International Regulations",
              "value": "We are subject to a variety of regulations in jurisdictions outside of the U.S."
            },
            {
              "key": "Clinical Trials Regulation EU",
              "value": "The Clinical Trials Regulation (EU) 536/2014 harmonizes assessment across EU."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 97,
          "title": "Regulatory Approval Processes for Medicinal Products in the EU",
          "data": [
            {
              "key": "Centralized Procedure",
              "value": "A single marketing authorization application (MAA) granted by the European Commission valid across the EU, Iceland, Liechtenstein, and Norway, compulsory for human drugs derived from biotechnology, containing new active substances, orphan drugs, and advanced-therapy medicines."
            },
            {
              "key": "Maximum Evaluation Timeframe",
              "value": "210 days for MAA evaluation by EMA, excluding clock stops."
            },
            {
              "key": "Accelerated Evaluation",
              "value": "Granted in exceptional cases for medicinal products of major public health interest, with a maximum evaluation period of 150 days."
            },
            {
              "key": "Mutual Recognition Procedure (MRP)",
              "value": "Alternative for national marketing authorizations within the EU for human drugs not requiring the centralized procedure, based on mutual recognition of existing national authorizations."
            },
            {
              "key": "Reference Member State",
              "value": "The member state where initial marketing authorization is granted, used as reference for MRP."
            },
            {
              "key": "Decision Making Process",
              "value": "Involves consultation with various European Commission DGs and scientific committees when there's a refusal to recognize marketing authorization."
            },
            {
              "key": "U.K. Legislation Update",
              "value": "Post-Brexit legislation updates via Human Medicines Regulations (Amendment etc.) (E.U. Exit) Regulations 2019, affecting marketing authorizations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 98,
          "title": "Pharmaceutical Legislation and Regulatory Challenges",
          "data": [
            {
              "key": "Legislation Source",
              "value": "Negotiations between the UK and EU"
            },
            {
              "key": "Potential Model",
              "value": "Swiss model"
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Fines, suspension of clinical trials, withdrawal of approvals, product recalls, seizure of products, criminal prosecution"
            },
            {
              "key": "Coverage and Reimbursement Uncertainty",
              "value": "Significant uncertainty for FDA regulatory approval products"
            },
            {
              "key": "Third-party Payors",
              "value": "Coverage determined by payors including Medicare, Medicaid, and private insurers"
            },
            {
              "key": "Price Control Interest",
              "value": "Focus on controlling healthcare costs by the government"
            },
            {
              "key": "American Rescue Plan Act 2021",
              "value": "Eliminates the Medicaid drug rebate cap starting January 1, 2024"
            },
            {
              "key": "Inflation Reduction Act 2022 Key Aspects",
              "value": "Price negotiations and penalties for price increases above inflation starting in 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 100,
          "title": "Healthcare Compliance and Regulatory Challenges",
          "data": [
            {
              "key": "Federal Transparency Requirements",
              "value": "Requirements under the Physician Payments Sunshine Act to report payments and transfers of value."
            },
            {
              "key": "State Laws and Regulations",
              "value": "State anti-kickback and false claims laws that may impose similar restrictions."
            },
            {
              "key": "Compliance Costs",
              "value": "Substantial time and money required to ensure compliance with healthcare laws."
            },
            {
              "key": "Healthcare Reform Legislation",
              "value": "Strengthened federal and state healthcare laws under the ACA."
            },
            {
              "key": "Criminal and Civil Sanctions",
              "value": "Potential penalties for violations of healthcare laws."
            },
            {
              "key": "Impact of Regulatory Changes",
              "value": "Changes to FDA policies that may influence regulatory approval."
            },
            {
              "key": "Cost Containment Trends",
              "value": "Federal and state proposals to control healthcare costs."
            },
            {
              "key": "Patient Protection and Affordable Care Act",
              "value": "Increased Medicaid rebates and other regulations affecting drug manufacturers."
            },
            {
              "key": "Judicial Challenges to ACA",
              "value": "Recent Supreme Court dismissal of challenges to the ACA."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 101,
          "title": "Regulatory challenges and legal proceedings related to pharmaceutical pricing and healthcare access.",
          "data": [
            {
              "key": "Summary of Government Actions",
              "value": "Heightened scrutiny over drug pricing by federal and state agencies."
            },
            {
              "key": "Impact of Legislation",
              "value": "Legislation could limit amounts paid for healthcare products and services."
            },
            {
              "key": "Litigation Overview",
              "value": "Ordinary course business litigation; no materially adverse pending litigation."
            },
            {
              "key": "European Patent",
              "value": "Granted EP 2955190 covering sofosbuvir."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 102,
          "title": "EPO Opposition and Legal Proceedings Summary",
          "data": [
            {
              "key": "EPO Opposition Details",
              "value": "Filed an Opposition to patent at EPO."
            },
            {
              "key": "EPO Decision Date",
              "value": "March 24, 2023"
            },
            {
              "key": "EPO Decision Outcome",
              "value": "Revoked EP 190."
            },
            {
              "key": "Court Case",
              "value": "Gilead Lawsuit against us in U.K. Patents Court."
            },
            {
              "key": "Counterclaim Date",
              "value": "March 2021"
            },
            {
              "key": "Additional Patent",
              "value": "EP 3904365 issued in 2022."
            },
            {
              "key": "U.K. Court Judgment Date",
              "value": "March 21, 2023"
            },
            {
              "key": "U.K. Court Outcome",
              "value": "EP 190 and EP 365 deemed invalid in the U.K."
            },
            {
              "key": "German Court Proceedings",
              "value": "Initiated against Gilead Sciences in German Regional Court."
            },
            {
              "key": "German Court Judgment Date",
              "value": "July 2022"
            },
            {
              "key": "German Court Outcome",
              "value": "Found Gilead Sciences infringed EP 190."
            },
            {
              "key": "Legal Fees Liability",
              "value": "Liable to pay Gilead’s legal fees for proceedings in the U.K. and Germany."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 143,
          "title": "Standard of Conduct for Directors",
          "data": [
            {
              "key": "Statutory Duties",
              "value": "Directors must act in good faith for the benefit of shareholders, avoid conflicts of interest, follow company constitution, and exercise reasonable care."
            },
            {
              "key": "Fiduciary Duties",
              "value": "Directors owe duties of care and loyalty, acting without self-interest and in the best interest of the corporation."
            },
            {
              "key": "Derivative Claims",
              "value": "Shareholders can bring claims on behalf of the company in cases of director negligence or breach of duty."
            },
            {
              "key": "Delaware Law",
              "value": "Directors are presumed to act in the corporation's best interest, with loyalty and care."
            },
            {
              "key": "Standard of Conduct",
              "value": "Heightened standards apply during actions designed to thwart control changes; must seek highest value during sales."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 144,
          "title": "Material Contracts and Exchange Controls",
          "data": [
            {
              "key": "Litigation Considerations",
              "value": "Affairs have been or are being conducted in a manner that is unfairly prejudicial to some or all of its shareholders."
            },
            {
              "key": "Court Approval",
              "value": "Action will not be dismissed or compromised without the approval of the Delaware Court of Chancery."
            },
            {
              "key": "Exchange Control Regulations",
              "value": "No governmental laws in the UK affecting capital import/export or dividend remittance."
            },
            {
              "key": "Taxation Overview",
              "value": "Discusses material U.S. federal income tax consequences to U.S. Holders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 149,
          "title": "Taxation of Dispositions of ADSs",
          "data": [
            {
              "key": "Taxable Gain/Loss Recognition",
              "value": "A U.S. Holder recognizes taxable gain or loss on sale of an ADS equal to the difference between the amount realized and the tax basis in the ADS."
            },
            {
              "key": "Capital Gains Treatment",
              "value": "The gain or loss is generally capital gain or loss and may be long-term capital gain or loss."
            },
            {
              "key": "Long-term Capital Gain Tax Rate",
              "value": "Long-term capital gain is taxable at a reduced rate for non-corporate U.S. Holders."
            },
            {
              "key": "Deductibility of Capital Loss",
              "value": "The deductibility of capital losses is subject to limitations."
            },
            {
              "key": "U.S. Source Income",
              "value": "Gain or loss is treated as U.S. source income for foreign tax credit purposes."
            },
            {
              "key": "Foreign Currency Considerations",
              "value": "U.S. Holders should consult tax advisors on tax consequences of non-U.S. currency received."
            },
            {
              "key": "Net Investment Income Tax",
              "value": "A 3.8% Medicare tax may apply to a U.S. Holder's net investment income."
            },
            {
              "key": "Information Reporting and Backup Withholding",
              "value": "Distributions and proceeds from ADSs may be subject to IRS reporting and backup withholding."
            },
            {
              "key": "Exemption from Backup Withholding",
              "value": "Backup withholding does not apply if taxpayer ID number is correct and certification is made."
            },
            {
              "key": "Foreign Financial Asset Reporting",
              "value": "U.S. Holders may have to report beneficial ownership of ADSs if not held by a financial institution."
            },
            {
              "key": "Penalties for Noncompliance",
              "value": "Penalties may apply if required information is not submitted to the IRS."
            },
            {
              "key": "UK Tax Considerations",
              "value": "Summary of UK tax considerations related to ADSs is provided, subject to change."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 152,
          "title": "Tax Implications for ADS Holders in the United Kingdom",
          "data": [
            {
              "key": "Taxation of ADSs for individuals",
              "value": "Chargeable gain potentially subject to U.K. capital gains tax on disposals."
            },
            {
              "key": "Corporate holders of ADSs",
              "value": "Not liable for U.K. corporation tax on chargeable gains unless engaged in a trade."
            },
            {
              "key": "Stamp Duty and SDRT",
              "value": "No U.K. stamp duty on issue of ordinary shares; SDRT applies generally."
            },
            {
              "key": "Transfer of ordinary shares",
              "value": "Generally subject to stamp duty; 0.5% for sale transfers."
            },
            {
              "key": "Issue/Transfer of ADSs",
              "value": "No U.K. stamp duty or SDRT on depositary receipts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 173,
          "title": "Significant accounting policies",
          "data": [
            {
              "key": "Company Name",
              "value": "NUCANA PLC"
            },
            {
              "key": "Provision for legal proceedings",
              "value": "£4.1 million (2021: £nil)"
            },
            {
              "key": "Legal proceedings status",
              "value": "Ongoing litigation and legal proceedings"
            },
            {
              "key": "Basis of consolidation",
              "value": "Consolidated financial statements comprise the financial statements of the Company and its subsidiaries."
            },
            {
              "key": "Functional currency",
              "value": "Pounds Sterling"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "regulatory_litigation",
          "page": 179,
          "title": "Significant accounting policies",
          "data": [
            {
              "key": "IFRS 1",
              "value": "First-time Adoption of International Financial Reporting Standards – Subsidiary as a first-time adopter (effective from January 1, 2022)"
            },
            {
              "key": "IFRS 9",
              "value": "Financial Instruments – Fees in the ‘10 per cent’ test for derecognition of financial liabilities (effective from January 1, 2022)"
            },
            {
              "key": "IAS 41",
              "value": "Agriculture – Taxation in fair value measurements (effective from January 1, 2022)"
            },
            {
              "key": "IFRS 17",
              "value": "Insurance Contracts (effective from January 1, 2023)"
            },
            {
              "key": "IAS 1 Amendments",
              "value": "Presentation of Financial Statements – Classification of Liabilities as Current or Non-Current (effective from January 1, 2023)"
            },
            {
              "key": "IAS 1 and IFRS Practice Statement 2 Amendments",
              "value": "Disclosure of Accounting Policies (effective from January 1, 2023)"
            },
            {
              "key": "IAS 8 Amendments",
              "value": "Accounting Policies, Changes in Accounting Estimates and Errors – Definition of Accounting Estimates (effective from January 1, 2023)"
            },
            {
              "key": "IAS 12 Amendments",
              "value": "Deferred Tax related to Assets and Liabilities arising from a Single Transaction (effective from January 1, 2023)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 200,
          "title": "Provisions and Legal Proceedings",
          "data": [
            {
              "key": "Date",
              "value": "At January 1, 2022"
            },
            {
              "key": "Column1",
              "value": "—"
            },
            {
              "key": "Column2",
              "value": ""
            },
            {
              "key": "Column3",
              "value": "46"
            },
            {
              "key": "Total",
              "value": "46"
            },
            {
              "key": "Date",
              "value": "Charge for year"
            },
            {
              "key": "Column1",
              "value": "4,100"
            },
            {
              "key": "Column2",
              "value": ""
            },
            {
              "key": "Column3",
              "value": "—"
            },
            {
              "key": "Total",
              "value": "4,100"
            },
            {
              "key": "Date",
              "value": "At December 31, 2022"
            },
            {
              "key": "Column1",
              "value": "4,100"
            },
            {
              "key": "Column2",
              "value": ""
            },
            {
              "key": "Column3",
              "value": "46"
            },
            {
              "key": "Total",
              "value": "4,146"
            },
            {
              "key": "Classification - Current",
              "value": "4,100"
            },
            {
              "key": "Classification - Non-current",
              "value": "46"
            },
            {
              "key": "Classification - Total",
              "value": "4,146"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "regulatory_litigation",
          "page": 201,
          "title": "Judgment and Events Related to SVBUK Acquisition and Patent Dispute",
          "data": [
            {
              "key": "Event",
              "value": "Acquisition of SVBUK by HSBC"
            },
            {
              "key": "Date of Bank Acquisition Announcement",
              "value": "March 13, 2023"
            },
            {
              "key": "Judgment Date",
              "value": "March 21, 2023"
            },
            {
              "key": "Invalidity Decision",
              "value": "UK designations of EP 190 and EP 365 deemed invalid"
            },
            {
              "key": "Company Incurred Costs Due to Judgment",
              "value": "£3.0 million provision recognized"
            },
            {
              "key": "Patent Opposer",
              "value": "Gilead Sciences, Inc."
            },
            {
              "key": "Patent Decision Effect Date",
              "value": "March 24, 2023"
            },
            {
              "key": "Additional Provision Recognized",
              "value": "£1.1 million provision"
            },
            {
              "key": "Nature of Patent",
              "value": "Composition of matter of phosphoramidate nucleotide compounds (including sofosbuvir)"
            }
          ],
          "currency": "GBP"
        },
        {
          "type": "regulatory_litigation",
          "page": 215,
          "title": "Certification Required by Rule 13A-14(A) or 15D-14(A)",
          "data": [
            {
              "key": "Name",
              "value": "Donald Munoz"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer (Principal Financial Officer)"
            },
            {
              "key": "Date",
              "value": "April 4, 2023"
            },
            {
              "key": "Certification",
              "value": "Certifies that the annual report does not contain untrue statements and presents the company's financial condition fairly."
            },
            {
              "key": "Disclosure Controls and Procedures",
              "value": "Established and maintained for ensuring material information is known."
            },
            {
              "key": "Internal Control",
              "value": "Designed to provide reasonable assurance regarding reliability of financial reporting."
            },
            {
              "key": "Evaluation of Controls",
              "value": "Reviewed effectiveness of controls and stated conclusions."
            },
            {
              "key": "Changes in Internal Control",
              "value": "Any changes disclosed in the report that could materially affect controls."
            },
            {
              "key": "Deficiencies and Weaknesses",
              "value": "Disclosed significant deficiencies and weaknesses in internal control."
            },
            {
              "key": "Fraud Disclosure",
              "value": "Disclosed any fraud involving management or significant employees."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": false,
      "elements": []
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 87,
          "title": "Patent Strategy and Coverage",
          "data": [
            {
              "key": "Priority Filing Office",
              "value": "U.K. Intellectual Property Office"
            },
            {
              "key": "Patents Owned",
              "value": "844 granted patents"
            },
            {
              "key": "U.S. Patents",
              "value": "28 issued patents"
            },
            {
              "key": "Pending Applications",
              "value": "263 pending patent applications"
            },
            {
              "key": "Commercially Important Territories",
              "value": "Australia, Canada, China, Eurasia, Europe, Hong Kong, India, Israel, Japan, South Korea, Malaysia, Mexico, Philippines, Singapore, South Africa"
            },
            {
              "key": "NUC-3373 Patents Granted",
              "value": "102 granted patents"
            },
            {
              "key": "NUC-3373 Expiry Year",
              "value": "2032"
            },
            {
              "key": "NUC-7738 Patents Granted",
              "value": "76 granted patents"
            },
            {
              "key": "NUC-7738 Expiry Year",
              "value": "2035"
            },
            {
              "key": "Acelarin Patents Granted",
              "value": "88 granted patents"
            },
            {
              "key": "Acelarin Expiry Year",
              "value": "2024"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 88,
          "title": "Patents and Collaboration with Cardiff University",
          "data": [
            {
              "key": "Patent Overview",
              "value": "Acelarin patents granted in the US, Europe, and Japan expiring in 2035-2036."
            },
            {
              "key": "Patent Term Length",
              "value": "Generally, 20 years from earliest filing date for non-provisional applications."
            },
            {
              "key": "U.S. Patent Extensions",
              "value": "Potential for extensions under certain conditions including FDA review."
            },
            {
              "key": "Collaboration Agreement",
              "value": "Research partnership with Cardiff University starting in August 2009, extended with amendments."
            },
            {
              "key": "Funding Amounts",
              "value": "£175,052 in 2020, £136,481 in 2021, £68,737 in 2022."
            },
            {
              "key": "Exclusive License",
              "value": "Granted for Cardiff intellectual property related to ProTides, surviving agreement expiration."
            }
          ],
          "currency": "GBP"
        }
      ]
    }
  },
  "currency": {
    "USD": 2,
    "EUR": 43,
    "GBP": 39,
    "AUD": 14,
    "CAD": 1,
    "ZAR": 3
  },
  "sha1": "9b7fdb871fc4d4a8babc25448257ae0b81a6442d"
}